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Abstract 
My aim for this thesis was to study the costs of anticancer drugs in Australia and their 
consequences, to better inform discussions about treatments for individuals, the funding of 
anticancer drugs, and health policy. 
  
Pharmaceutical Benefits Scheme (PBS) expenditure on anticancer drugs increased on average 
19% per annum from 2000 to 2012.  Inadequate cost-effectiveness and uncertainties about the 
evidence supporting submissions for listing on the PBS were the main reasons for rejection by 
the Pharmaceutical Benefits Advisory Committee from 2005 to 2014.  Most (69%) 
submissions for a new listing were rejected at least once, and initial submissions were more 
often rejected from 2010 to 2014 than from 2005 to 2009 (70% vs 54%, p=0.04).  
 
Australian medical oncologists I surveyed reported frequent discussions (average 3 patients 
per month) and prescriptions (average 1 patient per month) of expensive, unfunded anticancer 
drugs; and concerns about causing patients financial harm.  In a separate discrete choice 
experiment, I found that Australian medical oncologists required a minimum survival benefit 
of 2 to 3 months before recommending a treatment for advanced cancer that might financially 
burden a patient.  My appraisal of frameworks for assessing the value of new anticancer drugs 
recently developed by the peak US and European oncology societies concluded that they 
provide a useful starting point for individuals considering treatment with expensive anticancer 
drugs.  
 
The rising costs of anticancer drugs pose major challenges for individuals and health systems.  
When treatment with a new, expensive, anticancer drug is not publicly subsidised, judgements 
about value and expenditure shift from public funders and policy makers, to individual 
patients and their oncologists facing decisions about treatments with high out-of-pocket costs.  
Improving our understanding of how individual patients and their doctors think, 
communicate, and decide about expensive treatments could help minimise financial harms 
that are unexpected and/or unnecessary.   
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1 INTRODUCTION 
 
1.1 Rationale for the thesis 
 
The number of anticancer drugs available to treat individuals with cancer has grown 
exponentially in recent years.  Targeted anticancer drugs and immunotherapy are now 
available as treatment for many cancers in addition to traditional cytotoxic chemotherapy.  
The larger number of treatment options is welcomed by individuals with cancer and the 
oncologists who treat them. 
 
This growth in the number of anticancer drugs has been accompanied by a rapid growth in 
expenditure on anticancer drugs.  The growth in expenditure on anticancer drugs is far 
outstripping growth in other areas of healthcare expenditure in most developed countries.  
One of the main reasons for this rapid growth in expenditure is the high price of new 
anticancer drugs. 
 
The costs of anticancer drugs have the potential to significantly impact on patient care.  For 
example, the high price of many new anticancer drugs puts strain on publicly funded health 
systems.  This can limit universal access to treatment as not all new anticancer drugs can be 
publicly funded. If an anticancer drug is not publicly funded then for many individuals it will 
be unaffordable. 
 
2 
Oncologists are obliged to discuss all treatment options with their patients and this includes 
expensive anticancer drugs that are not publicly funded.  Determining the value of an 
unfunded anticancer drug – that is determining whether the potential benefits are worth the 
potential side effects and out-of-pocket costs – can be incredibly challenging.  If a patient 
chooses to have treatment with an expensive unfunded anticancer drug, then they are at risk of 
financial harm. 
 
The work in this thesis was motivated by discussions with my patients about the costs of 
anticancer drugs – both for the Australian taxpayer and the individual with cancer.  Patients 
and their families often expressed their frustration when informed of a treatment option that 
was not publicly funded.  When I commenced this thesis, issues relating to the high cost of 
anticancer drugs and the consequences for the care of individuals with cancer had not been 
well examined in Australia.  This was despite increasing concern from individuals with 
cancer, their families and caregivers.  By focusing on the Australian context the work in this 
thesis hopes to address the paucity of knowledge about the consequences of the high costs of 
new anticancer drugs in Australia. 
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1.2 Selection of studies for the thesis 
 
This is a hybrid thesis combining traditional chapters (chapters 1, 2 and 8) with journal 
publications (chapters 3, 4, 5 and 7).  Chapter 6 is presented as a manuscript in publication 
format.  At the time I submitted my thesis the manuscript presented in Chapter 6 had been 
submitted to a journal and was under review.  The related journal publications and the 
manuscript presented in Chapter 6 are complemented and unified by the traditional chapters 
that consider the thesis as a whole: the background (chapter 2), and the discussion (chapter 8). 
The outline of each individual chapter is found in section 1.4. 
 
The theme of this thesis relates to costs of anticancer drugs from an Australian perspective.  
The studies in this thesis have been chosen because they address consequences of the rising 
costs and high prices of new anticancer drugs.  These include gaining a better understanding 
of the reasons anticancer drugs are not recommended for public funding, how often 
oncologists discuss and prescribe unfunded anticancer drugs and their attitudes and beliefs 
about their use, and how different attributes of anticancer drugs affect oncologists’ 
recommendations to their patients.  The work in this thesis is primarily aimed at oncologists – 
doctors involved in the care of individuals with cancer.  Health policymakers and individuals 
with cancer may also have an interest in the information presented in this thesis.  As a whole, 
the studies in this thesis add original data to the growing body of work on the consequences of 
rising anticancer drug costs in Australia. 
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1.3 Aims and objectives 
 
The general aim of the work in this thesis was to study the costs of anticancer drugs in 
Australia to better inform discussions about treatments for individuals, the funding of 
anticancer drugs and health policy. 
 
The specific objectives were to: 
i. determine the costs of anticancer drugs in Australia and if they were rising 
ii. determine the reasons why anticancer drugs are rejected for public subsidy and the 
frequency of rejection 
iii. determine the practices, attitudes and beliefs of Australian medical oncologists 
regarding discussing and prescribing anticancer drugs that are not publicly subsidised 
iv. determine how different attributes of anticancer drugs, including their out-of-pocket 
costs, influence oncologists’ recommendations to patients with cancer 
v. compare two recently constructed value frameworks and consider their relevance to 
clinical practice and healthcare policy 
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1.4 Outline of chapters 
 
Chapter 2 reviews the relevant background for the research work presented in the subsequent 
chapters.  The first sections (2.2 and 2.3) are an introduction to cancer and its treatment with 
anticancer drugs.  This is followed by information on the Australian healthcare system, costs 
of anticancer drugs and how they are made available to individuals with cancer (sections 2.4-
2.6).  The next section (2.7) focuses on anticancer drugs that are not funded by the 
government and how individuals with cancer access them.  The final section (2.8) outlines 
how the value of anticancer drugs is considered from both the perspective of healthcare 
funders making decisions about public funding of anticancer drugs, and of individuals with 
cancer making decisions about treatment with anticancer drugs.  
 
Chapter 3 is a published study on the costs of anticancer drugs in Australia aimed at a clinical 
audience.  Pharmaceutical Benefits Scheme (PBS) expenditure on anticancer drugs and prices 
paid by the PBS for anticancer drugs are reported for the period 2000 to 2012.  Costs of 
anticancer drugs and costs of other categories of drugs listed on the PBS are compared.  The 
reasons for the rising cost of anticancer drugs, and the implications, are explored and 
complement the information discussed in Chapter 2. 
 
Chapter 4 is a published study, aimed at a clinical audience, on the reasons the Pharmaceutical 
Benefits Advisory Committee rejects submissions to list anticancer drugs on the PBS.  The 
study reviewed publicly available information on decisions made by the PBAC between 2005 
and 2014.  The rejection rate for submissions over this time period was also determined. 
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Chapter 5 is a publication of the results of a survey of Australian medical oncologists asking 
them about expensive unfunded anticancer drugs.  It reports on the frequency of discussion 
about, and prescription of, unfunded anticancer drugs.  It also explores contemporary attitudes 
and beliefs of medical oncologists about the treatment of patients with unfunded anticancer 
drugs in Australia.  
 
Chapter 6 is a report of a study of medical oncologists’ treatment recommendations about 
unfunded anticancer drugs.  Australian medical oncologists were invited to complete a 
discrete choice experiment.  The influence on treatment recommendations of four attributes of 
anticancer drugs (improvements in survival; improvements in cancer related symptoms; 
chance of a serious adverse event; out-of-pocket costs) was examined by asking oncologists to 
choose between two possible treatment recommendations for a hypothetical patient with 
advanced cancer.  
 
Chapter 7 is a published manuscript aimed at a clinical audience.  It explores the challenge of 
determining the value of anticancer drugs with a focus on two recently developed 
frameworks.  The American Society of Clinical Oncology value framework (version 1.0, 
2015) and the European Society for Medical Oncology (version 1.0, 2015) value framework 
are described and compared.  Their potential application to decision making and the 
importance of credibly determining the value of expensive new anticancer drugs is discussed. 
 
Chapter 8 is a discussion of the work in the thesis as a whole.  It summarises the principal 
findings of the thesis and outlines its strengths and limitations.  Implications of the work in 
the thesis are discussed and recommendations for future research are made.  
7 
2 BACKGROUND 
 
2.1 Overview 
 
This chapter provides a background for the thesis as a whole.  It begins with an introduction 
to cancer (section 2.2) and its treatment with anticancer drugs (section 2.3).  This is followed 
by a brief summary of the Australian healthcare system (section 2.4), to provide some context 
for sections on the costs of anticancer drugs in Australia (section 2.5) and how anticancer 
drugs are made available to individuals with cancer (section 2.6).  Readers who are already 
familiar with cancer, its treatment and the Australian healthcare system may wish to skip 
sections 2.2 to 2.4. Section 2.7 focuses on anticancer drugs that are not funded by the 
government and how individuals with cancer access them.  Section 2.8 discusses the value of 
anticancer drugs from the perspectives of healthcare funders making decisions about funding 
treatments, and from the perspective of individual healthcare users making decisions about 
having treatments.  It also discusses the conceptual frameworks in which these decisions are 
made.  
 
  
8 
2.2 Cancer 
 
Cancer is a term used to describe a number of related diseases characterised by the abnormal 
growth of cells which have the ability to invade or spread to other parts of the body.1  Cancer 
is caused by changes in genes that regulate normal cell growth, division, function, and death.2 
 
Cancer can arise from any part of the body.  The most common type of cancer is carcinoma, 
arising from epithelial cells, those that line or cover the skin and other organs.3  Common 
examples of carcinomas are those that arise from epithelial cells in the breast, colon, rectum, 
lung, prostate and skin.  Other types of cancer arise from mesenchymal cells, e.g. in bone, 
muscle, or other connective tissues (sarcomas), blood and immune system cells (leukaemia, 
lymphoma and multiple myeloma), melanocytes in skin and other tissues (melanoma), 
nervous tissue cells (brain and spinal cord cancers), and from the germ cells that give rise to 
sperm and eggs (germ cell tumours).3 
 
When individuals are diagnosed with cancer, the extent of their disease is assessed or staged.  
Early stage cancers usually refer to cancers that are confined to their organ of origin.  The 
goal of treatment of early stage cancers is usually cure.  When the term late-stage or 
“advanced cancer” is used, this usually means the cancer has spread beyond where it started.  
This is also called cancer that has metastasized.  Most advanced cancers are incurable, and the 
goals of treatment for incurable cancers are prolonging survival and improving quality of 
life.4  
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Cancer is an increasingly common disease.  The Australian Institute of Health and Welfare 
estimated that the incidence of cancer had more than doubled from 1982 (47, 417 diagnoses) 
to 2014 (123,920 diagnoses).5  It is estimated that 1 in 2 current Australians will be diagnosed 
with cancer before the age of 85, and that almost 1 in 3 Australians will die of cancer.6    
 
Most individuals diagnosed with advanced cancer will die of their disease.  However, survival 
rates for most cancers have improved over time, and cancer survival rates in Australia are 
amongst the highest in the world.6  Declining cancer mortality rates are due to a combination 
of earlier diagnosis and improved treatment.7  The improved treatments include drugs to treat 
cancer, which are the focus of this thesis, and are introduced in the next section. 
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2.3 Anticancer drugs 
 
Cancer can be treated in multiple ways.  Three of the major ways to treat cancer are with 
surgery, radiotherapy and drugs.  Drugs used to treat cancer are henceforth referred to as 
“anticancer drugs”. Anticancer drugs are defined as medicines that control or kill cancer 
cells.8  For the purposes of this thesis we have restricted anticancer drugs to those that have 
demonstrated biological activity against cancer in individuals affected by cancer.  
 
The number of anticancer drugs available to treat cancer is growing rapidly.  Thirty three new 
anticancer drugs became available in the United Kingdom (UK) from 2010 to 2014, almost 
triple the number (12) that became available from 2000 to 2004.9  Anticancer drugs can be 
classified into the following major types: cytotoxic chemotherapy, targeted therapy, endocrine 
therapy, and immunotherapy.   
 
 Cytotoxic chemotherapy 2.3.1
Cytotoxic chemotherapy was one of the first types of drug treatment developed and used to 
treat cancer.  Cytotoxic chemotherapeutics are types of drugs that act by killing rapidly 
dividing cells – a property of many cancer cells.10  Due to a lack of selectivity, normal cells 
that are rapidly dividing are also damaged by chemotherapy, leading to common side effects 
such as low blood counts, mouth ulcers, and diarrhoea.11  
 
 Targeted anticancer drugs 2.3.2
Targeted drugs are anticancer drugs that block specific pathways within cancer cells that 
contribute to their ability to divide, proliferate, and spread.12  Targeted cancer therapies are 
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designed to take advantage of differences between normal cells and cancer cells and, while 
they still have important side effects, they are often better tolerated than cytotoxic 
chemotherapy.13 
   
Targeted anti-cancer drugs include:14  
• small-molecule, orally active tyrosine kinase inhibitors used to treat some types of 
lung cancer (e.g. erlotinib, gefitinib), leukaemia (e.g. imatinib), and kidney cancer 
(e.g. sunitinib, pazopanib) 
• monoclonal antibodies targeted at specific kinds of breast cancer (e.g. trastuzumab, 
pertuzumab), and colorectal cancer (e.g. cetuximab, panitumumab)  
 
Endocrine (hormone) therapies can also be classified as targeted therapies.15  Hormones have 
been long been implicated in the proliferation of cancer cells.  Anticancer drugs that reduce 
hormone levels or block the binding of hormones to cancer cells therefore aim to reduce 
cancer cell proliferation and induce cell death.14  
 
 Anticancer immunotherapy 2.3.3
The term immunotherapy denotes drugs that harness the host’s immune system in the 
treatment of disease.  Drugs harnessing the immune system to treat cancer have been a major 
focus of recent drug development.  Anticancer drugs of this type allow the host’s (patient’s) 
immune system to attack cancer cells by removing brakes that inhibit immune attacks on host 
normal cells.16  Examples of this type of immunotherapy are the immune checkpoint 
inhibitors (e.g. ipilimumab, pembrolizumab, nivolumab).  The class of immune checkpoint 
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inhibitors has specific side effects caused by the immune system attacking normal host cells 
and tissues resulting in side effects such as rash, thyroid dysfunction, colitis, and 
pneumonitis.17   
 
 Other drugs 2.3.4
This thesis includes consideration of anticancer drugs used to treat bone metastases, for 
example the bisphosphonate zoledronic acid, and the RANK ligand inhibitor denosumab.18  In 
Australia, these drugs are funded with similar mechanisms to other anticancer drugs.  
However, this thesis does not consider the use of radio-isotopes to treat bone metastases, 
because these drugs are funded and handled differently in Australia.  
 
This thesis does not consider the costs and effects of other types of drugs used in individuals 
affected by cancer.  It does not include:  
• corticosteroids used to treat some haematological malignancies 
• supportive care drugs used to treat the symptoms of cancer rather than the cancer itself 
(e.g. opioids and other analgesics) 
• supportive care drugs used to prevent or treat the side effects of anticancer treatments 
(e.g. anti-emetics or colony-stimulating factors)  
• vaccines used for cancer prevention or treatment 
• gene therapies used for cancer treatment 
• complementary or alternative therapies 
13 
 
 Side effects of anticancer drugs  2.3.5
Most anticancer drugs have side effects that can impair health related quality of life.  These 
range from being mildly troublesome without major consequences (e.g. fatigue, anorexia, 
nausea) to severe requiring hospitalisation or even fatal (e.g. infection with low blood white 
cells, bleeding with low platelets, or respiratory failure due to lung damage).19  Side effects 
can be acute – occurring within days or weeks of treatment; or late – occurring months or 
even years after treatment.  Most side effects of anticancer drugs improve with time and with 
appropriate management, but some may be permanent (e.g. neuropathy and cardiomyopathy). 
 
 Intent of treatment with anticancer drugs 2.3.6
The intent of prescribed treatment with an anticancer drug depends on the nature and extent of 
the cancer, on its prior treatment, and on the characteristics of the person with cancer.  The 
treatment intent may be curative or palliative.  
 
Treatment given with curative intent aims to eradicate the cancer.  Anticancer drugs given 
with curative intent can be given as the primary treatment (e.g. for leukaemia, lymphoma, 
metastatic germ cell tumours); or as (neo)adjuvant treatment given in addition to local 
treatment(s), i.e. surgery or radiation. Adjuvant therapy denotes treatment with an anticancer 
drug(s) given after the primary treatment (surgery and/or radiotherapy) with the goal of 
eradicating any subclinical disease.  Neoadjuvant therapy denotes treatment with an 
anticancer drug(s) given before the primary local treatment(s). 
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Treatment given with palliative intent aims to improve length and/or quality of life without 
realistic hope of cure.  The treatment of most patients with advanced cancer is given with 
palliative intent.  The goals of anticancer drugs given with a palliative intent are to prolong 
survival and improve cancer-related symptoms by shrinking the tumours, and/or delaying 
their growth and progression.  
 
 Methods of treatment delivery 2.3.7
Anticancer drugs are usually administered intravenously by injection or orally by mouth.  
Oral treatments tend to be more convenient for patients and less resource intensive. 
Intravenous treatments require intravenous cannulation, specialist nursing, pharmacy, and 
administration areas, and may generally require one to several hours to complete.  Some 
intravenous treatments are given continuously and require insertion of a permanent or semi-
permanent delivery device.  Other less common ways of delivering treatment include 
subcutaneous or intramuscular injection, intraperitoneal, intrathecal, intra-arterial, and topical.  
Administration of some treatments can require an admission to hospital.  
 
Anticancer drugs can be delivered as single agent therapy or in combination with other 
anticancer drugs depending on the type, stage and intent of the treatment.  One of the major 
aims of combining treatments is to increase efficacy but this often comes with the increased 
risk of side effects.  Anticancer drugs can also be delivered in combination with radiotherapy 
aiming to potentiate its effect.20   
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 Dosing of anticancer drugs 2.3.8
The basis of dose calculations for each anticancer drug is different.  The doses of many 
anticancer drugs are based on weight alone (e.g. trastuzumab used to treat some types of 
breast cancer) or a combination of weight and height used to estimate body surface area (e.g. 
docetaxel used to treat prostate cancer and other solid organ malignancies).21  Some 
anticancer drugs are administered at a fixed (or flat) dose (e.g. oral tyrosine kinase inhibitors 
such as erlotinib and dabrafenib) which means all patients start at the same dose regardless of 
any differences in size or weight.  The dose of some anticancer drugs is determined by the 
patient’s renal function (e.g. carboplatin).22  The dose of anticancer drugs prescribed may be 
adjusted downward if the patient experiences side effects that are serious or difficult to 
tolerate despite supportive care measures.  
 
 Treatment frequency and duration 2.3.9
Anticancer drugs can be given on a continuous daily basis (e.g. oral treatments), or 
intermittently in repeating cycles of variable lengths, usually in the order of 2-6 weeks.  A 
period of receiving an anticancer drug or combination of drugs is a “course” of treatment.  
Some courses of anticancer drugs are for a set period.  Set courses are most often seen in the 
adjuvant setting.  For example, patients who have surgery with curative intent for pancreas 
cancer may be offered a six month course of adjuvant chemotherapy.23  For advanced cancer 
the treatment course is often, but not always, undefined.  Many drugs used to treat advanced 
cancer are given until there is evidence they are no longer working (tumour progression on 
imaging or worsening symptoms attributable to the cancer) or until they are no longer 
tolerable (e.g. significant side effect such as peripheral neuropathy limiting function).  
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The next section of this background chapter is a brief summary of the Australian healthcare 
system.  It provides context for the studies reported in this thesis, and for the information 
presented in subsequent sections of the background chapter.  
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2.4 Summary of the Australian healthcare system 
 
 Components of the Australian healthcare system involved in cancer care 2.4.1
Australia’s health system is a complex network of different healthcare providers, services and 
settings, funded from different sources, and supported by different regulatory mechanisms.24  
The healthcare providers in the Australian health system include both organisations and 
individuals.  The individuals include medical practitioners (e.g. general practitioners, medical 
oncologists, surgeons, and radiation oncologists who provide care to cancer patients), nurses 
(e.g. an oncology nurse trained in the administration of chemotherapy), pharmacists (e.g. an 
oncology pharmacist who has specific expertise in anticancer drugs), and other allied health 
professionals (e.g. a psychologist who has expertise in dealing with the mental health of 
cancer patients).  The organisations in the Australian healthcare system include hospitals, 
pharmacies, clinics, government departments of health, and other non-government agencies.  
 
These organisations and healthcare professionals provide the range of healthcare services.24 
These include preventive services (e.g. breast cancer screening programs), primary health care 
(e.g. a primary care practitioner may diagnose a cancer and refer to a specialist for further 
care), emergency health services (e.g. urgent care needed for a complication of cancer such as 
pulmonary embolus), hospital-based treatment in public and private hospitals (e.g. a patient 
having bowel cancer surgery, or chemotherapy to treat an advanced lung cancer), 
rehabilitation services (e.g. pulmonary rehabilitation after lung cancer surgery) and palliative 
care (e.g. end of life care in a palliative care unit). 
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Support for Australia’s health system also comes from training facilities (e.g. universities, 
professional colleges) and regulatory bodies for health professionals (e.g. Australian Health 
Practitioner Regulation Agency), research bodies (e.g. fund, conduct or support research in 
cancer biology, treatment, health care, prevention, etc.), consumer groups (which may aim to 
inform healthcare decision makers), and cancer charities (e.g. Cancer Council Australia).24 
 
 Funding of the Australian healthcare system 2.4.2
The majority of the Australian healthcare system is publicly funded, that is funded by 
government spending.25  The Australian (Federal) government, State, and Territory 
governments share responsibility for this funding.  The remainder of the Australian healthcare 
system is privately funded.  This private funding comes from individual users, private health 
insurance, and other non-government sources.25   
 
The Australian government is responsible for Medicare, Australia’s universal public health 
insurance scheme.24  Medicare provides free and/or subsidised access to health care provided 
by public hospitals and treatment by health professionals.  Medicare also covers access to 
subsidised prescription medicines, including anticancer drugs, through the Pharmaceutical 
Benefits Scheme (PBS).  The PBS will be discussed further in section 2.6. 
 
 Provision of medical oncology services 2.4.3
A medical oncologist is a doctor with specialist training in internal medicine and the treatment 
of cancer with anticancer drugs.1  Medical oncologists provide care for individuals with 
cancer and help them make decisions about treatment (discussed in more detail in section 
2.8).  
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Medical oncology services are provided in public and private settings.  Individuals with 
cancer in Australia may choose to seek advice and treatment from a public setting, private 
setting or a mixture of both.  The arrangements and exact processes differ among states, but 
broadly speaking, the costs of medical oncology services provided in public settings are 
covered by Medicare (through the Medicare Benefits Schedule), and the public hospitals 
providing the service.  Medical oncology services provided in private settings entail additional 
out-of-pocket costs to patients for the medical consultations, treatments, and their 
administration.  Some of the costs, for example of administering chemotherapy in a private 
facility, may be covered by private health insurance.  In both private and public settings, the 
costs of most anticancer drugs themselves are largely met by the PBS if the anticancer drug(s) 
are listed on the PBS.  
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2.5 Costs of anticancer drugs 
 
This next section introduces the costs of anticancer drugs preceded by a brief introduction to 
healthcare costs and cancer care costs in general in Australia.  Some of the information 
covered in this section is also covered in chapter 3, and included here for clarity and flow. 
 
 Costs of health care and cancer care in Australia 2.5.1
Government spending accounted for about two-thirds of total health expenditure in Australia 
in 2014-15 with the remainder coming from non-government sources.25,26  Non-government 
sources include co-payments for health goods and services partly subsidised by the 
government (e.g. the patient co-payment required to access anticancer drugs listed on the PBS 
– explained  in more detail in section 2.6) and payments for goods and services that are not 
subsidised (e.g. payments to access anticancer drugs that are not listed on the PBS).26  
 
In Australia, health expenditure has been consistently growing in recent years.  In 2014-15, 
Australia spent A$162 billion on health.25  In real terms (i.e. increases beyond those due to 
inflation) this is approximately 3 times the expenditure on health in 1989-90.26  As a 
proportion of gross domestic product (GDP), health expenditure increased from 6.5% in 
1989-90, to 10% in 2014-15.25,26  
 
The cost of health care in most developed countries has been growing over recent decades and 
represents a substantial proportion of their GDP.27  In recent years many Organisation for 
Economic Co-operation and Development (OECD) countries have moved to limit increases in 
health spending due to concerns that continued growth is unsustainable.28  In the United 
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States (US) for example, the proportion of GDP spent on health in 2011 was 17.7%.27 This 
compares to 6% of GDP in 1960.29  In the US, health spending has increased an average of 
2.3% more per year than GDP and is projected to be 19.3% of GDP (approximately 4.3 
trillion USD) in 2019.29,30 
 
The most recent comprehensive analysis of expenditure on cancer care in Australia estimated 
that total health system expenditure on cancer in the 2008-09 financial year was 
approximately A$4.5 billion, which was about 1.5 times the expenditure in 2000-01 in real 
terms, and represented 7% of total health system expenditure on chronic disease.31  
Expenditure on cancer care is expected to continue rising and is projected to total 
approximately A$7.8 billion in 2022–23, and A$10.1 billion in 2032–33.32 
 
One of the major causes of rising healthcare and cancer care costs has been the development 
and uptake of new medical technologies, including anticancer drugs.29  The rising costs of 
anticancer drugs is discussed in more detail in the following sections. 
 
 The rising costs of anticancer drugs  2.5.2
The costs of anticancer drugs are rising rapidly around the world.33  The estimated value of 
the global anticancer drug market is expected  to reach 150 billion USD in 2020.34  Total 
expenditure on anticancer drugs in the US is expected to rise by 50% from 2010 to 2020.34  In 
Europe, spending on anticancer drugs accounted for more than a quarter of cancer care costs 
in a study published in 2013.35 
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 Reasons more money is being spent on anticancer drugs 2.5.3
There are many reasons why the amount spent on anticancer drugs is increasing.  One of the 
major factors is their increasing prices which will be discussed subsequently in this section.  
Other reasons include: 
• the increasing incidence of many cancers, which is partly due to aging populations and 
reductions in competing causes of mortality.  The rising incidence of cancer means 
more individuals are treated with anticancer drugs.33,36-39 
• the increasing number of anticancer drugs available.  New drugs usually add to the 
existing pool of available treatments, rather than replace some of them.  This means 
that each individual with cancer is likely to be treated with more drugs, increasing the 
amount of money spent per individual on anticancer drugs.33,40   
• new anticancer drugs are often used for longer durations as they become more 
tolerable and more effective 41,42.  Better tolerability of the newer drugs (e.g. 
immunotherapy vs chemotherapy) also results in higher uptake in the elderly and those 
with comorbidities for whom chemotherapy might be unsuitable.43 
• less than expected effects of cheaper generics on expenditure because higher-priced 
original brands maintain their market share.40  This may be due to prescriber 
familiarity and/or generics being regarded as less effective or less safe.  
Pharmaceutical companies may also pay fees to delay the introduction of competing 
generics.44  
• difficulties researching cheaper alternatives.  For example, it is difficult to attract 
funding for clinical trials of effective but cheaper alternatives to expensive anticancer 
drugs because these trials are usually not of commercial interest to pharmaceutical 
companies.45 
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 The high prices of anticancer drugs 2.5.4
Although there are multiple reasons why expenditure on anticancer drugs is increasing, one of 
the major factors is their increasingly high prices.46,47  Most new anticancer drugs approved 
by the US Food and Drug Administration (FDA) since 2010 have exceeded 100,000 USD per 
year or treatment course.48-50  The price for new anticancer drugs when launched in the US 
market, adjusted for inflation, increased by 10% per year from 1995 to 2013.51  The average 
cost for a course of a new anticancer drug in the UK between 2010 and 2014 was 4.4 times 
the cost between 2000 and 2004.41   
 
What defines a high price for an anticancer drug?  
There is no definition of what constitutes a “high-priced” anticancer drug.  Consideration of 
whether a drug is high-priced depends on who is paying for it and their available resources.52  
For example an anticancer drug that costs one thousand dollars per month may be considered 
high priced by those with limited resources (e.g. publicly funded health systems in developing 
countries, or an individual with modest personal wealth who must bear the total cost of the 
drug), but reasonably priced by those with substantial resources.  For the purpose of this 
thesis, an anticancer drug that costs more than A$1000 per month is considered high priced.  
Determining the value of anticancer drugs, that is the costs expended for the health outcomes 
gained, is the real challenge for those paying for them.  Determining the value of anticancer 
drugs will be discussed later in section 2.8.  
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Why are prices of anticancer drugs high?  
Anticancer drugs are first and predominantly sold in developed, high-income economies such 
as the US, Europe, and Japan.  These markets are where the prices of new anticancer drugs 
are set.  Explanations for the high price of new anticancer drugs include:  
• the cost of developing new anticancer drugs is high.40  For example, pharmaceutical 
companies spend hundreds of millions of dollars on clinical trials needed to establish a 
new anticancer drug’s safety, activity, and effectiveness so that it can gain approval 
for marketing.48  Pharmaceutical company estimates of the current costs of getting a 
drug to market exceed 1 billion USD.53  However, these estimates have been widely 
criticised for being inflated, and for neglecting contributions to research from 
governments and/or philanthropy.34,54  
• pharmaceutical companies try to recoup their high expenditure on marketing, 
promotion and other business costs.  Pharmaceutical company expenditure on 
marketing is widely accepted to exceed that on research and development.34 
• the commercial imperative to maximise profits and satisfy shareholders.34,54 
• in health systems like that of the United States, the prices of new anticancer drugs are 
determined by what the market will bear, not their value.44,49,55  Nine of the 12 
anticancer drugs launched in the US in 2012 were priced at more than 10,000 USD per 
month, regardless  of their benefits.56 There is no correlation between price of 
anticancer drugs in the US and magnitude of benefit.57,58  The US legislation for the 
FDA and for Medicare preclude negotiation on prices; many US states mandate that 
insurance plans cover anticancer drugs.39 
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• many health systems include incentives for oncologists to prescribe more expensive 
drugs.39  For example, medical oncologists in the US obtain a substantial proportion of 
their income from their sale and administration of anticancer drugs to patients.59 
 
These factors that drive up the prices of anticancer drugs in high income economies, affect 
their prices globally, and in Australia.  Chapter 3 examines the recent increases in expenditure 
and prices of anticancer drugs in Australia in more detail.  The next section of this 
background chapter describes how anticancer drugs are made available to individuals with 
cancer in Australia. 
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2.6 Anticancer drugs in the Australian healthcare system 
 
Access to medicines in Australia is governed by the National Health Act 1953 and informed 
by the National Medicines Policy.60,61  The central objectives of the policy include:61  
• “timely access to the medicines that Australians need, at a cost individuals and the 
community can afford; 
•  medicines meeting appropriate standards of quality, safety and efficacy; 
• quality use of medicines; and 
• maintaining a responsible and viable medicines industry”.  
 
 Marketing approval of anticancer drugs 2.6.1
For a prescription drug like an anticancer drug to be lawfully supplied in Australia, and made 
available to an individual with cancer, the Therapeutic Goods Administration (TGA) must 
first grant marketing approval.62  The TGA has the responsibility for assessing quality, safety 
and efficacy of drugs, much like the US FDA.63  Once marketing approval is granted, the drug 
is entered into the Australian Register of Therapeutic Goods (ARTG) and a medical doctor 
can prescribe it to a patient.64  However, listing on the ARTG does not mean the government 
subsidises the cost; government subsidy only occurs if the drug is also listed on the PBS, 
which is explained in the next section. 
 
 Public funding of anticancer drugs in Australia 2.6.2
The PBS is a taxpayer funded, multibillion-dollar, national drug formulary that subsidises the 
cost of listed prescription drugs.  The PBS is a significant component of the Australian 
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government’s National Medicines Policy.61,65  The PBS aims to obtain value for money (for 
taxpayers) by ensuring that additional expenditure results in a proportionate gain in positive 
health outcomes.66  Most prescription drugs available in Australia are subsidised through the 
PBS.67,68 PBS expenditure accounted for approximately 7% of total health expenditure in 
Australia in 2014-15.69 
 
The PBS subsidises anticancer drugs prescribed by oncologists and dispensed by pharmacists 
(community or hospital) that are listed on the PBS.  Prior to 1990, drugs provided to public 
hospital inpatients were specifically precluded by the PBS, and were generally covered by the 
public hospital’s drug budget (funded by the state government) at no cost to the patient.  More 
recently, anticancer drugs administered in public hospitals and specialist treatment centres 
have been covered by the PBS (Section 100 drugs).70  The PBS also covers PBS listed drugs 
administered to inpatients in private hospitals. 
 
In Australia, like many other countries, health technology assessments and 
pharmacoeconomic evaluations play an important role in determining whether anticancer 
drugs are subsidised by the government.71,72  Applications to list drugs on the PBS are 
assessed by the Pharmaceutical Benefits Advisory Committee (PBAC). Applications are 
made by a “sponsor”, usually a pharmaceutical company, but non-profit organisations or 
clinicians can also act as a sponsor.  Applications are prepared according to the PBAC 
guidelines.73  More details about the constitution, membership, and processes of the PBAC 
are provided in the following paragraphs and in section 2.8. 
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There are three decisions the PBAC can make when it is assessing an application to list a drug 
on the PBS.  The PBAC can make a positive recommendation to list the drug on the PBS, it 
can reject the application, or it can defer its decision.74  If the PBAC defers its decision or 
rejects an application, then the sponsor is invited to resubmit its application. Resubmissions 
may include updated evidence of clinical benefit, a revision of economic modelling, or a 
change in price. 
 
If the PBAC makes a positive recommendation about a drug, the Department of Health begins 
confidential negotiations with the pharmaceutical company about the price of the drug.75  This 
negotiation determines the dispensed price for maximum quantity (DPMQ) or dispensed price 
for maximum amount (DPMA), which is the maximum amount reimbursed to the pharmacist 
by the Australian government minus the patient co-payment (patient co-payments are 
discussed later in this section).  The DPMQ and DPMA is not the price the pharmaceutical 
company receives for the drug.  It includes the requested price (the ex-manufacturer price) 
and can include a wholesaler margin, a pharmacy mark-up and a dispensing fee.76-78 
 
Prior to 2014, price negotiations were conducted by the Pharmaceutical Benefits Pricing 
Authority.  Price negotiations are currently conducted directly by the Australian Government 
Department of Health.77  Price negotiations can involve risk-sharing agreements and managed 
entry schemes, especially for new high cost drugs.66  Such arrangements can be performance-
based or financially-based.73  For example, outcome data may be collected after a new 
anticancer drug is listed on the PBS and if the benefits are not as proposed, then the 
pharmaceutical company may have to provide a rebate to the Australian Government.   
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The final decision to list a drug on the PBS is made by the Federal Health Minister.  The 
Federal Health Minister cannot list a drug on the PBS without a positive recommendation of 
the PBAC.74  There is no explicit cap to the total PBS budget, but since 2013, the Federal 
Health Minister has required approval from the Federal Cabinet if a drug is expected to have 
cost the government more than A$20 million per year.79 
 
When a drug is listed on the PBS it may be categorised as:65 
i. unrestricted – can be prescribed and subsidised by the PBS without restriction on the 
therapeutic use 
ii. restricted – to attract a PBS subsidy it can only be prescribed for specific therapeutic 
indications stipulated in the PBS listing 
iii. authority required – to attract a PBS subsidy can only be prescribed for specific 
therapeutic indications stipulated in the PBS listing, and doctors need to seek approval 
from the Australian Government.  A doctor will declare (by use of a streamlined 
authority code, by phone, or by writing) the specific conditions and circumstances that 
justify the use of these drugs.   
 
Six weeks after the PBAC has met to make its decision, it publicly announces the outcomes 
on the website of the Australian Government Department of Health.  The PBAC releases a 
public summary document (PSD) approximately 10 weeks after its decisions are made 
public.80 PSDs are intended to provide the public with information about PBAC 
recommendations to help individuals with cancer, doctors and the community understand the 
rationale behind each recommendation.81 
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 Obtaining a prescription for an anticancer drug 2.6.3
For a patient to receive treatment with an anticancer drug it requires a consultation with a 
doctor – usually a specialist oncologist.  If appropriate, the oncologist can provide the patient 
with a prescription.  Patients may fill their prescriptions at a community pharmacy (e.g. for 
oral anticancer drugs), or treatment may be organised at a public hospital or specialist centre 
if the treatment requires parenteral administration (e.g. intravenous infusion). 
 
 Patient co-payments for prescription drugs listed on the PBS 2.6.4
Patients in Australia make a contribution to the cost of prescription drugs that are listed on the 
PBS.  As of 1 July 2017, the contribution or co-payment per prescription was A$6.30 for 
individuals with low incomes, and A$38.80 for all other individuals.76  The PBS also has a 
“Safety Net Scheme” which is aimed at protecting patients and their families from financial 
burden if they require a large number of prescription drugs that are listed on the PBS.  If a 
patient reaches a certain threshold within a calendar year they qualify for cheaper or free 
prescription drugs listed on the PBS for the rest of the year.76 
 
The co-payment amounts are the maximum amount that can be charged for a PBS 
prescription.  The amount may occasionally be less if the price of the drug is less than the co-
payment.  The costs of new anticancer drugs are much higher than the cost of the patient 
contribution.  The next section of this background chapter introduces anticancer drugs that are 
not listed on the PBS, referred to as ‘unfunded anticancer drugs’. 
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2.7 Unfunded anticancer drugs 
 
 Definition of an unfunded anticancer drug 2.7.1
When a prescribed anticancer drug is not listed on the PBS (i.e. is unfunded), patients may 
incur substantial out-of-pocket costs.  For the purpose of this thesis, in particular the studies 
presented in Chapters 5 and 6, unfunded anticancer drugs are defined as those: 
• not listed on the PBS, and 
• not used as part of a clinical trial or free access program, and 
• that require the patient to pay substantially more than standard pharmacy dispensing 
fees 
 
 Categories of unfunded anticancer drugs 2.7.2
Unfunded anticancer drugs can be categorised into those that are: 
• not listed on the ARTG (i.e. do not have marketing approval in Australia) 
• listed on the ARTG but not listed on the PBS for any indication 
• listed on the ARTG, and listed on the PBS for other indication(s), but not listed for the 
indication required by a particular patient 
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Anticancer drugs not listed on the ARTG 
An anticancer drug may not be listed on ARTG because:82 
• it has never been submitted by a sponsor for evaluation by the TGA 
• it has been evaluated by the TGA but was not recommended for listing on the ARTG 
• the sponsor has withdrawn the drug from the Australian market (this may be forced or 
voluntary) 
 
In some circumstances, a drug may be listed on the ARTG but not for all indications in which 
there is evidence of a therapeutic benefit.  This may be due to the same reasons outlined 
above and does not necessarily imply TGA disapproval for the specific indication.  There is 
no obligation or legislative requirement for a sponsor to submit all indications for a drug for 
evaluation by the TGA.  This situation often arises when the patent for a drug expires but the 
number of indications for use is still growing.82 
 
There are mechanisms by which individuals with cancer can access drugs that have not been 
approved for use in Australia.83  For example the TGA may grant a medical oncologist 
authority to become an authorised prescriber of an unapproved anticancer drug to specific 
patients under specific circumstances.  The TGA also has a Special Access Scheme which 
allows for the importation and/or supply of an unapproved therapeutic good, such as an 
anticancer drug, for a single patient, on a case-by-case basis.  The Category ‘A’ Special 
Access Scheme allows prescription of non-approved drugs for a life threatening condition.84 
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Another common way that individuals with cancer access anticancer drugs not listed on the 
ARTG is as participants in clinical trials.  Unregistered drugs used in clinical trials are usually 
provided to patients free-of-charge and are not considered further in this thesis. 
 
Anticancer drugs listed on the ARTG but not listed on the PBS 
It is possible in Australia for an anticancer drug to be listed on the ARTG, because it is safe 
and efficacious, but not listed on the PBS.  This situation arises when: 
• a sponsor has not made an application to the PBAC 
• an application to list an anticancer drug on the PBS has been judged by the PBAC to 
have insufficient comparative effectiveness or cost-effectiveness compared to the 
Australian standard of care 
• rarely, a drug is removed from the PBS list but retains its listing on the ARTG 
These drugs can be prescribed by an oncologist but their cost is not subsidised by the 
Australian government and must be borne by the patient or some other source.  
 
Some drugs listed on the ARTG never achieve PBS listing.  For example, vinflunine, which 
was listed on the ARTG for the treatment of advanced urothelial cancer in 2011, has not been 
PBS listed as of February 2018.85,86  For drugs that are PBS listed, there is typically a delay of 
many months, and sometimes a year or more, between TGA approval and PBS listing.87  
Patients who seek treatment with anticancer drugs in the interval between TGA approval and 
PBS listing face substantial out-of-pocket costs. 
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Anticancer drugs listed on the PBS for only some of the indications approved by the 
TGA 
When new anticancer drugs are listed on the PBS, their use is typically restricted to specified 
indications.  These specifications include the cancer type, stage of cancer, and/or previous 
treatments.  Sometimes a test is required as a condition of use which may further restrict the 
population in which the drug can be used.  For example, as of January 2018 pembrolizumab is 
listed on the ARTG for the treatment of metastatic melanoma, certain types of non-small cell 
lung cancer and recurrent or metastatic head and neck cancer.64  However, it is only listed on 
the PBS for the treatment of metastatic melanoma.86  
 
Over time, older anticancer drugs are sometimes recategorised as ‘Unrestricted’ (see 
definition of ‘unrestricted’ in section 2.6).  This usually occurs when the price drops 
substantially because patents have expired and cheaper generics have become available.  
Examples of anticancer drugs that have been recategorised as unrestricted and subsidised 
regardless of indication are paclitaxel and irinotecan.86 
 
 Paying for unfunded anticancer drugs 2.7.3
Patients seeking treatment with an unfunded anticancer drug have a few options for gaining 
access.  They may pay the full price of the anticancer drug after receiving a “private 
prescription” from a doctor.88  Some public hospitals provide their patients access to unfunded 
anticancer drugs, usually based on an application from a medical specialist, and with major 
differences between institutions in what they will provide.89  Some private health insurers 
may, on a case by case basis, provide partial coverage of anticancer drugs not listed on the 
PBS.  Charitable organisations like the John Logan Foundation and Rare Cancers Australia 
allow patients to apply for subsidies to help pay for expensive unfunded anticancer drugs.90,91  
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Fundraising by community groups, social networks, and using social media (“crowd 
funding”), has also been used to help pay for expensive unfunded anticancer drugs. 
 
One of the most common mechanisms for individuals with cancer to access unfunded 
anticancer drugs outside a clinical trial is through pharmaceutical company shared access or 
compassionate access programs.89  Pharmaceutical companies usually start these schemes 
when they judge that their commercial launch is imminent (within 6 months).  In Australia, 
this means that there is data on effectiveness, safety, and cost-effectiveness sufficient to 
support successful applications to the TGA and PBAC.89  These programs typically involve a 
cost-share arrangement between the pharmaceutical company and the patient.  Some 
programs provide the anticancer drug to the patient free of charge.  These programs are akin 
to “product familiarisation programs” designed to familiarise prescribers with a new medicine 
approved by the PBAC, while PBS listing is pending.92  The study presented in Chapter 5 
only considers anticancer drugs provided by these programs if they require additional out-of-
pocket payments by patients. 
 
Pharmaceutical companies are not obliged to supply anticancer drugs listed on the ARTG 
through a shared access or compassionate access program, and those that do exist are not 
always transparent.89  For example it is not always clear about how many patients may access 
the program, and they may be inequitable because they are only available in a limited number 
of locations.75,93  Availability of access programs and their specific arrangements can also 
differ substantially between companies with similar drugs. 
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 Unfunded anticancer drugs in other countries 2.7.4
There are no published studies comparing the proportion of anticancer drugs that are available 
(i.e. have marketing approval) but unfunded (i.e. not publicly subsidised) between Australia 
and other countries that also use a health technology assessment process for decisions about 
their public subsidy. Studies that compare public subsidy decisions between Australia, the UK 
and Canada demonstrate similar rates of rejection.72,94,95 The rates of rejection could be 
considered a surrogate for the proportion of unfunded anticancer drugs available in each 
country and therefore the proportion available in each country is plausibly similar. 
 
The next section in this background chapter introduces the determination of the value of 
anticancer drugs.  Specifically, it examines how healthcare payers determine if the value of an 
anticancer drug is sufficient for them to subsidise it, and how individuals determine if the 
value of an anticancer drug is sufficient for them to be treated with it. 
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2.8 Determining the value of anticancer drugs: decisions about funding and 
treatment 
 
 Definition of value 2.8.1
Value is a multi-faceted concept with many definitions.96  In health care, value can be thought 
of as the health outcomes achieved per unit of money expended.37,97  Although costs are an 
important element of the value equation, they only matter relative to the outcomes achieved 
and therefore value can be considered outcome-focused.97  Ramsey & Schickedanz define a 
valuable intervention as one for which: “patients, their families, physicians, and health 
insurers all agree that the benefits afforded by the intervention are sufficient to support the 
total sum of resources expended for its use”.96 
 
Measuring the value of a cancer treatment is challenging.97,98  The potential benefits, harms, 
and costs are complex, multidimensional, and uncertain for any individual.97  The main 
domains of value considered in cancer care are: length of life, quality of life, and healthcare 
costs.  The effects of anticancer treatments on these domains can be positive (e.g. lengthen 
life by delaying or preventing cancer progression; improve quality of life by relieving or 
delaying cancer-related symptoms; reduce downstream costs), or negative (e.g. shorten life by 
treatment-related mortality; impair quality of life with adverse effects of treatment; and 
increase downstream costs).96  Value determination is essential for rational decision-making 
about healthcare policy for society, and about clinical practice in individuals.  The next 
sections describe the perspectives for determining value, and the outcomes and costs of 
anticancer drugs that are the major determinants of their value.   
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 Defining perspectives for determining value 2.8.2
The perspective of the decision-maker is an important consideration when determining the 
value of a treatment.96  In health economics, perspective is often defined in terms of the 
‘payer’ for the intervention being valued.99  In Australia, while there are multiple payers for 
health care in general, there are only two main ‘payers’ for anticancer drugs: the Australian 
Government, via the PBS, on behalf of Australian taxpayers (a healthcare funder perspective); 
and individuals (patients) paying for their own treatment, sometimes without government 
subsidies (an individual healthcare user perspective).  This thesis restricts its focus to these 
two main perspectives from which the value of an anticancer drug is determined in Australia.  
 
From the perspective of the Australian healthcare funder, value is determined on behalf of the 
Australian government and taxpayers by the PBAC.  This may be described as a healthcare 
system perspective, as distinct from a societal perspective, because its view of benefits and 
costs is narrower.  For example, the perspective of the Australian healthcare funder accounts 
for the costs of anticancer drugs to the health budget, and the benefits to individuals receiving 
treatment, but it does not include wider societal costs and benefits such as the indirect costs of 
having treatment (e.g. loss of productivity from a caregiver taking time off work to care for a 
patient receiving intensive treatment).  In this thesis, the term healthcare funder will be used 
to denote the perspective of the Australian Government. 
 
From the perspective of the individual healthcare user, value is determined in terms of direct 
benefits and costs to the individual, ignoring benefits and costs to the healthcare system 
and/or society as a whole. For example, an individual paying for their own treatment with an 
anticancer drug is likely to put greater weight on their own out-of-pocket costs than the costs 
that are attributable to the Australian government.  In this thesis, the term individual 
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healthcare user will be used to denote the perspective of individuals (patients) seeking 
treatment with anticancer drugs.  Other perspectives that are relevant, but not considered in 
this thesis, include private health insurers, public hospitals, and other providers or funders of 
health care. 
 
 What are the outcomes of treatment with anticancer drugs?  2.8.3
An outcome is a consequence of interest.  Medical treatments typically have multiple 
outcomes: some positive (benefits) and others negative (harms).  The outcomes used to judge 
the value of anticancer drugs should be patient-centred, in other words they should be 
important to patients (relevant) and affect them directly.97  
 
The potential positive outcomes (benefits) of treatment with an anticancer drug that are most 
relevant to patients include: increasing the chance of cure, increasing survival time (overall 
survival), and improving quality of life (by reducing, delaying, and/or preventing cancer-
related symptoms).  These benefits may be brought about by tumour shrinkage resulting in a 
surrogate outcome of tumour response, or a reduction of tumour growth resulting in a 
surrogate outcome of prolonged time to progression.  However, tumour response and time to 
progression are outcomes reflecting the biological activity of an anticancer drug, and while 
they may be associated with other direct benefits to individuals, they are not, in themselves, 
sufficient to qualify as a direct benefit to an individual.100 
 
The potential negative outcomes (harms) of treatment with anticancer drugs that are most 
relevant to patients include: earlier than expected death due to an adverse effect, impaired 
quality of life due to adverse effects, and financial burden due to the costs of treatment.37,100  
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Other important harms that are not considered further in this thesis include the inconvenience 
of having treatment (e.g. the time spent having treatment) and burdens placed on family 
members and/or caregivers.  
 
The information regarding the possible benefits and harms of treatment with an anticancer 
drug comes predominantly from individual clinical trials, or from systematic reviews and 
meta-analyses of multiple clinical trials.  Other possible sources of information include 
registries, clinical databases, and case series.  Pivotal studies of new, expensive anticancer 
drugs are typically randomised, phase 3 trials designed to demonstrate benefits in overall 
survival.101  However, many pivotal phase 3 trials use surrogate endpoints such as recurrence-
free survival or progression-free survival.  These surrogate endpoints are accepted by 
regulatory authorities if they have been previously demonstrated to be valid surrogates for 
more direct measures of patient benefit, such as overall survival, in the relevant setting.  For 
example, the US FDA regards recurrence free survival as a validated surrogate endpoint for 
trials of adjuvant endocrine therapy in early breast cancer.102  Improvements in surrogate 
endpoints often do not translate into improvements in survival or quality of life and therefore 
should be interpreted cautiously without evidence of benefit in these more desirable 
endpoints.103,104 
 
 What are the costs of treatment with anticancer drugs in Australia? 2.8.4
The costs of treatment with anticancer drugs include costs directly related to treatment (e.g. 
the cost of purchasing an anticancer drug; cost of administration of treatment; cost of treating 
a side effect), and indirectly related to treatment (e.g. loss of income due to inability to work; 
costs borne by family and/or caregivers).105  The costs of anticancer drugs studied in this 
thesis are restricted to those relevant to the perspective of the healthcare funder and individual 
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healthcare user.  These include the Australian government’s expenditure on anticancer drugs 
(Chapters 3 and 4), and the out-of-pocket costs borne by patients for treatment with anticancer 
drugs not listed on the PBS (Chapters 5 and 6).  These studies focus on the costs of 
purchasing anticancer drugs and ignore other costs associated with treatment.  Costs of 
anticancer drugs borne by private health insurers, or by private and public hospitals, were also 
not considered in this thesis. Such costs are haphazardly held in multiple unlinked databases, 
which are not publicly available. Obtaining such data was not feasible for this thesis. The 
costs borne by private health insurers and hospitals for purchasing anticancer drugs is likely to 
be a very small proportion of the purchasing costs of anticancer drugs in Australia, which is 
undertaken by the Australian government through the PBS. The costs of treating side effects 
of anticancer drugs however would be largely borne by hospitals, but these, and the indirect 
costs related to treatment with anticancer drugs was beyond the scope of this thesis.  
 
Information regarding the possible cost of treatment with an anticancer drug, for Australian 
patients, depends on whether it is listed on the PBS.  For anticancer drugs listed on the PBS, 
the costs to patients are relatively modest and covered earlier in section 2.6.  For anticancer 
drugs not listed on the PBS, the costs to patients depend on the price(s) set by the sellers – 
pharmacies, wholesalers, importers and pharmaceutical companies.   
 
Determining the cost to a patient for one months’ worth of treatment or a single prescription is 
relatively straightforward.  Determining the cost of a course of treatment can be much more 
difficult.  For a patient receiving adjuvant, neoadjuvant or definitive treatment, the planned 
duration of treatment (i.e. number of months and/or cycles) is generally specified by the 
clinical trial from which the evidence of benefit is derived.  Therefore, the total cost of the 
prescribed treatment can be estimated.  However, for patients with advanced cancer, the 
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duration of treatment is generally uncertain because many protocols specify continuing 
treatment in the absence of cancer progression or prohibitive toxicity.  Mean and median 
times on treatment in the pivotal clinical trial(s) may provide guidance on average and typical 
durations of treatment, and therefore average and typical costs to patients, but the ranges are 
often wide and the uncertainties substantial.  
 
 Determining value of anticancer drugs from the perspective of the Australian 2.8.5
healthcare funder  
 
Who is involved? 
The PBAC is the main body responsible for determining the value of anticancer drugs from 
the perspective of the Australian government.  The PBAC is an expert body, appointed by the 
Health Minister, but independent from the Australian Government.  It makes 
recommendations to the Health Minister about which drugs should be listed on the PBS. 
Members of the PBAC include health professionals (e.g. doctors and pharmacists), health 
economists, and consumer representatives.106  
 
How does the PBAC determine value?  
The PBAC uses a number of criteria to estimate the value of an anticancer drug when 
assessing applications requesting listing on the PBS.73  These include quantitative factors:  
• comparative health gain – includes the safety and effectiveness of the anticancer drug 
being valued compared with the standard of care, and takes into account both the 
magnitude and importance of its effects 
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• comparative cost-effectiveness – takes into account the incremental costs and 
incremental effects of the drug to be listed when compared with the current standard 
of care.  
• the predicted impacts on the PBS budget and the Australian government healthcare 
budget 
 
The PBAC also takes into account less quantifiable factors including:73  
• the level of certainty or confidence in the clinical and economic evidence submitted – 
hence their certainty in the value of the anticancer drug 
• the severity of the condition the drug is intended to treat 
• ability to target the drug to patients likely to benefit the most 
Other factors that the PBAC may consider include:73 
• affordability to the patient in the absence of PBS subsidy 
• the clinical need of the drug (e.g. by assessing the presence of effective alternatives)  
• equity of access 
• issues that may affect public health as a result of the application 
These factors are consistent with those considered by health technology assessment bodies in 
other countries, for example the National Institute for Health and Care Excellence (NICE) in 
the UK, and the Canadian Agency for Drugs and Technologies in Health in Canada.71,72 
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Cost-effectiveness and the Quality-Adjusted Life Year 
The cost-effectiveness of a new anticancer drug is arguably the most direct measure of its 
value that the PBAC determines.  At its inception in 1953, decisions to add new drugs to the 
PBS were based on clinical considerations only, but since 1993 the PBAC has been required, 
by law, to consider cost-effectiveness.66,75  The aim of this change was to ensure that 
government expenditure on new drugs represented value for money.  Analyses of cost-
effectiveness are pivotal when the PBAC considers application for listing new drugs, but it 
does not use a strict threshold for cost-effectiveness, unlike other similar bodies like 
NICE.72,74  
 
The PBAC considers cost-effectiveness by evaluating evidence submitted by sponsors about 
the incremental cost-effectiveness of a new drug compared with the current standard of care.  
The incremental cost-effectiveness is defined as the incremental cost-effectiveness ratio 
(ICER), that is the difference between the average costs of two treatments divided by the 
difference between their average effects.99   The ICER represents the “additional cost for 
obtaining one additional unit of outcome (e.g. one additional year of life) for the new 
intervention compared with the old intervention”.105   
 
The outcome measure of effect preferred by the PBAC is the quality-adjusted life year 
(QALY).73  A QALY represents health over time (years of life) weighted by the preference 
for living in a particular state of health.105,107  One QALY is equivalent to a year of life in 
perfect health. A major advantage of using QALYs for health technology assessments is that 
it allows direct comparisons of value across different interventions and different 
diseases.107,108  Cost-effectiveness can also be evaluated using other health measures, for 
example overall survival, which would be presented as the cost per life year gained. 
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 Determining value of anticancer drugs from the perspective of an individual 2.8.6
healthcare user  
 
Who is involved? 
A diagnosis of cancer usually results in referral to one or more doctors specialising in cancer 
for information and advice about treatment options.  Such specialists include surgeons, 
radiation oncologists, and medical oncologists.  Anticancer drugs are usually recommended 
and prescribed by medical oncologists, so this thesis focuses on interactions between medical 
oncologists and their patients.  
 
What is the decision-making framework for oncologists and patients? 
When deciding about treatment with anticancer drugs, oncologists and patients usually use a 
framework of shared-decision making.  Shared decision-making means that the oncologist 
and patient jointly participate in making a decision about treatment after discussing the 
options and their associated benefits, harms and costs.109  The circumstances and preferences 
of the patient, and of their oncologist, affect this complex process.110,111  Ultimately, it is the 
patient who weighs up the trade-offs between the benefits, harms, and costs of competing 
treatment options, with the assistance of their oncologist.112  
 
Decision-making about treatment with an anticancer drug typically occurs during one or more 
meetings (consultations) between an individual with cancer and their medical oncologist(s). 
These consultations usually occur in an ambulatory (outpatient) clinic, but can occur while the 
individual is hospitalised (an inpatient).  Family members, friends and/or carers may also be 
present and involved in the decision-making process.  Other health professionals may also 
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speak with the patient (e.g. specialist oncology nurse) to provide additional information about 
treatment options.  
 
Oncologists gather all the appropriate information about the individual with cancer and their 
diagnosis.  This includes detailed information about the individual’s current problem and 
medical history, their social circumstances and the results of any investigations already 
undertaken.  A recommendation for treatment can then be made by the oncologist. In some 
cases, there may be multiple appropriate treatment options.  
 
What information should oncologists provide to help individuals with cancer determine 
the value of an anticancer drug?  
To ensure that a healthcare user can make an informed decision the oncologist needs to 
explain the potential pros and cons of the treatment options available.  This means discussing 
the potential benefits and harms of treatments, including their costs.37  The benefits and harms 
of anticancer drugs relevant to individuals (patients) were outlined earlier in this section, and 
that the information is usually garnered from published reports of clinical trials.  
 
For example when discussing treatment options with a patient who has an advanced cancer, 
oncologists may explain the expected survival benefit of treatment with anticancer drug A 
versus anticancer drug B based on reports of one or more randomised trials.  The reported 
survival benefit can be communicated in multiple ways.113  For example, the oncologist may 
explain that, “on average”, patients treated with drug A lived 3 months longer than those 
treated with drug B.  Alternatively, the oncologist might explain that 30% of patients treated 
with drug A were alive at 1 year, versus 15% of patients treated with drug B.  Oncologists are 
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trained to make treatment recommendations based on evidence from clinical trials, but 
applying this evidence to an individual patient’s circumstances can be challenging.114  
 
The harms of treatment are also discussed.  One of the potential harms of treatment with an 
anticancer drug is the financial burden of their costs.  Meeting the costs of an expensive 
treatment can impair an individual’s quality of life. The terms “financial toxicity” and 
“financial harm” were coined to denote this problem, and to indicate that costs of treatment 
should be disclosed like other possible adverse effects of treatment.115,116  Financial toxicity 
has been defined by Zafar as the “harmful personal financial burden faced by patients 
receiving cancer treatment”.117  However, information about costs is often undisclosed or 
unknown.118  When costs are discussed, they are usually those incurred directly by the 
healthcare user – out-of-pocket costs – rather than those incurred by the healthcare system or 
insurers. For example, an oncologist may tell a patient about an unfunded anticancer drug that 
will cost the patient approximately $5,000 per month and that it has better survival outcomes 
than the PBS-listed alternative that will cost the patient approximately $40 per month.  It is 
important to discuss these costs because they may influence the patient’s decisions.  For 
example patients may wish to choose a less expensive but less effective alternative to avoid 
financial harm.115 
 
Considerations other than the direct benefits, harms, and costs of treatments may also 
influence the valuation of a treatment by an individual user of healthcare.37,98,114  These 
include: 
• the clinical setting and goals of treatment (e.g. is the intent of treatment curative or 
palliative?) 
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• convenience of treatment (e.g. oral vs intravenous administration, frequency of visits, 
duration of treatment) 
• the individual’s financial circumstances and insurance coverage  
• the individual’s age, comorbidities, and other life circumstances 
• the individual’s attitudes, values, priorities, and goals 
 
Oncologists guide patients through the shared decision-making process, and should ensure 
that patients are aware of all the relevant considerations.  However, consideration of the 
additional factors listed above reminds us of the potential for oncologists’ values, preferences, 
and priorities to influence a patient’s decision-making.110,111  Oncologists themselves should 
consider their own values, priorities and preferences, and how these might affect their advice 
and recommendations to patients.  For example, an oncologist’s greater familiarity and 
comfort with older anticancer drug X may influence their willingness to prescribe it rather 
than the new less familiar anticancer drug Y.  There are also likely to be differences in how 
individual oncologists value the various attributes of anticancer drugs.119 
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2.9 Summary 
 
This chapter provided an overview of the background information needed to understand the 
subsequent chapters in this thesis.  It first introduced cancer and how anticancer drugs are 
used to treat it (sections 2.2 and 2.3).  In Australia, the incidence of cancer is increasing, but 
the mortality rate of cancer is decreasing. Improvements in mortality are partly due to 
treatment with anticancer drugs. 
 
Section 2.4 provided a brief summary of the Australian healthcare system.  Health care in 
Australia is funded both publicly (by government) and privately (by individuals and private 
insurers).  Australians affected by cancer may seek advice and treatment in the public system, 
the private system, or a mixture of both. 
 
Section 2.5 explained that healthcare costs are rising in Australia, partly due to the rising cost 
of new anticancer drugs.  It outlined a number of possible reasons for increasing expenditure 
on anticancer drugs, including the increasing incidence of cancer, the growing number of 
available anticancer drugs, and the increasing price of new anticancer drugs.  The reasons for 
the high prices of new anticancer drugs include the costs of research, development, marketing, 
and the profit motive of pharmaceutical companies.   
 
Section 2.6 explained how anticancer drugs are made available to individuals with cancer in 
Australia.  To be lawfully supplied, anticancer drugs must be approved by the TGA.  Public 
subsidy depends on a recommendation for listing on the PBS by the PBAC, based on cost-
effectiveness.  This was followed by an explanation of how individuals with cancer can access 
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unfunded anticancer drugs: those that are not listed on the PBS (section 2.7).  Patients seeking 
treatment with an unfunded anticancer drug must find some way of covering the costs of 
buying the drug, either by paying for it themselves, or having the costs covered by some other 
body, for example: a public hospital, charitable organisation, or the pharmaceutical company 
via a shared access or compassionate access program. 
 
The final section (2.8) of this introductory background chapter introduces the idea of value 
determination from the perspective of healthcare funders making decisions about funding the 
healthcare system and from the perspective of individual users of healthcare making decisions 
about their own treatment.  The PBAC determines value based on analyses that determine the 
incremental cost-effectiveness of a new treatment compared with the established standard of 
care.  Individual users of healthcare determine the value of a treatment within a framework of 
shared decision-making, supported by their doctors.  For individuals affected by cancer 
seeking advice and treatment about new anticancer drugs, this means having their oncologist 
explain the possible benefits, harms, and costs of the available treatment options.  
 
The next chapter of this thesis provides additional, more detailed background information 
about the rising costs of anticancer drugs in Australia. 
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3 RISING COST OF ANTICANCER DRUGS IN AUSTRALIA 
 
3.1 Overview 
 
Chapter 3 is a published work aimed at a clinical audience. It is a report on the costs of 
anticancer drugs in Australia.  The reasons for the rising cost of anticancer drugs, and the 
implications, are explored and complement the information discussed in Chapter 2.  The 
entire manuscript is quoted verbatim.  
 
Publication details 
Karikios DJ, Schofield D, Salkeld G, Mann KP, Trotman J, Stockler MR. Rising cost of 
anticancer drugs in Australia. Intern Med J; 44:458-63, 2014. 
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DJK conceived and developed the research proposal and methods, collected and analysed the 
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manuscript. 
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manuscript. 
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JT contributed to the research proposal, interpretation of findings and revision of the 
manuscript. 
MS conceived the research proposal and methods, and contributed to the interpretation of the 
findings and revision of the manuscript. 
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3.2 Abstract 
 
Background 
Anticancer drugs are often expensive and are contributing to the growing cost of cancer care.  
Concerns have been raised about the effect rising costs may have on availability of new 
anticancer drugs. 
 
Aim 
This study aims to determine the recent changes in the costs of anticancer drugs in Australia.  
 
Methods 
Publicly available expenditure and prices paid by the Australian Pharmaceutical Benefits 
Scheme (PBS) for anticancer drugs from 2000 to 2012 were reviewed.  The measures used to 
determine changes in cost were total PBS expenditure and average price paid by the PBS per 
prescription for anticancer drugs and for all PBS listed drugs.  An estimated monthly price 
paid for newly listed anticancer drugs was also calculated.  
 
Results 
Annual PBS expenditure on anticancer drugs rose from A$65 million in 1999-2000 to A$466 
million in 2011-2012; an average increase of 19% per annum.  The average price paid by the 
PBS per anticancer drug prescription, adjusted for inflation, increased 133% from A$337 to 
A$786.  The real average annual increase in the price per anticancer drug prescription was 
more than double that for all other PBS drugs combined (7.6% vs 2.8%, difference 4.8%, 95% 
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confidence interval -0.4% to 10.1%, p=0.07).  The median price for a month’s treatment of 
the new anticancer drugs listed was A$4919 (range A$1003 to A$12578, 2012 prices).  
 
Conclusions 
PBS expenditure and the price of anticancer drugs in Australia rose substantially from 2000 to 
2012.  Dealing with these burgeoning costs will be a major challenge for our health system 
and for those affected by cancer.   
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3.3 Introduction  
 
The cost of health care is rapidly rising.  Health spending in Australia in recent years has 
increased at a faster rate than spending on all other goods and services.120  This increase in 
costs creates major challenges for healthcare systems, particularly those like Australia’s that 
are publicly funded.  
 
The cost of cancer care has more than doubled over the past 20 years with a most recent 
estimate of over A$5 billion per year in 2009.121  The causes are complex and include the 
growing availability and use of new and expensive anticancer drugs.122  Spending on drugs is 
one of the fastest growing components of healthcare costs in developed countries.120  
Anticancer drugs are estimated to represent 10% of cancer costs in Organisation for Economic 
Co-operation and Development countries.33 
 
Concerns have been raised about the effects of rising prices on the availability of new 
anticancer drugs.33,123,124  In Australia, widespread access to expensive drugs depends on 
whether they are listed on the PBS. PBS listing requires a favourable assessment of cost-
effectiveness which is not forthcoming for every effective anticancer drug.  Gaining access to 
effective anticancer drugs that are not listed on the PBS is a major dilemma for patients and 
doctors.  However, we were unable to find published reports focusing on the costs of 
anticancer drugs in Australia that might inform clinicians and patients facing this increasingly 
common challenge.  
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The aims of this study were to:  
i. determine changes in PBS expenditure on anticancer drugs from 2000 to 2012; 
ii. compare price increases for anticancer drugs to other drugs listed on the PBS; 
iii. determine the monthly price paid for newly listed anticancer drugs; and, 
iv. consider the reasons for, and implications of, our findings. 
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3.4 Methods  
 
 PBS expenditure and average prescription prices  3.4.1
We determined annual expenditure and prescription volumes for all PBS listed drugs, and for 
anticancer drugs (using the PBS subcategory Anti-neoplastics), from the publicly available 
Pharmaceutical Benefits Pricing Authority Annual Reports (2000- 2010) and PBS 
Expenditure and Prescription reports (2003-2012).125,126  The average price paid by the PBS 
per prescription was calculated by dividing the total expenditure by prescription volumes for 
each year.  Patient co-payments were not included in these calculations.  All prices were 
adjusted to reflect 2012 values (“real” prices) using the average health prices inflation figure 
of 3.0% from 1999-2000 to 2010-2011.120,127 
 
 Monthly prices of newly listed anticancer drugs 3.4.2
PBS schedules from January 2000 to June 2012 were searched for listings of new anticancer 
drugs that were categorised under the PBS subcategory Anti-neoplastics.128  Drugs that were 
listed on the PBS prior to 2000 but granted additional indications from 2000 to 2012 were not 
included.  Prices paid by the PBS for a month’s treatment (28 days) were calculated for each 
new anticancer drug using the recommended schedule and ‘typical’ dose calculated for a 
patient with body surface area (1.73m2) and/or body weight (70kg).129  If a drug dose varied 
during a treatment protocol, then the dose used for the majority of the protocol was chosen for 
the typical dose calculation.   
 
For each new anticancer drug listed, the dispensed price for maximum quantity was 
determined from the PBS schedule in the year the drug was listed.128  An approximation of 
the price paid by the PBS for each dose was determined by calculating the proportion of the 
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maximum quantity required for a typical dose.  For intravenous drugs, we determined the 
price using the most efficient combination of vials required for the typical dose.  The 
estimated price paid per month was determined by multiplying the price per dose by the 
number of doses required per month.  
 
We did not consider anticancer drugs listed under subcategories other than Anti-neoplastics, 
for example, endocrine therapies, vaccines, supportive care drugs, and drugs for non-
melanoma skin cancer.   
 
 Statistical analysis 3.4.3
Descriptive statistics were used to analyse the monthly prices of new drugs listed on the PBS.  
A paired t-test was used to compare the annual average price rise in anticancer drugs to the 
annual average price rise for all other PBS listed drugs combined.  Data were analysed with 
SPSS version 20.  
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3.5 Results 
 
PBS expenditure on anticancer drugs and the average price paid by the PBS for anticancer 
drugs both climbed markedly from 2000 to 2012.  Expenditure on anticancer drugs rose from 
A$64.8 million in 1999-2000 to A$466.3 million in 2011-2012.  The peak expenditure 
occurred in 2010-2011 and was A$561.3 million (Figure 3.1).  PBS expenditure, excluding 
anticancer drugs, climbed at a lower rate from A$3.1 billion in 1999-2000 to A$8.6 billion in 
2011-2012.  The average annual increase in PBS expenditure on anticancer drugs over this 
time period was 19.1% compared with 9.0% for all other drugs combined.  Expenditure on 
anticancer drugs was a small but growing proportion of total PBS expenditure: 2.0% in 1999-
2000, 6.4% in 2010-2011 and 5.1% in 2011-2012 (Figure 3.2).   
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Figure 3.1. Pharmaceutical Benefits Scheme expenditure on anticancer drugs (without 
adjustment for inflation) 
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Figure 3.2. Percentage of Pharmaceutical Benefits Scheme expenditure on anticancer drugs 
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The average price paid by the PBS per anticancer drug prescription increased 133% in real 
terms from A$338 in 1999-2000 to A$786 in 2011-2012 (all adjusted to 2012 prices, Figure 
3.3).  The average price reached a peak of A$850 in 2009-2010.  The average price paid by 
the PBS for all prescriptions, excluding anticancer drugs, increased 37% in real terms from 
A$32 to A$44.  The real average annual increase in the average price paid by the PBS per 
anticancer drug prescription from 2000 to 2012 was more than double that for all other PBS 
drugs combined (7.6% vs 2.8%), but this trend was not statistically significant (difference 
4.8%, 95% confidence interval -0.4% to 10.1%, p=0.07). 
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Figure 3.3. Average price paid by the Pharmaceutical Benefits Scheme (PBS) per 
prescription: all anticancer drugs versus all other PBS drugs (adjusted to 2012 prices) 
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There were 23 new anticancer drugs listed on the PBS between January 2000 and June 2012 
(Table 3.1).  Most drugs were listed in the second half of the study period, and 14 of the 23 
(61%) were listed for treatment of solid malignancies. Chronic myeloid leukaemia was the 
malignancy with the highest number of new drugs listed.  The median price for a month’s 
treatment of the new anticancer drugs listed during the study period was A$4919 (2012 
prices).  Prices per month for individual drugs ranged from A$1003 to A$12578 (Figure 3.4; 
See Appendix 10.1 for list of individual drugs).  
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 Characteristics of newly listed anticancer drugs (2000 – 2012) Table 3.1.
Drug characteristics n (%) 
Total  23 
Year PBS listed  
   2000 – 2006 
   2007 – 2012  
9 (39) 
14 (61) 
Drug class  
   Cytotoxics 
   Tyrosine kinase inhibitors 
   Monoclonal antibodies 
   Other 
8 (35) 
8 (35) 
3 (13) 
4 (17) 
Tumour type   
   Chronic myeloid leukaemia  
   Myeloma 
   Breast 
   Colorectal 
   Lung 
   Other 
4 (17) 
3 (13) 
3 (13) 
3 (13) 
3 (13) 
7 (30) 
PBS: Pharmaceutical Benefits Scheme 
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Figure 3.4. Monthly prices for newly listed anticancer drugs (adjusted to 2012 prices) 
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3.6 Discussion 
  
This is the first report in the medical literature describing the increasing costs of anticancer 
drugs to the Australian PBS.  The sevenfold increase in expenditure from 2000 to 2012 is 
identical to that seen in Europe from 1993 to 2004.130  The median price paid by the PBS for a 
year’s treatment of the new anticancer drugs listed during the study period was approximately 
A$60,000 in 2012 prices.  The average price paid by the PBS per prescription for anticancer 
drugs has more than doubled in real terms, climbing an average of 7.6% per annum, which 
echo US price rises over a similar period.131   In comparison, the average price paid by the 
PBS for all other PBS drugs combined has increased more gradually.  
 
The many and complex reasons for the rise in PBS expenditure on anticancer drugs include 
increases in the prevalence of cancer and in the proportions of patients for whom there are 
suitable treatments.132  The 7.6% rise per annum in the average price paid by the PBS per 
prescription for anticancer drugs is driven by rapid growth in the number of new expensive 
drugs.  This may explain why the average prices paid for prescriptions used to treat other 
high-burden diseases, in which the number of newly available drugs has grown more slowly, 
have changed much less.  For example, for drugs used to treat diabetes, the average annual 
increase in the average prescription price paid by the PBS over the study period was 1.6%, 
while for lipid-modifying drugs and psychoanaleptics used to treat mental illness, there have 
been average annual falls of 2.4% and 2.0% respectively.125,126 
 
The effort to develop newer and better drugs to treat patients with cancer has resulted in over 
70 anticancer drugs being currently listed on the PBS, many with multiple indications.128  The 
United States (US) Food and Drug Administration approved 12 new anticancer drugs in 2012 
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alone.56  Some have argued that the price of new anticancer drugs is increasing rapidly 
because of the increasing cost of drug development, with estimates ranging from A$500 
million to A$2 billion per new drug approved.133  This figure includes substantial expenditure 
on drugs that fail to reach the market.  For example, it is estimated that of the 920 drugs tested 
in clinical trials between 1990 and 2006, only 32 were approved in the US.134  Debate 
continues about whether these costs justify the asking price for new anticancer drugs, 
particularly when marketing budgets and profits are also substantial.56 
 
Many new anticancer drugs are molecularly targeted and are substantially more expensive 
than traditional cytotoxic drugs.130  The beneficial effects of targeted anticancer drugs are 
usually confined to a subgroup of all patients.  The presence of a testable molecular target 
offers the potential to identify and treat only those for whom treatment is most likely to be 
beneficial.  This reduces the total number of patients to be treated, which should reduce total 
costs, but also provides a commercial rationale for increasing the price to make up for a 
smaller market.  Another factor tending to increase the total costs of molecularly targeted 
agents is that they are often used for longer periods than their cytotoxic counterparts.135  
Furthermore, older anticancer drugs are commonly not phased out with the introduction of 
new drugs but rather used sequentially or in combination which also significantly contributes 
to growing costs.40 
 
Reductions in prices of anticancer drugs due to the availability of generic equivalents can help 
mitigate the effect of expensive new drugs on the growth rate of expenditure.  Australia’s 
pricing and reimbursement system may result in a lower price for new drugs, but a higher 
price for generic drugs, in comparison with similarly developed countries.136  Therefore, the 
potential cost savings due to the use of generic drugs may not be as substantial in Australia as 
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in other developed countries, an effect that is compounded by the speed of oncology drug 
development.  Newer, more expensive versions of existing anticancer drugs that are either 
equivalent or offer only modest additional benefits may penetrate the market and reduce the 
use of cheaper generics by making them seem suboptimal and superseded.40   
 
This study is limited by its short time frame (2000 to 2012) and focus on drugs listed under 
the Anti-neoplastics subcategory which does not include endocrine drugs used to treat breast 
cancer or prostate cancer or immunomodulating drugs, such as the colony stimulating factors 
commonly used in conjunction with chemotherapy.  Our estimates of the monthly prices for 
new anticancer drugs are based on the price listed on the PBS schedule, whereas the actual 
prices paid by the PBS are negotiated in confidence by the Pharmaceutical Benefits Pricing 
Authority, and can involve special pricing arrangements and risk sharing agreements.137  This 
study also ignores variations in total costs attributable to variations in durations of use. 
 
It was surprising to see that total expenditure on anticancer drugs and the average prescription 
price paid by the PBS dropped in 2011-2012.  This was partly due to PBS listing of cheaper 
generics for high-use drugs such as docetaxel and the introduction of the Australian 
Commonwealth government’s Efficient funding of chemotherapy drugs policy.138 
 
Despite rapid rises in total expenditure on anticancer drugs, and in the average price paid by 
the PBS per prescription, anticancer drugs accounted for less than 6% of the total PBS budget 
in 2012.  Anticancer drugs are estimated to account for about 10-15% of expenditure on 
cancer care; hospitalisation of cancer patients is estimated to account for about 70%.13  
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Nevertheless, the rising costs of anticancer drugs substantially strain publicly funded 
healthcare systems like Australia’s.  
 
The Pharmaceutical Benefits Advisory Committee (PBAC), the body that makes 
recommendations to the Federal Health minister as to whether new drugs should be publicly 
reimbursed, is just as likely to make a positive recommendation for an anticancer drug as it is 
for other drugs.139  Despite this, the high price asked for many new anticancer drugs often 
results in an initial rejection for PBS listing due to the PBAC’s reasonable assessment of 
unsatisfactory cost-effectiveness.  This delays, and therefore reduces access to reimbursed 
new anticancer drugs.  
 
This study indicates that patients wanting to use new anticancer drugs that are not reimbursed 
currently face bills of about A$5000 per month.  Physicians will increasingly find themselves 
in the difficult position of having to discuss with patients whether the financial toxicity of 
these new drugs is warranted by their benefits, which are often relatively modest.47   
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3.7 Conclusion 
 
This study demonstrates a substantial increase in the average prescription price paid by the 
PBS for anticancer drugs, over and above inflation for health prices in general, alongside a 
rapid growth in total government expenditure on anticancer drugs.  Dealing with these 
burgeoning costs at both the societal level, and for individuals, while retaining effective, 
equitable and readily accessible cancer care, poses a major challenge for all health systems. 
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4 IS IT ALL ABOUT PRICE? WHY REQUESTS FOR 
GOVERNMENT SUBSIDY OF ANTICANCER DRUGS WERE 
REJECTED IN AUSTRALIA 
 
4.1 Overview 
 
Chapter 4 is a published work aimed at a clinical audience.  It identifies the reasons the 
Pharmaceutical Benefits Advisory Committee rejects submissions to list anticancer drugs on 
the Pharmaceutical Benefits Scheme.  The rate of rejection over time was also determined.  
The entire manuscript is quoted verbatim. 
 
Publication details 
Karikios DJ, Chim L, Martin A, Nagrial A, Howard K, Salkeld G, Stockler MR. Is it all 
about price? Why requests for government subsidy of anticancer drugs were rejected in 
Australia. Intern Med J; 47:400-407, 2017.  
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manuscript 
KH contributed to the research methods, interpretation of the findings and revision of the 
manuscript 
GS contributed to the research proposal, interpretation of the findings, and revision of the 
manuscript 
MRS conceived and developed the research proposal and methods, contributed to analysis of 
the data, interpretation of the findings and revision of the manuscript 
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4.2 Abstract 
 
Background 
Australians access anticancer drugs predominantly through the Pharmaceutical Benefits 
Scheme (PBS).  
 
Aim 
To determine why the Pharmaceutical Benefits Advisory Committee (PBAC) rejects 
submissions to list anticancer drugs on the PBS. 
 
Methods 
We reviewed publicly available information about submissions made to the PBAC for PBS 
listing of anticancer drugs from 2005 to 2014.  Submission characteristics, including clinical 
and economic evidence, PBAC recommendations, and the reasons offered for rejection were 
recorded.  Two reviewers independently categorised the reason for rejection offered by the 
PBAC.  Logistic regression was used to determine submission characteristics associated with 
rejection. 
 
Results 
We identified 213 submissions for 110 unique indications of 60 anticancer drugs.  The overall 
rejection rate was 56% (119/213).  Of the 110 indications assessed, 69% (76/110) were 
rejected at least once.  The annual rejection rate ranged from 50 to 73% with little evidence of 
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a trend over time (p=0.2).  Submission characteristics strongly associated with rejection in 
multivariable analysis included: PBAC judged the clinical evidence to be problematic or 
uncertain (p <0.001); PBAC judged the economic evidence to be problematic or uncertain (p 
<0.001); and, inactive comparator used (p <0.001).  The most frequent reason for rejection 
offered by the PBAC was ‘inadequate cost-effectiveness or drug price too high’ (75/109, 
69%). 
 
Conclusions 
Inadequate cost-effectiveness and PBAC uncertainty about the clinical and economic 
evidence were the most frequent reasons for rejection.  Clarity of information about PBAC 
deliberations and their reasons for rejection are important for patients and doctors grappling 
with decisions about the use of expensive unfunded anticancer drugs. 
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4.3 Introduction 
 
The Australian PBS is a multibillion dollar, government-funded, national drug formulary 
which subsidises the cost to patients of listed prescription drugs, including anticancer drugs.66  
Submissions for listing a drug on the PBS are prepared by a sponsor, usually a pharmaceutical 
company, and assessed by the PBAC using the following criteria: safety and effectiveness; 
cost-effectiveness and budget impact; certainty of the evidence; and, degree of clinical 
need.140  
 
Submissions to the PBAC fall under two broad categories – major or minor.   A major 
submission requires an economic evaluation and includes submissions to list new drugs on the 
PBS or to make substantial changes to an existing listing.  A submission can be classified as 
minor if it is a resubmission without substantiative changes (e.g. a price reduction only); or, if 
the purpose of the submission is to make minor changes to an existing listing (e.g. the 
addition of a new strength).140  
 
The type of economic evaluation required for a major submission depends on the therapeutic 
claim put forward.  If the claim is superiority to the standard of care, then the sponsor will 
usually submit a cost-effectiveness analysis.  If the claim is therapeutic equivalence or non-
inferiority, then a cost-minimisation analysis is sufficient.  These analyses are required to help 
the PBAC appraise the clinical effect and cost of the new drug relative to the current standard 
of care. 
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After assessing a submission, the PBAC can recommend that a drug be listed on the PBS, 
reject the submission for listing, or defer its decision.  A rejected submission can be 
reconsidered if new evidence is provided.74  The PBAC first announces its recommendations 
on the website of the Department of Health, and subsequently provides more details about the 
rationale underpinning these recommendations as public summary documents (PSDs).141  
 
Understanding the rationale for rejections of submissions to list anticancer drugs on the PBS 
is important to those affected by cancer and their doctors.  A rejection for listing will often 
make a new drug unaffordable to all, but those with the resources needed to cover the 
substantial treatment costs.  The details are also important for oncologists to have informed 
discussions with their patients about the value and costs of unfunded anticancer drugs.142-144 
 
The main purpose of this study was to determine the reasons why the PBAC rejected 
submissions to list anticancer drugs on the PBS.  We sought to determine the characteristics 
of rejected submissions for listing of anticancer drugs, the reasons offered for rejection by the 
PBAC, and if there were changes over time in the rate of rejection.  
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4.4 Methods 
 
We reviewed all submissions made to the PBAC for listing of anticancer drugs on the PBS 
from July 2005 to July 2014.  Details about these submissions were identified from PSDs and 
brief summaries of outcomes (BSOs) published on the PBS website.145,146  July 2005 was 
chosen as the start date as this was the first time PSDs were made available.  We reviewed 
both major submissions, which were always reported in PSDs and BSOs, and minor 
submissions, which were sometimes only reported in BSOs.  
 
We included submissions about anticancer drugs used for the treatment of solid cancers 
(including non-melanoma skin cancers), haematological cancers, and bone metastases.  We 
excluded submissions about drugs used for supportive care during treatment (e.g. antiemetics 
and immunomodulating drugs), submissions requesting simultaneous assessment of more than 
two indications for a single drug, and minor submissions when clinical or economic data were 
not considered.  Different indications identified from the same PSD or BSO were considered 
as separate submissions. 
 
The set of characteristics extracted from submissions was developed from characteristics 
previously reported as being influential in the decision making of the PBAC and similar 
health technology assessment bodies in other countries.139,140,147-151  The characteristics 
included information submitted to the PBAC (e.g. clinical trial evidence of an overall survival 
benefit),  judgements or opinions of the PBAC that were reported in PSDs, and 
recommendations made by the PBAC (see Appendix 10.2 for full list of characteristics).  
Definitions of characteristics and possible responses were specified before data were 
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extracted.  Recommendations made by the PBAC were dichotomised as either a 
recommendation for listing or a rejection (including rejections and deferrals).  
 
The reasons for rejection offered by the PBAC, as distinct from the characteristics of the 
submission, were exclusively extracted from the final section of the PSDs that specifically 
records this information.  Reasons for rejection were extracted verbatim, and then later 
categorised after the initial data entry was completed.  Two of the authors extracted all data 
from submissions independently and resolved any disagreements by consensus.  
 
Standard descriptive statistics were used to summarise the characteristics of all submissions, 
and the reasons for rejection offered by the PBAC.  An association between the submission 
year and likelihood of rejection was tested using a logistic regression.  The logistic regression 
model was fitted using generalised estimating equations (GEE) to account for repeated 
submissions for the same drug and indication.  Individual characteristics were evaluated for 
univariable associations with rejection using logistic regression (fitted with GEE).  
Characteristics that were statistically significant on univariable analysis, from major 
submissions, and not explicit judgements of sponsor claims (e.g. acceptance of efficacy claim) 
were then evaluated in a recursive partitioning analysis.  The subset of these characteristics 
that had wide applicability across the major submissions was included in a multivariable 
logistic regression model.  Backward elimination was used to select variables that were 
independently significant at p<0.05.  Recursive partitioning analysis was performed with the 
rpart package in R (R Foundation for Statistical Computing, Vienna, Austria).  All other 
statistical analyses were performed with SAS version 9.3 (SAS Institute Inc., Cary, NC, 
USA). 
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4.5 Results  
 
We identified 213 evaluable submissions for PBS listing of anticancer drugs between July 
2005 and July 2014, 182 in both PSDs and BSOs, and 31 in BSOs alone.  Of the 213 
submissions, 154 (72%) were a major submission and 59 (28%) were a minor submission.  
All major submissions were reported in a PSD compared with just under half (28) of minor 
submissions.  There was a similar proportion of resubmissions (113, 53%) and initial 
submissions (100, 47%), and 86 (40%) submissions were for anticancer drugs not already 
listed on the PBS for another indication. 
  
The 213 submissions covered 110 unique indications for 60 anticancer drugs.  Of the 110 
indications assessed, the most common tumour types were breast cancer (19, 17%), non-small 
cell lung cancer (12, 11%) and colorectal cancer (12, 11%); 90 (82%) were for treatment with 
non-curative or palliative intent; and, 36 (33%) required testing for a biomarker or treatment 
target as a condition of use.  
 
The rejection rate for all submissions was 119/213 (56%), and for the subset of submissions 
reported in a PSD, it was 109/182 (60%).  Of the 110 indications assessed, 76 (69%) were 
rejected at least once, and 31 (28%) were rejected more than once (Figure 4.1).  By October 
2015, of the 110 indications assessed over the study period, 91 (83%) were listed on the PBS 
and 19 (17%) remained unlisted.  The rejection rate by calendar year from 2005 to 2014 
ranged from 50 to 73% with little evidence of a trend over time (p=0.2) (Figure 4.2).  
However, the rate of rejection for initial submissions was higher from 2010 to 2014 than from 
2005 to 2009 (37/50=70% vs 27/50=54%, p = 0.04).  
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Figure 4.1. Frequency of rejection among 213 submissions for 110 indications assessed by 
the Pharmaceutical Benefits Advisory Committee 
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Figure 4.2. Submission rejection rate by calendar year 
 
*2005 only included submissions from July onwards; 2014 only included submissions up to and including July 
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Results of the univariable logistic regression analyses used to identify submission attributes 
associated with rejection are shown in Table 4.1.  Submissions in which the PBAC did not 
accept the sponsors’ comparator or efficacy claims were strongly associated with rejection, as 
were submissions in which the PBAC judged either the clinical or the economic evidence, 
problematic or uncertain.  Rejection was also associated with submissions that had indications 
with a palliative intent, inactive comparators, and base case incremental cost-effectiveness 
ratios (ICERs) >$45,000/quality-adjusted life year (QALY).  Only one of 20 submissions with 
an ICER range >$75,000/QALY was recommended for listing on the PBS.  The one 
submission with an ICER range <$15,000/QALY was rejected.  All 10 submissions the 
PBAC judged to have an inappropriate comparator were rejected. 
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 Univariable logistic regression analyses of the associations between each Table 4.1.
individual submission characteristic and rejection 
Submission characteristic Reject [n(%)] Approve [n(%)] Total P value† 
Information submitted to the PBAC     
   Listing request‡    0.11 
         New listing 54 (63%) 32 (37%) 86  
         Extend existing listing 65 (51%) 62 (49%) 127  
   Submission type‡    0.01 
         Initial submission 64 (64%) 36 (36%) 100  
         Resubmission 55 (49%) 58 (51%) 113  
   Treatment intent    0.006 
          Curative/Adjuvant 10 (33%) 20 (67%) 30  
          Palliative 99 (65%) 53 (35%) 152  
   Test required before drug can be used    0.59 
          Yes 41 (65%) 22 (35%) 63  
          No 68 (57%) 51 (43%) 119  
   Comparator type    0.003 
          Active 68 (57%) 51 (43%) 119  
          Inactive (e.g. placebo, best supportive care) 30 (86%) 5 (14%) 35  
   Type of trial evidence submitted    0.43 
          Direct comparison trial(s) only 43 (67%) 21 (33%) 64  
          Indirect comparison trials included  55 (62%) 34 (38%) 89  
   Evidence of an overall survival benefit    0.28 
          Yes 38 (70%) 16 (30%) 54  
          No 32 (60%) 21 (40%) 53  
   Type of economic analysis    0.01 
          Cost-effectiveness analysis and/or Cost-utility analysis 90 (66%) 47 (34%) 137  
          Cost-minimisation analysis; Other 17 (41%) 24 (59%) 41  
   ICER (cost/QALY)    <0.001 
          ≤$45,000/QALY 12 (41%) 17 (59%) 29  
          >$45,000/QALY 62 (78%) 18 (23%) 80  
   Estimated impact on the PBS budget per year    0.04 
          <$10 million 55 (59%) 38 (41%) 93  
          ≥$10 million 41 (76%) 13 (24%) 54  
PBAC judgements of sponsor claims     
   Comparator claim     0.005 
          Accepted 69 (58%) 50 (42%) 119  
          Partially accepted; Rejected 25 (89%) 3 (11%) 28  
   Efficacy claim    <0.001 
          Accepted 39 (48%) 42 (52%) 81  
          Partially accepted; Rejected; Unclear 59 (81%) 14 (19%) 73  
   Toxicity claim    0.47 
          Accepted  42 (67%) 21 (33%) 63  
          Partially accepted; Rejected; Unclear 56 (62%) 35 (38%) 91  
Other judgements made by the PBAC     
   PBAC judged clinical evidence problematic or uncertain    <0.001 
          Yes 73 (81%) 17 (19%) 90  
          No 25 (39%) 39 (61%) 64  
   PBAC judged economic evidence problematic or uncertain    <0.001 
          Yes 75 (76%) 24 (24%) 99  
          No 22 (41%) 32 (59%) 54  
   PBAC judged there to be a high clinical need    0.12 
          Yes 32 (73%) 12 (27%) 44  
          No 66 (60%) 44 (40%) 110  
†Logistic regression fitted with GEE. 
‡No PSD is required to determine these variables and so applicable to all 213 submissions. All other variables were determined from the 182 
submissions with a PSD. 
ICER = Incremental Cost-Effectiveness Ratio; PBAC = Pharmaceutical Benefits Advisory Committee; PBS = Pharmaceutical Benefits 
Scheme; QALY = Quality-Adjusted Life Year 
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Table 4.2 shows the results of our multivariable logistic regression analysis.  A PBAC 
judgement of problematic or uncertain clinical evidence and an inactive comparator had the 
strongest association with rejection.  The results of the recursive partitioning analysis applied 
to characteristics that were significantly associated with rejection in the univariable analysis 
are illustrated in Figure 4.3.  The characteristic that best discriminated between rejection and a 
recommendation for listing was PBAC judged the clinical evidence problematic or uncertain 
– 81% (73/90) of major submissions with this characteristic were rejected, versus 39% 
(25/64) without this characteristic.  Of the 64 major submissions without this characteristic, 
an ICER >$45,000/QALY was the strongest discriminator between a recommendation for 
listing and rejection.  Major submissions most likely to be rejected were those when the 
PBAC judged the clinical evidence problematic or uncertain and an inactive comparator was 
used (24/25, 96%). 
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 Multivariable logistic regression analysis of the associations between submission Table 4.2.
characteristics and rejection 
 Univariable† Multivariable† 
Submission characteristic OR 95% CI P  value OR 95% CI P  value 
PBAC judged clinical evidence 
problematic or uncertain  
(Yes vs No) 
6.76 3.24 to 14.1 <0.001 8.47 3.25 to 22.1 <0.001 
Comparator type  
(Inactive vs Active) 
4.29 1.66 to 11.1 0.003 10.8 3.20 to 36.3 <0.001 
PBAC judged economic evidence 
problematic or uncertain  
(Yes vs No) 
4.54 2.21 to 9.30 <0.001 4.35 1.82 to 10.4 <0.001 
Estimated impact on the PBS budget 
per year  
(≥$10 million vs <$10 million) 
2.17 1.05 to 4.55 0.037 4.17 1.56 to 11.1 0.005 
Treatment intent 
(Palliative vs Curative/Adjuvant) 
3.85 1.47 to 10.0 0.006 2.70 1.00 to 7.14 0.05 
Type of economic analysis 
(Cost-effectiveness and/or Cost-utility vs 
Cost-minimisation or other) 
2.68 1.26 to 5.70 0.010 NS - - 
ICER 
 (>$45,000/QALY vs ≤$45,000/QALY) 
7.70 2.9  to 20.4 <0.001 NA‡ - - 
†Logistic regression fitted with GEE. 
‡Not included as a candidate variable in principal analysis as only applicable to 57% (88/154) of major submissions. In a sensitivity analysis 
when it was included, an ICER >$45,000/QALY was significantly associated with rejection, as were: PBAC judged clinical evidence 
problematic or uncertain; PBAC judged economic evidence problematic or uncertain; and an inactive comparator. 
 
CI = confidence interval; ICER = Incremental Cost-Effectiveness Ratio; NA = not applicable; NS = not significant; OR = odds ratio;  
PBAC = Pharmaceutical Benefits Advisory Committee; PBS = Pharmaceutical Benefits Scheme; QALY = Quality-Adjusted Life Year 
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Figure 4.3. Recursive partitioning analysis applied to characteristics from major submissions 
associated with rejection on univariable analysis 
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Table 4.3 summarises our categorisation of the reasons for rejection offered by the PBAC.  
Multiple reasons were documented for nearly all submissions that were rejected (101/109, 
93%); the most frequent number of reasons per rejection was 3 (27/109, 25%).  The reason for 
rejection that we categorised as most frequent was cost-effectiveness was inadequate or the 
drug price too high (75/109, 69%). 
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 Our categorisation of reasons offered by the PBAC for rejecting submissions for Table 4.3.
listing on the PBS 
Reason for rejection Rejected submissions (n = 109) 
 Number of 
submissions in which 
reason was offered 
% 
PBAC stated the cost-effectiveness was inadequate or the 
drug price too high 
75 69 
PBAC judged economic evidence problematic or uncertain 73 67 
PBAC stated they were uncertain about the cost-
effectiveness  
64 59 
PBAC judged clinical evidence problematic or uncertain 61 56 
PBAC judged the drug’s nominated clinical place and/or 
comparator problematic or uncertain 
41 38 
Supplementary data or analysis was required by the PBAC  22 20 
PBAC had concerns about the PBS or health budget impact 16 15 
PBAC had concerns about the safety or toxicity of the drug 11 10 
PBAC had concerns about the test required as a condition of 
use 
8 7 
Other miscellaneous reasons 17 16 
PBAC = Pharmaceutical Benefits Advisory Committee; PBS = Pharmaceutical Benefits Scheme 
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4.6 Discussion 
  
Our study has found several important factors contributing to rejection by the PBAC of 
submissions for listing of anticancer drugs. The importance of inadequate cost-effectiveness 
was demonstrated, amongst applicable submissions, by the association between rejection and 
an ICER >$45,000/QALY in both the univariable analysis and the recursive partitioning 
analysis.  Inadequate cost-effectiveness or drug price too high was also the most frequent 
reason for rejection based on our categorisation of the reasons for rejection offered by the 
PBAC.  PBAC uncertainty about the clinical and economic evidence was also an important 
factor. PBAC judgements of uncertain or problematic clinical evidence, and uncertain or 
problematic economic evidence, were submission characteristics significantly associated with 
rejection in our multivariable logistic regression analysis and were frequently offered as 
reasons for rejection based on our categorisation.  The recursive partitioning analysis also 
demonstrated that a PBAC judgement of uncertain or problematic clinical evidence best 
discriminated between a recommendation for listing and rejection.  
 
We were surprised to find that submissions for drugs without a demonstrated survival benefit 
over their nominated comparator were no more likely to be rejected.  At first glance, this 
suggests the erroneous conclusion that survival benefits are unimportant to the PBAC.  
Recommendations for listing in the absence of a demonstrated survival benefit may have been 
based on strong evidence from important surrogate endpoints such as progression-free 
survival, or because of demonstration of non-inferiority with a drug already proven effective. 
For example, recommendations for erlotinib and gefitinib in the treatment of non-small cell 
lung cancer with driver mutations of the gene for epidermal growth factor receptor, were 
based on improvements in important surrogate endpoints, progression-free survival and 
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quality of life, in comparison with chemotherapy using a platinum-based doublet, the prior 
standard of care.  Pazopanib was recommended for listing for the treatment of metastatic renal 
cell carcinoma based on evidence of non-inferiority in comparison with sunitinib which had 
already been PBS listed for this indication.  Such submissions will not have been recorded as 
demonstrating evidence of a survival benefit in our study, even if there is available evidence 
for the anticancer drugs in question against placebo or other unnominated comparators.  
 
Conversely, some submissions for listing drugs with a demonstrable survival benefit were 
rejected by the PBAC.  Examples in our study include the first submission for listing 
bevacizumab in combination with chemotherapy as first-line treatment of metastatic 
colorectal cancer, and the first submission for listing abiraterone in metastatic, castration-
resistant prostate cancer, following treatment with chemotherapy.  Robust evidence of a 
substantial survival benefit may justify a high asking price, but a higher asking price will 
reduce cost-effectiveness, perhaps resulting in rejection.  It is important to note that most 
submissions for listing anticancer drugs with a demonstrable survival benefit, including the 
previous examples, were eventually approved.  Of the 19 indications assessed in our study 
that remained unlisted in October 2015, only 5 were supported by statistically significant 
survival benefits. 
 
The main strength of this study is its comprehensive review of all submissions made to the 
PBAC regarding the PBS listing of anticancer drugs since PSDs became available up until 
July 2014.  This is timely given the growing community concern about the issue of high cost 
anticancer drugs and a recent Senate Inquiry into access to innovative cancer drugs in 
Australia.152,153  Inclusion of all PBAC recommendations since 2005, not just those reported 
in PSDs, ensures that the rejection rate is not overestimated.  Independent data extraction by 
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two investigators also contributes to the credibility of our results.  This study builds on our 
previous study by exploring the reasons the PBAC rejects anticancer drugs for listing.139  
Other studies, including our previous one, were not limited to analysis of anticancer drugs, 
but also found that the frequency of rejections by PBAC was increased by uncertainty, 
inadequate cost-effectiveness and health budget impact.139,148,154-156 
 
The main limitations of our study stem from its reliance on publicly available information.  
PSDs aim to provide the public information about PBAC recommendations, but they arose as 
a result of requests for more transparency about the basis of subsidy of pharmaceuticals to 
Australians, as part of the Australian-United States Free Trade Agreement.141   The PBAC is 
governed by the National Health Act, therefore content published in PSDs is subject to 
Commonwealth law, and is negotiated by the PBAC and the sponsor to protect commercial 
confidentiality.157  As a result, pertinent information considered by the PBAC may be omitted. 
 
Uncertainty about the cost-effectiveness of a new anticancer drug reduces the likelihood that 
it will be publicly funded, especially if the price of a new anticancer drug is high and would 
result in substantial total expenditure.149,158  Sources of uncertainty for the PBAC include 
aspects of clinical trial design that obscure the magnitude of benefit (e.g. crossover from 
control group to experimental treatment); applicability of submitted trial evidence to the 
Australian context (e.g. inappropriate comparator); and assumptions or flaws in the economic 
models submitted (e.g. extrapolation of trial results beyond the duration of follow-up).159-161  
PSDs for drugs rejected by the PBAC because of ‘uncertainty’ are often unclear about 
whether the ‘uncertainty’ is about the benefits, the costs, the cost-effectiveness, or some other 
unspecified consideration.  We recommend that PSDs should explicitly specify the areas and 
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reasons for uncertainty and how these uncertainties contributed to the PBAC’s 
recommendation. 
 
Despite challenges faced by the PBAC, such as high prices and uncertain benefits, our study 
has not demonstrated clear evidence of an increasing linear trend over time in the rejection 
rate for anticancer drugs.  The rejection rate of initial submissions was nevertheless greater in 
the second half of the study period compared to the first.  Policy arrangements that promote 
rapid access to new anticancer drugs to allay the concerns of patients and doctors, while 
ensuring value for money is still considered, should be encouraged.162,163 
 
Funding decisions in health systems that fund anticancer drugs significantly affect the practice 
of medical oncologists and the anticancer drugs that are accessible to patients.164  Surveys 
demonstrate that patients want information about the availability of high cost, unfunded 
drugs, and may feel that it is unfair that these drugs are not funded.143,165  Understanding that a 
drug was rejected because of doubts about its efficacy, rather than its high cost, might help 
patients deciding whether or not to pursue an expensive treatment.  
 
Cancer is sometimes paid special attention by health technology assessment agencies and 
reimbursement authorities.71  For example a “Cancer Drugs Fund” was created in the United 
Kingdom to provide access to anticancer drugs, which were increasingly receiving negative 
recommendations from the National Institute for Health and Care Excellence.166,167  Our study 
of recommendations from 2005-2008 showed that the PBAC was equally likely to 
recommend or reject drugs for cancer versus other indications, but recommendations since 
2008 warrant analysis.139  Further research is also needed to determine the extent to which the 
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criteria used by PBAC to value new anticancer treatments match those of the wider 
community.168 
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4.7 Conclusion 
 
The rapidly rising cost of new anticancer drugs has made rigorous determination of their 
value an urgent and important priority.  Rejection of a submission for listing on the PBS 
moves the problem from the domain of health policy to that of individual clinical decision 
making.  This makes it even more important that the PBAC provide clear information about 
its deliberations and the reasons for rejection or recommendation for listing of expensive new 
anticancer drugs.  Better information about the reasons for rejection should help patients and 
doctors make more informed decisions about the use of expensive unfunded treatments. 
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5 DISCUSSING AND PRESCRIBING EXPENSIVE UNFUNDED 
ANTICANCER DRUGS IN AUSTRALIA 
 
5.1 Overview 
 
Chapter 5 is a published work.  It reports the results of a survey of Australian medical 
oncologists asking them about discussing and prescribing expensive unfunded anticancer 
drugs.  The entire manuscript is quoted verbatim. 
 
Publication details 
Karikios DJ, Mileshkin L, Martin AJ, Ferraro D, Stockler MR. Discussing and prescribing 
expensive unfunded anticancer drugs in Australia. ESMO Open. 2(2):e000170, 2017.  
 
Contribution of authors 
DJK conceived and developed the research proposal and methods, collected and analysed the 
data, interpreted the findings and drafted and revised the manuscript. 
LM contributed to the research proposal, interpretation of findings and revision of the 
manuscript. 
AM contributed to the research proposal and methods, analysis of the data, interpretation of 
the findings and revision of the manuscript. 
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DF contributed to the research proposal, interpretation of the findings and revision of the 
manuscript. 
MRS conceived the research proposal and methods and contributed to analysis of the data, 
interpretation of the findings and revision of the manuscript. 
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5.2 Abstract 
 
Objective 
Australia has a publicly-funded, universal healthcare system which heavily subsidises the cost 
of most registered anticancer drugs.  The use of anticancer drugs that are unfunded, that is, not 
subsidised by the government, entails substantial out-of-pocket costs for patients.  We sought 
to determine how frequently Australian medical oncologists discuss and prescribe unfunded 
anticancer drugs, and their attitudes and beliefs about their use. 
 
Methods 
Members of the Medical Oncology Group of Australia (MOGA) completed an online survey 
about their clinical practices over a recent three-month period.  A negative binomial 
regression model was used to examine the influence of respondent characteristics on the rate 
of discussions about, and prescription of, unfunded anticancer drugs. 
 
Results 
Of the 154 respondents (27% of 575 MOGA members), 92% had discussed and 68% had 
prescribed at least one unfunded anticancer drug in the last three months.  Respondents 
reported discussing unfunded anticancer drugs with an average of 2.5 patients per month 
(95% CI 2.1 to 2.9), and prescribed them to an average of 0.9 patients per month (95% CI 0.7 
to 1.2).  The rate of discussing unfunded anticancer drugs was associated with being fully 
qualified (p=0.01), and being in a metropolitan practice (p=0.009); the rate of prescription 
was associated only with being in metropolitan practice (p=0.006).  The concerns about 
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discussing and prescribing unfunded anticancer drugs rated most important were as follows: 
‘potential to cause financial hardship’ and ‘difficulty for patients to evaluate the benefits 
versus the costs’.  
 
Conclusions 
Australian medical oncologists frequently discuss and prescribe unfunded anticancer drugs, 
and are concerned about their patients having to face difficult decisions and financial 
hardship.  Further research is needed to better understand the factors that affect how 
oncologists and patients value expensive, unfunded anticancer drugs. 
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5.3 Introduction 
 
The number of drugs developed to treat cancer has greatly increased over recent years.  Over 
60 new anticancer drugs were approved by the United States (US) Food and Drug 
Administration (FDA) between 2005 and 2014, and a further 70 existing anticancer drugs had 
their indications expanded.169  The growth in the number of new anticancer drugs is 
welcomed by patients and oncologists as new treatments can increase response rates, delay 
progression, extend survival, improve the quality of life of patients with cancer, and in some 
circumstances increase the chance of cure.   
 
Along with the benefits of new anticancer drugs comes their considerable expense.33  The 
prices of new anticancer drugs have created challenges for payers, providers and patients.170  
In predominantly publicly funded health systems like Australia’s, payers grapple with 
determining whether the benefits of a new anticancer drug are worth the extra cost.  To be 
lawfully supplied in Australia, prescription drugs require marketing approval from the 
Therapeutic Goods Administration.171  If the drug is approved pharmaceutical companies can 
submit applications to the Pharmaceutical Benefits Advisory Committee for drugs to be listed 
on the Pharmaceutical Benefits Scheme (PBS).172  Drugs listed on the PBS are provided to 
patients at a heavily subsidised price.  
 
Even in Australia, where most prescription medicines are subsidised, the rising cost of 
anticancer drugs creates problems for patients.173  For example, it is often months, and 
sometimes years, from the publication of positive trial results to the listing of a drug on the 
PBS.89  If a new anticancer drug is not listed on the PBS then accessing it may require 
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patients to pay its full cost, which can amount to thousands of dollars per month.165,174  In 
some instances, pharmaceutical companies provide access to these drugs via compassionate 
access programs or cost-sharing programs; however these still may involve substantial out-of-
pocket costs.  This means that the cost of treatment can become a major factor in decision 
making for cancer patients.175  Many patients will forego high-cost treatments altogether, or 
discontinue them early if the expense becomes prohibitive.176 
 
A recent survey of medical oncologists from the US indicated that the vast majority felt 
obliged to offer all available treatment options to their patients regardless of their cost.177  
Discussing expensive treatment options can be difficult for oncologists who do not wish to 
impose a financial hardship on their patients, especially if the incremental benefit of the 
treatment is modest or uncertain.142  Oncologists may also spend time and effort trying to find 
ways to reduce or avoid this financial hardship for their patients, for example, by seeking 
alternative sources of funding.178  As the cost of anticancer drugs continues to rise, 
oncologists and their patients will increasingly have to face the difficulty of determining their 
value.143 
 
Unfunded anticancer drugs are those that are not subsidised by the government and therefore 
entail substantial out-of-pocket costs to patients. A study of  the practices and attitudes of 
Australian medical oncologists regarding disclosure of expensive unfunded anticancer drugs 
in 2006 found that almost half of the responding oncologists reported prescribing at least one 
unfunded anticancer drug.179  Since then, the available number of unfunded anticancer drugs 
has grown.  A recent study at a single Australian institution found that almost half of the 
anticancer drug treatment protocols contained a drug that was not PBS listed.82  The extent to 
which Australian medical oncologists currently discuss and prescribe unfunded anticancer 
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drugs is unknown.  The aim of this study was to examine the current practices, attitudes and 
beliefs of Australian medical oncologists regarding the discussion and prescription of 
unfunded anticancer drugs. 
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5.4 Methods 
 
We performed a cross-sectional survey of medical oncologists and medical oncology trainees 
throughout Australia.  We asked respondents to recall their discussions about, and 
prescriptions of, unfunded anticancer drugs over the last three months.  Based on previous 
definitions used in Australian studies, we defined unfunded anticancer drugs as any 
prescription anticancer drug that: 
• Was not listed on the PBS, and 
• Was not used as part of a clinical trial or free access program, and 
• May require the patient to pay substantially more than standard pharmacy dispensing 
fees165,179 
 
Respondents also provided details about their personal and practice characteristics; and, their 
attitudes and opinions about issues related to unfunded anticancer drugs, including concerns 
about discussing and prescribing them.  
 
The survey instrument was developed by three medical oncologists.  A focus group of five 
medical oncologists was used to assess face validity, content validity, and clarity, before 
wider distribution.  See Appendix 10.3 for the final version of the survey. 
 
Potential participants were members of the MOGA.  The MOGA is the peak national body 
representing medical oncologists in Australia.  All members of the MOGA (medical 
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oncologists and medical oncology trainees) were invited to participate by email in August 
2014.  The email included a brief explanation of the survey, a participant information 
statement, and a hypertext link to the survey.  The survey took approximately 15 minutes to 
complete, and respondents were not offered any inducements to complete the survey.  A 
reminder email was sent to all potential participants one month after the initial invitation.  The 
study was approved by the University of Sydney Human Research Ethics Committee (Project 
number: 2014/173).  All responses to the survey were anonymous and non-identifiable.  
 
The analysis set comprised respondents who answered at least one question about the 
discussion or prescription of unfunded anticancer drugs.  A negative binomial regression 
model was used to examine the influence of personal and professional characteristics on the 
rate of discussion and prescription of unfunded anticancer drugs.  Characteristics were first 
tested individually, and then after adjusting for clinical workload (hours per week on average 
spent in outpatient clinics).  Backwards elimination was used to develop a multivariable 
model comprising statistically significant, independent predictors adjusting for clinical 
workload.  
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5.5 Results 
 
We received evaluable responses from 154 of the 575 (27%) medical oncologists in the 
MOGA database, including 142 who answered all questions.  The characteristics of the 154 
respondents are summarized in Table 5.1.  Qualified oncologists outnumbered trainees by 4:1, 
but more than half the respondents were 40 years or younger, and only 40% had more than ten 
years’ experience in oncology practice.  The numbers of females and males were similar.  
Most respondents practised in public clinics in metropolitan areas.  
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 Personal and professional characteristics of 154 responding oncologists Table 5.1.
Characteristic n (%) 
Age  
   ≤30 
   31 – 40 
   41 – 50 
   51 – 60 
   >60 
    4 (3) 
  81 (52) 
  34 (22) 
  23 (15) 
  12 (8) 
Role   
   Qualified oncologist 
   Trainee oncologist 
  124 (19) 
30 (81)  
Sex   
   Female 
   Male 
  72 (47) 
  82 (53)  
Years worked in medical oncology   
   ≤10 
   11-20 
   >20 
  91 (59) 
  29 (19)  
  34 (22) 
Hours spent in outpatient clinics per week   
   ≤20 
   >20 
  89 (58)  
  65 (42)  
Hours spent in research per week   
   ≤20 
   >20 
129 (84) 
  25 (16) 
Practice type   
   Mostly public  
   Mostly private  
   Othera 
105 (68)  
  21 (14) 
  28 (18)  
Practice location   
   Mostly metropolitan 
   Mostly regional/rural 
   Otherb  
121 (79) 
  26 (17) 
  7 (5) 
aIncludes respondents with an equal mix of public and private practice, or no clinical practice 
bIncludes respondents with an equal mix of metropolitan and regional/rural practice, or no clinical practice 
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In a recent three-month period, respondents currently in practice, reported discussing 
unfunded anticancer drugs with an average of 2.5 patients per month (95% CI 2.1 to 2.9), and 
prescribing unfunded anticancer drugs to an average of 0.9 patients per month (95% CI 0.7 to 
1.2).  Almost all of the respondents had discussed (99%) or prescribed (93%) an unfunded 
anticancer drug at some time in the past.  Ninety-two percent of respondents had discussed, 
and 68% had prescribed, an unfunded anticancer drug in the last three months.  Sixty-nine 
percent thought they were currently prescribing more unfunded anticancer drugs than they 
had five years ago, and 77% thought they would be prescribing more unfunded anticancer 
drugs in ten years’ time than they are now.   
 
Respondents reported discussing or prescribing unfunded anticancer drugs more often to:  
patients considering palliative treatment (88% of respondents) versus adjuvant/curative 
treatment (12%); patients considering last-line treatment (68%) versus first-line treatment 
(32%); and patients younger than 70 (96%) versus older than 70 (4%). Respondents reported 
that, on average, patients or their support-person initiated about 15% of discussions about 
unfunded anticancer drugs.  Respondents reported that, on average, they recommended 
against treatment with an unfunded anticancer drug in about 27% of discussions.  
 
Associations between the characteristics of respondents, and the rate of both discussion and 
prescription of unfunded anticancer drugs, are summarised in Table 5.2.  Working in private 
practice, and working in a metropolitan practice were each associated with an increased rate 
of both discussion and prescription in univariable analyses adjusting for clinical workload.  
Metropolitan practice was the only variable significantly associated with both discussion and 
prescription rate in multivariable analysis.  Being a qualified medical oncologist, rather than a 
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trainee, was also significantly associated with the rate of discussion, but not with the rate of 
prescription, in both univariable and multivariable analyses. 
 
The median maximum out-of-pocket cost respondents estimated that their patients had paid, 
or would be expected to pay, for a course of an unfunded anticancer drug, typically lasting a 
few months, was A$7500 (around US$5800; €5400); range: A$200 to A$100,000.  The 
frequency with which various methods were used to cover the costs of unfunded anticancer 
drugs is summarized in Figure 5.1.  Respondents estimated that 60% of prescriptions were 
partially subsidised through a pharmaceutical company access program, and that 
approximately 30% of the prescriptions were fully paid for by their patients.   
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 Associations between respondents’ characteristics and the rates of discussion and prescription of unfunded anticancer drugs Table 5.2.
Outcome/ 
Characteristic 
Univariable analysis  
(adjusted for clinical workload) 
 Multivariable analysis  
(adjusted for clinical workload) 
Rate Ratio 95% CI p-value  Rate Ratio 95% CI p-value 
Discussion Rate        
Role  
     Qualified oncologist 
     Trainee oncologist (reference group) 
 
1.60 
 
 
1.08 to 2.37 
 
 
0.020 
 
  
1.67 
 
 
1.13 to 2.46 
 
 
0.01 
 
Sex  
     Male 
     Female (reference group) 
 
1.29 
 
 
0.92 to 1.81 
 
 
0.14 
 
  
- 
  
Age (per decade) 1.14 0.97 to 1.35 0.11  -   
Years worked in medical oncology (per decade) 1.09 0.92 to 1.28 0.32  -   
Practice type 
     Mostly private/other  
     Mostly public (reference group) 
 
1.66 
 
 
1.17 to 2.36 
 
0.005 
  
- 
  
Practice location 
     Mostly metropolitan  
     Mostly regional/rural/other (reference group) 
 
1.61 
 
 
1.08 to 2.39 
 
0.02 
  
1.68 
 
 
1.14 to 2.48 
 
0.009 
Prescription Rate        
Role  
     Qualified oncologist  
     Trainee oncologist (reference group) 
 
1.63 
 
 
0.94 to 2.83 
 
0.08 
 -   
Sex 
     Male  
     Female (reference group) 
 
0.89 
 
 
0.56 to 1.40 
 
0.61 
 -   
Age (per decade) 1.22 0.98 to 1.51 0.08  -   
Years worked in medical oncology (per decade) 1.21 0.97 to 1.51 0.09  -   
Practice type 
     Mostly private/other  
     Mostly public (reference group) 
 
1.70 
 
 
1.03 to 2.80 
 
0.04 
  
- 
  
Practice location 
     Mostly metropolitan  
     Mostly regional/rural and other (reference group) 
 
2.20 
 
 
1.25 to 3.87 
 
0.006 
  
2.20 
 
 
1.25 to 3.87 
 
0.006 
CI: confidence interval 
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Figure 5.1. Estimated frequency of methods used to cover the cost of unfunded anticancer 
drugs (more than one method possible for each prescription) 
  
9%
10%
10%
30%
60%
Partially subsidised by the
hospital/cancer centre
Partially subsidised by a charitable
organisation
Partially subsidised by a private
health insurer
Patient met the full cost
Partially subsidised through
pharmaceutical company access
program
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Out-of-pocket costs to patients were reported to influence the willingness to prescribe an 
unfunded anticancer drug, ‘somewhat’ or ‘a lot’ by 83% (118/143) of respondents, and ‘not at 
all’ by 6% (9/143) of respondents.  Eleven percent (16/143) of respondents felt it was never 
appropriate for a patient to pay for treatment with an unfunded anticancer drug.  Just over half 
the respondents (55%, 78/142) said they were comfortable discussing out-of-pocket costs with 
patients.  
 
The concerns we presented about discussing and prescribing unfunded anticancer drugs that 
were rated most important by respondents were “potential to cause financial hardship” and 
“difficulty for patients to evaluate the benefits versus the costs” (Figure 5.2).  Concerns about 
the “time it takes to discuss unfunded anticancer drugs with a patient” and “the need to refer a 
patient to another centre” were rated least important.  
 
We presented a list of possible aids to facilitate discussions about unfunded anticancer drugs 
(Figure 5.3).  Those rated most useful by respondents were “a website with a list of access 
programs available for unfunded anticancer drugs” and “a clear understanding of what drug 
costs private health funds will cover”. Those rated least useful were “written guidelines about 
how oncologists should communicate out-of-pocket costs with patients” and “communication 
workshops focusing on discussions with patients about out-of-pocket costs”. 
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Figure 5.2. Percentage of responding oncologists who rated as important the specified 
concerns about discussing and prescribing unfunded anticancer drugs 
 
  
0% 50% 100%
I would have to refer my patient to another centre
It takes too much time to discuss unfunded anticancer
drugs with a patient
It is hard for me find out how much an unfunded
anticancer drug will cost a patient
The ethics of pharmaceutical company shared access
programs concerns me
It takes too much work to obtain partial funding and/or
organise treatment
There is often an excessive delay between recommending
and starting treatment
Asking patients to make decisions about unfunded
anticancer drugs is not fair
I am concerned about distressing patients by discussing
unfunded anticancer drugs
I am concerned about not being able to offer the same
treatment to all my patients in my practice
It is difficult for patients to evaluate the benefits versus the
costs
The potential financial hardship to the patient and/or their
family concerns me
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Figure 5.3. Percentage of responding oncologists who rated as useful the specified aids to 
facilitate discussion about unfunded anticancer drugs 
   
0% 20% 40% 60% 80% 100%
Communication workshops focusing on discussions with
patients about out-of-pocket costs
Written guidelines about how oncologists should
communicate out-of-pocket costs with patients
Results of a cost-effectiveness analysis
Including the price of an unfunded anticancer drug in the
product information
A website with a list of drug prices for private
prescriptions
A clear understanding of what drug costs private health
funds will cover
A website with a list of access programs available for
unfunded anticancer drugs
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5.6 Discussion 
 
This survey indicates that in a health system which is predominantly publicly funded, 
responding medical oncologists discussed unfunded anticancer drugs with approximately 
three patients per month, prescribed them to approximately one patient per month, and that 
nearly all had prescribed an unfunded anticancer drug.  This is much higher than a 
comparable study published ten years ago which found that less than 50% of Australian 
medical oncologists had prescribed an unfunded anticancer drug.179 
 
The median maximum out-of-pocket costs that respondents recalled their patients had paid, or 
were expected to pay, for a course of an unfunded anticancer drug was A$7500.  This is a 
considerable amount of money in conjunction with other costs of care and may be 
unaffordable for many patients.  Costs were likely to be much higher for the 30% of patients 
who were meeting the full cost of the drugs.   Recommendations against treatment with an 
unfunded anticancer drug occur in over a quarter of discussions about them in our study but 
we did not ascertain whether the high cost was the main reason for recommending against 
their use.  It is likely to be a factor given that the potential to cause financial hardship was the 
concern rated most highly by respondents when discussing or prescribing unfunded anticancer 
drugs.  Other factors, such as the type of evidence used to make recommendations, the 
strength of that evidence, or the incremental benefit over less costly options may also be 
important, but we did not ascertain these in our study.  Patient factors and disease factors are 
also likely to have a significant role as respondents reported that it was more likely they 
would discuss and prescribe unfunded anticancer drugs to patients who were younger, had 
incurable disease, or were considering last line therapy.  It would be interesting to explore 
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how much willingness to discuss or prescribe an unfunded anticancer drug in the last line 
setting correlates with the level of discomfort of the oncologist in discussing palliative care.   
 
The proportion of respondents (16% [23/142]) that reported being uncomfortable with 
discussing the out-of-pocket costs of unfunded anticancer drugs was lower than anticipated.  
An Australian study published in 2008 reported that discussing high cost drugs was one of the 
most difficult communication issues for Australian oncologists.142  However, it may be that 
levels of discomfort have decreased over time as the frequency of these discussions has 
increased.  Like their North American counterparts, most Australian oncologists think that 
out-of-pocket costs affect their willingness to prescribe an unfunded anticancer drug, a finding 
that warrants further research.176,180 
 
Respondents reported that approximately six of ten occasions they prescribed unfunded 
anticancer drugs involved partial subsidies via pharmaceutical company access programs.  
Although these programs allow earlier access to novel therapies that are not yet PBS listed, 
their widespread use raises a number of ethical dilemmas reported to be a concern by 41% of 
respondents, such as their use as a medical marketing tool, the changing requirements of the 
programs depending on commercial imperatives, and the favouring of patients able to afford 
substantial contributions associated with the cost-sharing programs.181  Pharmaceutical 
companies are not permitted to advertise these programs directly to patients in Australia, and 
this may explain why over a third of respondents reported it was hard for them to find the 
costs of unfunded anticancer drugs.  This may also be why respondents judged that the most 
useful aids for clinical practice would be better access to information about the costs and 
methods of accessing unfunded anticancer drugs.  This lack of knowledge or resources about 
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the costs of care was rated the most important barrier to cost discussions by US oncologists in 
a recent survey.177 
 
Respondents in predominantly metropolitan practices were more likely to discuss and 
prescribe unfunded anticancer drugs than those in predominantly regional or rural practices.  
Possible explanations include differences in treatment preferences of oncologists and/or 
patients in regional or rural areas, and greater barriers to accessing unfunded drugs (or 
information about them) in these areas.  The lower likelihood that medical oncology trainees 
discussed unfunded anticancer drugs is likely to reflect their lower confidence and level of 
responsibility, but also supports the need for education about discussing unfunded anticancer 
drugs.  
 
The main strengths of our study are that it reflects the contemporary practice and attitudes of 
Australian medical oncologists and contributes to the growing evidence that the high cost of 
new anticancer drugs is a major concern and influence on the practice of medical oncologists.  
It also provides the first information about the frequency of their discussions about, and 
prescription of, unfunded anticancer drugs.  The main limitation of our study is the response 
rate of 27%, typical of physician surveys, and similar to a US study about communicating the 
costs of therapy.182,183  The age, gender, and proportion of trainees amongst responders was 
similar to that of the general MOGA membership, but this does not ensure that our 
respondents’ answers would accurately reflect those of non-responders.  Recall bias is another 
limitation because the study relied on medical oncologists’ recollections of past practice.  
Responding oncologists may have overestimated the frequency of their discussions and 
prescriptions.  However, even so, it is clear that the issue of unfunded anticancer drugs is 
sufficiently common and important to warrant further research and attention.  
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This study shows that Australian medical oncologists frequently discuss and prescribe 
unfunded anticancer drugs, and that they are concerned about causing their patients 
psychological distress and financial hardship.  Our study suggests that medical oncologists 
would value better information about the costs to their patients and methods for accessing 
unfunded anticancer drugs.  Research and education are needed to identify and implement 
better ways of thinking and talking about unfunded anticancer drugs with patients, and to 
better understand the complex factors that contribute to how oncologists value expensive 
unfunded anticancer drugs, and their willingness to discuss and prescribe them. 
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6 ONCOLOGISTS’ RECOMMENDATIONS FOR TREATMENT 
WITH UNFUNDED ANTICANCER DRUGS 
 
6.1 Overview 
 
Chapter 6 is a report of a study of medical oncologists’ treatment recommendations about 
unfunded anticancer drugs.  Australian medical oncologists were invited to complete a 
discrete choice experiment, to determine the influence on treatment recommendations of four 
attributes of anticancer drugs (improvements in survival; improvements in cancer related 
symptoms; chance of a serious adverse event; out-of-pocket costs).  The manuscript presented 
in this chapter is aimed at a clinical audience.  At the time I submitted my thesis this 
manuscript had been submitted to a journal and was under review. 
 
Manuscript authors:  
Karikios DJ, Howard K, Blinman P, Stockler MR. 
 
Contribution of authors 
DJK conceived and developed the research proposal and methods, collected and analysed the 
data, interpreted the findings and drafted and revised the manuscript. 
KH contributed to the research proposal and methods, analysis of the data, interpretation of 
the findings and revision of the manuscript. 
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PB contributed to the research proposal, interpretation of the findings and revision of the 
manuscript. 
MRS conceived the research proposal and methods and contributed to analysis of the data, 
interpretation of the findings and revision of the manuscript. 
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6.2 Abstract 
 
Background 
Oncologists and patients frequently face difficult decisions about treatment with expensive, 
unfunded anticancer drugs.  We sought to determine how attributes of anticancer drugs, 
including their out-of-pocket costs, influenced oncologists’ recommendations. 
 
Methods 
We invited Australian oncologists to complete an online, discrete choice experiment (DCE).  
Respondents were presented 15 choice sets, each comparing four attributes of two 
hypothetical anticancer drugs (A or B) and asking which drug they would recommend to a 
hypothetical patient with advanced cancer.  The four attributes were: survival; out-of-pocket 
cost; chance of a serious adverse event; and, chance of an improvement in cancer related 
symptoms.  A mixed logit model was used to determine the effects of drug attributes and 
respondent characteristics on oncologists’ recommendations. 
 
Results 
We received 101 evaluable responses (overall response rate = 17%).  The odds of 
recommending an anticancer drug were increased by longer survival (OR=2.16 per extra 
month, p<0.001) and a higher chance of improving cancer-related symptoms (OR=1.69 per 
absolute increase of 5%, p<0.001), and decreased by higher out-of-pocket costs (OR=0.92 per 
extra A$1000, p<0.001) and a higher chance of serious adverse events (OR=0.72 per absolute 
increase of 5%, p<0.001).  When survival was modelled linearly, respondents required an 
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average of 1.4 additional months of survival (95% CI 1.2 to 1.5, IQR 0.8 to 1.6), to justify an 
out-of-pocket cost to a patient of A$10,000.  When survival was modelled as an ordinal 
variable, there was a threshold minimum survival benefit of 2 to 3 months for oncologists to 
recommend an expensive, unfunded anticancer drug. 
 
Conclusions 
Australian oncologists were willing to recommend expensive, unfunded anticancer drugs, but 
required a minimum survival benefit of 2 to 3 months before financially burdening their 
patients.  Research is needed to better understand patients’ preferences for using expensive, 
unfunded anticancer drugs and how oncologists can best support their decision-making. 
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6.3 Background 
 
Oncologists and cancer patients often face choices between multiple anticancer drugs.  These 
choices can be challenging as they require an evaluation of the relative benefits, such as 
improvements in survival and/or cancer-related symptoms versus harms due to treatment 
toxicity.  Such choices are made more complex because many new anticancer drugs are 
expensive and entail substantial out-of-pocket costs to the patient.36,184  Previous studies have 
shown that individuals with cancer want to be informed about new  treatments, even if they 
entail substantial out-of-pocket costs.143 
 
Most anticancer drugs used in Australia are publicly subsidised through the Pharmaceutical 
Benefits Scheme (PBS).  For these subsidised anticancer drugs, patients bear only a small 
fixed cost (less than A$50 per month of treatment), which is typically a small proportion of 
the actual cost.76  However many new anticancer drugs are not publicly subsidised, increasing 
the frequency of difficult discussions and decisions for patients and their oncologists.179 
 
Shared decision-making is the recommended model, but discussions about treatment are often 
led by the oncologist, and decisions about treatment are strongly influenced by how 
oncologists present benefits, harms and trade-offs.109,182,185  There is little research about how 
oncologists value and trade-off the attributes of expensive, unfunded anticancer drugs – 
including their costs, benefits and harms – when making recommendations to their patients.  
 
DCEs are a method for eliciting the preferences of a decision maker for hypothetical 
treatment scenarios in a way that helps reveal the underlying factors that influence their 
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choices.  DCEs simulate real world decision-making; they require the decision maker to first 
appraise the profile of attributes for various treatment alternatives, and then select their 
preferred option.186  The method assumes that a given treatment option can be specified by a 
set of attributes (e.g. specific benefits and harms), and that the value or utility of a treatment 
alternative, and therefore the preference for that alternative, depends on the relative 
magnitude (levels) of these attributes (e.g. shorter versus longer survival; lower versus higher 
risk of serious side effects).187  The analysis of data from a DCE involves modelling the 
relationship between attribute levels and the decision maker’s stated preference between 
alternatives.188  The aim of this study was to determine the extent to which various attributes 
of anticancer drugs, including their out-of-pocket costs, influenced Australian oncologists’ 
willingness to recommend them to patients. 
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6.4 Methods 
 
We designed a DCE to determine the influence of various attributes of anticancer drugs on 
oncologists’ recommendations to patients.  Six hundred and three members of the Medical 
Oncology Group of Australia (MOGA) were invited by email to complete an online survey.  
The MOGA is the peak national body representing medical oncologists in Australia, including 
both those who have completed their training (consultants), and those being trained (advanced 
trainees).  The email included a brief description of the study, and an anonymised link to the 
online survey that was left active for 4 months from July 2015 to October 2015.  A reminder 
email was sent 2 months after the initial invitation.  Responses were anonymised and non-
identifiable.  The study was approved by the University of Sydney Human Research Ethics 
Committee (Project number: 2015/100).  
 
The DCE was designed using standard guidelines.189  Respondents were presented 15 choice 
sets describing two hypothetical anticancer drugs (drug A and drug B), and were asked to 
indicate for each choice set which of the two drugs they would recommend to a hypothetical 
patient.  The choice sets were accompanied by a single, detailed clinical scenario outlining 
disease characteristics and stating that the hypothetical patient desired treatment (Figure 6.1).  
The 4 attributes used to define the anticancer drugs in each choice set were: median overall 
survival; maximum out-of-pocket cost to the patient; chance of a serious adverse event; and, 
chance of an improvement in cancer related symptoms. Detailed definitions of each attribute 
were presented to respondents (see Appendix 10.4).  We were specifically interested in the 
influence of characteristics of the anticancer drug on choices, so we did not include other 
attributes such as patients’ preferences, circumstances, and health status, although these were 
mentioned in the clinical scenario. 
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Figure 6.1. Detailed hypothetical clinical scenario that respondents were asked to consider 
when deciding between drug A and drug B 
  
 Here are the characteristics of the patient we would like you to think about 
when deciding between drug A and drug B. 
The patient: 
• Has an advanced, incurable cancer 
• Has not received any treatment for their cancer in the past, and the only 
appropriate treatment at present is systemic therapy with an anticancer 
drug 
• Has some symptoms from their cancer which are affecting their quality of 
life 
• Is fit for treatment and has no medical comorbidities that would interfere 
with their treatment 
• Has indicated they wish to pursue active treatment 
• Has the same capacity to pay for unfunded treatments as the typical 
patients you see in your practice 
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The levels of each attribute were varied over a range that was plausible for the hypothetical 
clinical scenario (Table 6.1).  The differences between the survival time attribute for drug A 
and B were constrained to levels consistent with recent randomised trials, and the survival 
time for drug B was always the same or better than that for drug A.190  For example if drug A 
had a median survival time of 6 months, the survival time for drug B was constrained to levels 
of 6, 9 or 12 months.  Out-of-pocket costs were always A$0 for drug A (i.e. always subsidised 
by the PBS or supplied free to the patient by a pharmaceutical company) and varied across 5 
levels for drug B (A$: 0, 5000, 10000, 20000 and 100000).  Respondents were asked to ignore 
co-payments for anticancer drugs listed on the PBS and dispensing fees for anticancer drugs 
not listed on the PBS.76  Attributes were ordered randomly for each choice set to reduce 
presentation bias.   
 
The Ngene software package (www.choicemetrics.com) was used to construct an initial d-
efficient DCE design based upon a priori expectations of the likely direction of parameters.191  
We hypothesized that oncologists would recommend anticancer drugs with a longer survival, 
higher chance of improvement in cancer related symptoms, lower chance of serious adverse 
events, and lower out-of-pocket cost.  
 
The survey was pilot-tested by 10 oncologists to ensure content validity, acceptability, clarity, 
and consistency.  Responses from the pilot study were analysed with NLOGIT 5.0, using a 
mixed multinomial logit model (MMNL).  Data from the pilot study was used to generate a 
more statistically efficient DCE design for distribution to the entire MOGA membership.  The 
final design had d-error = 0.0000053, and a minimum sample size of 7.192  Responses from 
the pilot study were not included in the analysis reported here.  
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 Attributes of the anticancer drugs and their possible levels presented to Table 6.1.
respondents with each choice set 
Attribute Drug A Levels Drug B Levels 
Median overall survival  
in months 
6 
12 
24 
6, 7, 7.5, 8, 9 
12, 14, 15, 16, 18 
24, 28, 30, 32, 36 
Maximum out-of-pocket 
cost to the patient in 
Australian dollars 
$0 $0 
$5000 
$10,000 
$20,000 
$100,000 
Chance of a serious adverse 
event 
10 out of 100 patients 
20 out of 100 patients 
30 out of 100 patients 
10 out of 100 patients 
20 out of 100 patients 
30 out of 100 patients 
Chance of improvement in 
cancer related symptoms 
17 out of 100 patients 
33 out of 100 patients 
67 out of 100 patients 
17 out of 100 patients 
33 out of 100 patients 
67 out of 100 patients 
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Respondents were randomly allocated to see one of two blocks of 15 choice sets.  
Respondents had to choose between recommending drug A or drug B for each choice set, 
with no facility to opt-out of a recommendation for treatment.  An example choice set is 
shown in Figure 6.2.  Following presentation of the choice sets, participants were asked about 
personal and professional characteristics.  
 
Respondents who did not complete ≥50% of the choice sets were excluded from the analysis 
set.  We used NLOGIT 5.0, to construct a MMNL model to examine the influence of the 
chosen attributes, and respondent characteristics, on choices.  Attributes of the anticancer 
drugs were modelled in separate analyses as either linear or ordinal (effects coded) variables.  
The personal and professional characteristics of respondents were modelled as categorical 
(effects coded) variables.  These characteristics included age, gender, level of experience, 
whether they had dependent children, hours spent in research, hours spent in clinical practice, 
practice type and practice location.  All attributes and respondent characteristics were initially 
included as random parameters with normal distributions; any parameters that did not 
demonstrate significant heterogeneity were then re-specified as non-random in subsequent 
iterations of the choice model.  Interactions between attributes and respondent characteristics 
were evaluated in addition to main effects. 
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Figure 6.2. Example choice set presented to respondents 
 DRUG A DRUG B 
Median overall survival  7 months 9 months 
Maximum out-of-pocket cost to 
the patient 
$0 $20,000 
Chance of a serious adverse  event 10 of 100 patients 
receiving this drug 
20 of 100 patients 
receiving this drug 
Chance of improvement in cancer 
related symptoms 
17 of 100 patients 
receiving this drug 
33 of 100 patients 
receiving this drug 
Which drug would you 
recommend to the patient? 
Please tick one box 
□ □ 
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The final specification of the utility functions for drug A and drug B were: 
U(drug A) = β0(constant) +(β1 x survival) + (β2 x out-of-pocket cost) + (β3 x serious adverse 
event) + (β4 x symptom improvement) 
U(drug B) = (β1 x survival) + (β2 x out-of-pocket cost) + (β3 x serious adverse event) + (β4 x 
symptom improvement) + (β5 x practice location) + (β6 x clinic hours worked) 
 
Results are reported as regression coefficients (betas) and odds ratios (i.e. eβ), with 95% 
confidence intervals (CIs).  The odds ratios are interpreted in terms of the odds of 
recommending an anticancer drug, given a specified increase in that attribute level.  Trade-
offs between attributes were estimated by the ratios of mean regression coefficients from the 
analysis in which the attributes were modelled as linear variables.  Plots of regression 
coefficients for each level of survival benefit, from the analysis in which the attributes were 
modelled as ordinal variables, were used to estimate threshold levels of the minimum survival 
gain needed for respondents to recommend drug B over A. 
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6.5 Results 
 
 Respondents 6.5.1
The survey was distributed to 603 potential participants.  We received 101 evaluable 
responses (96 full completions, 5 incomplete but evaluable; overall response rate = 17%).  
Oncologists who responded were mostly fully qualified (72/96, 75%), were male (51/96, 
53%) and had a median age of 39 (Table 6.2).  Most respondents had practices that were 
predominantly metropolitan (75/96, 78%) and public (62/96, 65%).  
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 Personal and professional characteristics of respondents Table 6.2.
Characteristic n=96 
Age  
   ≤30 6 
   >30 to ≤40 48 
   >40 to ≤50 23 
   >50 to ≤60 15 
   >60 4 
Role  
   Qualified medical oncologist 72 
   Trainee medical oncologist 24 
Gender  
   Male 51 
Dependent children  
   Yes 56 
Years worked in medical oncology  
   ≤10 62 
   >10 to ≤20 14 
   >20 20 
Hours spent in clinic per week  
   ≤20 60 
   >20 36 
Hours spent in research per week  
   ≤20 78 
   >20 18 
Practice type  
   Predominantly public 62 
   Predominantly private 11 
   Other† 23 
Practice location  
   Metropolitan 75 
   Regional/rural area 10 
   Other‡ 11 
†Includes an equal mix of both public and private, or no current clinical practice 
‡Includes an equal mix of metropolitan and regional/rural practice, or no clinical practice 
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 Oncologists’ recommendations 6.5.2
All the attributes of anticancer drugs we included were significantly associated with the odds 
of a recommendation in the direction hypothesized a priori (Table 6.3).  The odds for 
recommending either drug increased with longer survival time (OR = 2.16 per extra month of 
survival, p<0.0001), and with a higher chance of improving cancer related symptoms (OR = 
1.69 for every 5% absolute increase, p<0.0001).  In other words, the odds of recommending 
an anticancer drug was approximately double for every month increase in survival time, and 
for every 7% increase in the chance of improving cancer related symptoms.  The odds for 
recommending either drug decreased with higher out-of-pocket costs (OR = 0.92 per extra 
A$1000 in out-of-pocket costs, p<0.0001), and with a higher chance of a serious adverse 
event (OR = 0.72 for each 5% absolute increase, p<0.0001).  In other words, the odds of 
recommending an anticancer drug was approximately halved per A$8000 increase in the out-
of-pocket cost, and per 11% increase in the chance of a serious adverse event.  The significant 
constant term (OR=6.57; 95% CI: 4.01 to 10.8, p<0.001) indicates that all else being equal, 
there was an underlying preference for recommending drug A (always A$0 out-of-pocket 
cost) over drug B (out-of-pocket cost varied). 
 
The characteristics of respondents were examined as predictors of choice and as interactions 
with attributes of the anticancer drugs, and were not significantly associated with the odds of 
recommending an anticancer drug.  Despite this, practice location and clinic hours were 
included in our final model, because they significantly improved the model fit (based on LL 
ratio test (chi sq = 94.95 (2df), p<0.0001) and lower AIC (1120.4 vs 1212.9)).  
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 The effects of drug attributes and respondent characteristics on the odds of Table 6.3.
recommending a new anticancer drug 
 Regression 
coefficient (β) 
Odds Ratio 
(95% CI) 
P value 
Random parameters   
(attributes of anticancer drugs) 
      
Median overall survival  
(per extra month of survival) 
0.77 2.16 (1.86 to 2.50) <0.0001 
Maximum out-of-pocket cost  
(per extra $1000) 
-0.09 0.92 (0.90 to 0.93) <0.0001 
Chance of a serious adverse event  
(per 5% absolute increase) 
-0.33 0.72 (0.65 to 0.81) <0.0001 
Chance of improvement in cancer related 
symptoms (per 5% absolute increase) 
0.53 1.69 (1.55 to 1.86) <0.0001 
Fixed parameters    
Constant (drug A) 1.88 6.57 (4.01 to 10.8) <0.0001 
Regional/rural practice location (vs 
metropolitan) 
-0.31 0.74 (0.48 to 1.12) 0.2 
Clinic hours >20 hours/week  
(vs <20hours/week) 
0.17 1.18 (0.90 to 1.55) 0.2 
Note: This mixed multinomial logit model had a log likelihood of -549, p<0.001, and McFadden pseudo R2 = 0.43, reflecting 
a ‘very good’ fit for the data.  
CI: confidence interval  
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 Trade-offs between attributes 6.5.3
To justify a cost of A$10,000 to the hypothetical patient, respondents required an average of 
1.4 additional months of survival (95% CI 1.2 to 1.5, IQR 0.8 to 1.6), when survival was 
modelled linearly.  Sixty-three percent (64/101) of respondents required more than one 
additional month of survival time to justify recommending drug B and 8% (8/101) required 
more than two additional months of survival time.  To justify a cost of A$10,000 to the 
hypothetical patient, respondents required an average absolute decrease of 17% in the chance 
of a serious adverse event (95% CI 14% to 21%, IQR 8% to 20%), or an average absolute 
increase of 9% in the chance of improving cancer related symptoms (95% CI 8% to 10%, IQR 
6% to 10%).  
 
 Minimum survival benefits required 6.5.4
Figure 6.3 is a plot of the regression coefficient (β) for each level of absolute survival benefit 
in numbers of months (difference of median survivals for drug B minus drug A).  It shows 
that the regression coefficients were not statistically significant different from zero for 
absolute survival benefits of 2 months or less.  This suggests a threshold of 2 to 3 months of 
additional survival time for respondents to recommend drug B over A.  Figure 6.4 is a plot of 
the regression coefficient for each level of relative survival benefit (ratio of median survivals 
for drug B over drug A).  It shows that the regression coefficients were not statistically 
different from zero for relative survival benefits less than 1.5. This suggests a threshold of 
1.33 to 1.5 times relative increase in survival for respondents to recommend drug B over A. 
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Figure 6.3. Effect of absolute increase in survival time on recommending drug B over A 
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Figure 6.4. Effect of relative increase in survival time on recommending drug B over A 
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6.6 Discussion 
 
This survey of Australian oncologists showed that the odds of recommending an anticancer 
drug were approximately doubled for every month it increased survival and for every 7% it 
increased the chance of improving cancer related symptoms.  The odds of recommending an 
anticancer drug were approximately halved for every A$8000 increase in out-of-pocket costs 
to patients, and for every 11% increase in the chance of a serious adverse event.  To justify an 
out-of-pocket cost to patients of A$10,000, respondents required on average, 1.4 months 
additional survival time if survival was modelled linearly.  If survival was modelled as an 
ordinal attribute, respondents appeared to require between 2 to 3 months of additional survival 
time before they would consider recommending an expensive, unfunded anticancer drug over 
one that had no out-of-pocket cost to the patient. 
 
Previous surveys have demonstrated that physicians’ recommendations are strongly 
influenced by the effects of treatment on survival time.193-196  However, no studies to our 
knowledge, have sought to determine the out-of-pocket costs to which oncologists were 
willing to subject their patients, for given improvements in survival, accounting for other 
important factors such as reductions in symptoms or toxicity.  Respondents appeared willing 
to expose the hypothetical patients to out-of-pockets costs ranging from a few thousand 
dollars to over A$20,000 for each additional month of survival time.  This variability in how 
oncologists value survival has been demonstrated previously.119,197,198  For example, in a study 
of North American oncologists, the minimum improvement in median survival required for 
them to prescribe a hypothetical new anticancer drug that was much more expensive than the 
existing standard, ranged from less than 1 month to more than 12 months.119  This variability 
in willingness to financially burden patients is likely to reflect differences in how oncologists 
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value improvements in survival, their attitudes about patients paying for health care, and the 
types of patients they typically see in practice.  For example, oncologists in private practices 
may be more likely to see patients with sufficient resources to pay for expensive treatments.  
However, we did not find that the nature of the oncologist’s practice influenced their 
recommendations. 
 
Our findings suggest that Australian oncologists were unwilling to recommend expensive, 
unfunded anticancer drugs over those with no out-of-pocket cost, unless there was an absolute 
survival gain of at least 2 months or a relative survival gain greater than 33%.  A relative 
survival gain of 33% is analogous to a hazard ratio of 0.75, i.e. a 25% reduction in the hazard 
of death.  Australian oncologists may be concerned about subjecting their patients to the 
financial burden of an expensive anticancer drug with a modest benefit if there is another 
anticancer drug with little or no financial burden.  It is important to note that the absolute 
minimum survival improvement was based on increments over baseline survival times of 6, 
12 and 24 months.  It is possible that the minimum survival benefit required would be smaller 
if we had asked oncologists to only consider baseline survival times shorter than 6 months, 
and might be larger if they only considered baseline survival times longer than 24 months.    
 
The main strength of our study is that it used DCE, a validated method for quantifying the 
simultaneous effects and importance of multiple attributes on individuals’ preferences, to 
clarify trade-offs between differences in in survival, cancer related symptoms, serious adverse 
events, and out-of-pocket costs, when recommending anticancer drugs.199  Asking oncologists 
to consider multiple attributes versus single trade-offs between two attributes should better 
reflect real world decision-making and the value oncologists place on these attributes.  
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The main limitations of this study stem from using a small set of attributes and range of levels 
- the results are only directly applicable to the clinical situations presented.  Secondly, these 
choices were hypothetical and may not actually reflect what oncologists do in practice.  
Thirdly, our response rate of 17% was low but typical of electronic surveys distributed to 
medical practitioners, and it is possible that non-responders might have made different 
recommendations.200  Lastly, respondents were oncologists from a health system in which 
prescription drugs are predominantly publicly funded.  Therefore, their recommendations may 
have been particularly sensitive to the out-of-pocket costs, although studies of United States 
(US) oncologists have also demonstrated the influence of out-of-pockets on discussions and 
recommendations about anticancer drugs.177,180,201 
 
An interesting finding from our study was the significance of the constant in our model, 
which indicates a preference for drug A over B regardless of the levels of the attributes.  That 
is, there was something else about drug A that made it preferable to drug B that was not 
captured in the four attributes presented.  It is likely that drug A was perceived as the publicly 
funded (PBS listed), standard of care.  Respondents may have preferred to recommend the 
established treatment and may have placed extra value on an anticancer drug that is PBS listed 
due to the rigorous regulatory process required to achieve PBS listing, including assessments 
about safety, efficacy and cost-effectiveness.  Alternatively, respondents may have considered 
drug B to be an “access program drug”, made available to patients by pharmaceutical 
companies before a drug is given regulatory and reimbursement approval.  Some oncologists 
have raised moral and ethical concerns about such anticancer drugs and hence may prefer not 
to recommend them under any circumstances.89  
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We chose to frame costs as the maximum out-of-pocket borne by patients to have treatment. 
With many new anticancer drugs, the duration of treatment for advanced disease, and 
therefore its total cost, is unknown until it has been completed.202,203  This uncertainty about 
the total cost may also influence oncologists’ recommendations.204   
 
The perceived certainty of a benefit or harm may also be important, above and beyond its 
actual magnitude.  A small improvement in survival may be more or less important depending 
on the certainty that it is beyond the play of chance.  For example a survival improvement of 
two months with a very low p-value and narrow confidence interval may be valued more than 
a survival improvement of three months with a higher p-value and wider confidence interval.  
When recommendations about new anticancer drugs are being made in routine clinical 
practice, the applicability of the evidence on which they are based may not be as clear cut as 
we presented.  This may be especially true for new unfunded anticancer drugs with only 
preliminary evidence of efficacy and safety.  
 
Our study focuses on the initial treatment of advanced cancer but it would be relevant to ask 
similar questions of oncologists making recommendations about second, subsequent and last 
line treatments, or about adjuvant therapies.  The range of attributes tested could also be 
broadened beyond those of the anticancer drugs (e.g. patient’s finances, age, type of cancer, 
etc.).  It would also be interesting to determine if the recommendations of oncologists 
working in health system with larger out-of-pocket costs, like the US, differ from those of 
oncologists in predominantly publicly funded systems with smaller out-of-pocket -costs. 
What patients deem minimal clinically important benefits when they are paying a substantial 
out-of-pocket context for treatment with an expensive anticancer drug should also be explored 
and compared to oncologists’ views. 
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Patients’ attitudes, values, priorities and preferences should be paramount when making 
decisions about cancer treatment.98,205  We assessed oncologists’ recommendations in this 
study because of the critical role of the oncologist in influencing patient decisions about 
cancer treatments and the consequent costs borne by patients.110  Our study increases 
understanding about the relative importance oncologists ascribe to survival gains, symptom 
benefits, toxicity harms, and out-of-pocket costs when recommending anticancer drugs.  It 
also suggests that there needs to be a minimum level of survival benefit for oncologists to 
consider financially burdening their patients.  Future studies should focus on patients’ 
preferences because they are likely to differ from those of oncologists.206-208  Oncologists 
should also be aware of their own attitudes and values, and how these influence their 
recommendations to patients. 
 
 
  
143 
7 VALUING THE BENEFITS OF NEW ANTICANCER DRUGS 
 
7.1 Overview 
 
Chapter 7 is a published manuscript aimed at a clinical audience. It explores the challenge of 
determining the value of anticancer drugs with a focus on two recently developed 
frameworks. The American Society of Clinical Oncology value framework (version 1.0, 
2015) and the European Society for Medical Oncology (version 1.0, 2015) value framework 
are described and compared. Their potential application to decision making and the 
importance of credibly determining the value of expensive new anticancer drugs is discussed.  
The entire manuscript is quoted verbatim. 
 
Publication details 
Lawrence NJ, Salkeld G, Stockler MR, Karikios D. Valuing the benefits of new anticancer 
drugs. Med J Aust; 204:403-405, 2016. 
Permission has been granted by the corresponding author (Nicola J Lawrence) to include this 
publication in my thesis.  
 
Contribution of authors 
NJL: Conceived the research proposal, contributed to the concept development, reviewed 
existing literature, analysed and compared the described examples, and drafted and revised 
the manuscript. 
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of the manuscript. 
DK: Contributed to the concept development, reviewed existing literature particularly relating 
to drug costs, health system and health economic data, analysed and compared the described 
examples, and drafted and revised the manuscript. 
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7.2 Manuscript 
 
Annual expenditure on anticancer drugs by the Pharmaceutical Benefits Scheme (PBS) has 
risen from A$65 million in 1999–2000 to A$466 million in 2011–2012 – an average annual 
increase of 19%.209  This is more than double Australia’s average annual increase in health 
expenditure of 8% over the same period.120  New techniques in radiation oncology and 
surgical oncology have also increased expenditure on cancer.  It has never been more 
important to assess the value of new cancer treatments, weighing up the balance between 
benefits, harms and costs.  In oncology, clinical benefit is defined by improvements in 
survival and cancer-related symptoms, and must be traded off against treatment-related 
adverse effects and financial burden.  In Australia, evaluation of the trade-offs for new 
anticancer drugs has been predominantly a matter of healthcare policy, and determined by the 
Pharmaceutical Benefits Advisory Committee (PBAC). 
 
People affected by cancer also face decisions about paying for unfunded treatments and need 
to understand the degree of benefit a treatment may offer.  This is not straightforward, as 
illustrated by an American study published in 2012, which reported that 69% of patients with 
metastatic lung cancer and 81% of patients with metastatic colorectal cancer did not 
understand that their treatment was ‘not at all likely to cure’ their cancer.210  It is even more 
difficult to balance modest benefits in survival against toxicity and cost, especially when new 
treatments are portrayed in the media as major breakthroughs. 
 
The world’s two leading medical oncology organisations, the American Society of Clinical 
Oncology (ASCO) and the European Society for Medical Oncology (ESMO), have recently 
formulated the first objective, validated and reproducible frameworks to assess the value of 
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anticancer drugs.37,211  These frameworks aim to improve transparency and provide 
independent measures of the degree of benefit a treatment offers.  Both frameworks use data 
from individual trials to assess the value of a new treatment in comparison with the standard 
of care used in the trial.  Important similarities between the frameworks include separate 
scoring systems for treatments given with curative intent versus palliative intent; higher value 
given to improvements in overall survival than to improvements in surrogate endpoints such 
as progression free survival (PFS) or response rate; and, upward adjustments for 
improvements in quality of life or reductions in toxicity.  In this article, we summarise and 
compare the frameworks using two examples, and discuss their relevance to clinical practice 
and healthcare policy.  
 
The ASCO has developed two instruments – one for potentially curable disease (adjuvant 
setting) and another for advanced disease – that yield a net health benefit (NHB) score for a 
new treatment in comparison with the standard of care, using published trial data.  In 
advanced disease, the maximum NHB score is 130, indicating substantial improvements in 
overall survival, toxicity, cancer-related symptoms, and treatment-free interval.  The primary 
outcome contributes a maximum of 80 points to NHB, with higher scores for bigger 
improvements and for benefits in overall survival rather than PFS or objective tumour 
response rate.  The adjustment for toxicity ranges from -20 for much more toxic to +20 for 
much less toxic.  Significant improvements in cancer-related symptoms contribute an 
additional 10 points.  An improvement in the treatment-free interval (from completion of the 
new treatment to initiation of the next treatment) contributes a maximum of 20 points.  The 
total NHB score is judged against the cost of acquiring the drug and patient co-payments.  The 
ASCO framework does not define benchmarks for the NHB indicating high value, or a level 
that justifies funding, leaving individuals and policy makers to draw their own conclusions. 
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The ASCO framework is summarised with two worked examples in Table 7.1.  An evaluation 
of erlotinib versus chemotherapy as first-line treatment for metastatic non-small cell lung 
cancer with a driver mutation of the epidermal growth factor receptor (EGFR), yielded a NHB 
score of 44/130, using the ASCO framework, indicating moderate benefit.212  In contrast, an 
evaluation of bevacizumab used in addition to chemotherapy in unselected patients with 
metastatic non-small cell lung cancer yielded a NHB score of 16/130, indicating modest 
benefit.213  The ASCO framework can also be used to compare the prices of two treatment 
strategies; however, in Australia, determining the additional costs of the new treatments is 
complex.  Erlotinib is listed on the PBS for the indication above, and in 2016 costs patients 
$38.20 per month ($6.20 per month for concession-card holders), with an approximate price 
paid by the PBS of A$1500/month.  Bevacizumab is not listed on the PBS for the indication 
above, and would cost patients about A$8000 per month.  
 
The ESMO instruments categorise the benefits of anticancer drugs compared with current 
standard of care.  The instruments yield an alphabetic grade (A, B, or C) for treatments that 
are potentially curative, and a numerical grade (5, 4, 3, 2 or 1) for treatments unlikely to be 
curative, both ranked in diminishing order of benefit.  The grades are assigned based on 
observed benefits in survival or PFS in both relative terms (hazard ratios [HRs]) and absolute 
terms (numbers of months).  This ensures an emphasis on benefits that are clinically 
important rather than just statistically significant.  The ESMO framework evaluates the 
survival benefit first, and then adjusts the benefit grade for toxicity and quality of life.  
Financial cost was deliberately excluded from the ESMO framework because of differences 
between countries in costs and health service delivery.  ESMO proposes that each healthcare 
jurisdiction make its own independent judgements about value for money and willingness to 
pay after considering the grade of clinical benefit.  
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The ESMO framework is summarised in Table 7.1 using the same two worked examples.  
Erlotinib compared with standard chemotherapy as first-line treatment for metastatic EGFR-
mutated non-small cell lung cancer was assigned a grade 4 benefit using the ESMO 
framework, the highest possible grade for a non-curative treatment with PFS as the primary 
endpoint.212  Erlotinib received a high clinical value rating as it substantially reduced the rate 
of progression (HR, 0.37), improved median PFS by 4.5 months, and had less toxicity than 
standard-of-care chemotherapy.  In contrast, bevacizumab in combination with chemotherapy 
for unselected metastatic non-small cell lung cancer was assigned a grade of 2, because the 
survival benefits were judged modest (HR for death, 0.79, with an absolute improvement in 
median survival of 2 months), and were not associated with improvements in toxicity or 
quality of life.213  
 
The ASCO and ESMO frameworks led to similar conclusions in the two examples, yielding 
higher benefit ratings for erlotinib in EGFR-mutated non-small cell lung cancer than for 
bevacizumab in unselected non-small cell lung cancer.  The conclusions are consistent with 
the PBAC decision to fund erlotinib, but not bevacizumab, for the indications specified. 
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 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) frameworks for evaluating clinical Table 7.1.
benefit in advanced cancer: worked examples 
HR = hazard ratio; NSCLC = non-small cell lung cancer; OS = overall survival; OTRR = overall tumour response rate; PFS = progression-free survival; QOL = quality of life; TFI = treatment-free interval 
 ASCO framework ESMO framework 
Domain Description 
Erlotinib v  
chemotherapy  
for EGFR-mutated NSCLC 
Bevacizumab + 
chemotherapy v 
chemotherapy alone for 
NSCLC Description 
Erlotinib  
v chemotherapy  
for EGFR-mutated NSCLC 
Bevacizumab + 
chemotherapy v 
chemotherapy alone for 
NSCLC 
Main outcome Maximum scores of 80 for 
doubling OS; 55 for doubling 
PFS; 40 for OTRR of 80%; 
lower scores for more modest 
improvements 
PFS prolonged by 4.3 
months (87%) from 5.2 
months in control group to 
9.7 months in erlotinib 
group: score, 44 
OS prolonged by 2.0 months 
(19%) from 10.3 months in 
control group to 12.3 months 
in bevacizumab group: score, 
16 
Preliminary grade from 1 
(smallest improvement in 
OS or PFS) to 4 (biggest 
improvement in OS or 
PFS) 
PFS prolonged by 4.3 
months from 5.2 months in 
control group to 9.7 months 
in erlotinib group (HR, 0.37): 
grade 3 
OS prolonged by 2.0 months 
from 10.3 months in control 
group to 12.3 months in 
bevacizumab group (HR, 
0.79): grade 2  
Toxicity The number of severe 
toxicities differs between the 
treatment groups by 50% or 
more: score, −20 to +20 
33% reduction from 12 in 
control group to 8 in erlotinib 
group: score, 0 
46% increase from 15 in 
control group to 22 in 
bevacizumab group: score, 0 
Upgrade one level if there 
is a statistically significant 
reduction in severe 
toxicities affecting daily 
wellbeing 
15% fewer severe toxicities: 
upgrade from preliminary 
grade 3 to grade 4 
No significant reduction in 
severe toxicities: remains at 
preliminary grade 2 
Other Significant palliation of 
symptoms: maximum score, 
10 
Symptoms no better: score, 0 Symptoms no better: score, 0 Upgrade one level if QOL 
improved 
QOL not improved: no 
upgrade 
QOL not improved: no 
upgrade 
TFI prolonged by ≥ 20%: 
maximum score, 20 
TFI not prolonged by ≥ 20%: 
score, 0 
TFI not prolonged by ≥ 20%: 
score, 0 
Total score Net health benefit score: −12 
(more toxic and no benefit) to 
130 (substantially better OS, 
TFI, symptoms and toxicity) 
44/130 16/130 Final adjusted clinical 
benefit grade: 1 (least 
benefit) to 5 (greatest 
benefit) 
Grade 4 Grade 2 
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The simultaneous development of these frameworks highlights the global recognition that 
healthcare costs are increasing rapidly while resources are limited, and the need to establish 
rigorous assessments of the value of new treatments.  This is important regardless of whether 
it is a jurisdiction or an individual deciding whether to pay for an expensive new anticancer 
drug. 
 
In Australia, the Therapeutic Goods Administration approves the marketing of new drugs 
based on safety and efficacy, but it is the PBAC that makes recommendations to the Health 
Minister, based on clinical and economic considerations, about which drugs should be PBS 
listed and hence funded by the government.  In the United States, the Food and Drug 
Administration is the sole agency responsible for the approval of new drugs for marketing, 
but it is not permitted to consider cost or cost-effectiveness in its deliberations.  The ASCO 
and ESMO frameworks allow policy makers and healthcare funders from different healthcare 
systems to consider the value of a new treatment together with local considerations such as 
costs, disease prevalence, and competing priorities.  These frameworks provide an 
independent, objective and structured approach that could increase transparency of decisions 
made by the PBAC and similar agencies.      
 
Clinicians should find the frameworks useful when assessing and explaining the value of new 
anticancer drugs, because they provide standardised metrics for expressing benefit.  This 
should allow clearer communication with patients, particularly in situations where new 
treatments are unfunded, expensive, and have modest benefits.  The ESMO framework is 
probably easier to use and expresses value in simple grades.  The ASCO framework is more 
complex, and expresses value with a numerical score that requires more explanation and 
interpretation.  The ASCO plans further development of its framework to facilitate doctor-
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patient communication and shared decision making.37  An important enhancement would be 
the capacity for individuals and groups to assign weights to the factors that are most important 
to them.  For example, some prioritise survival benefits regardless of cost or toxicity, whereas 
others prioritise quality of life over survival time.  The incorporation of such weights would 
help communities, patients and doctors make decisions that better reflect their preferences.  
 
The costs of health care are burgeoning and this approach warrants consideration beyond 
oncology.  All treatments require rigorous assessments of efficacy, safety and cost-
effectiveness.  These frameworks provide important first steps towards standard definitions, 
metrics and criteria for assessing the value of new anticancer drugs.  
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8 DISCUSSION 
 
8.1 Overview  
 
This chapter discusses the work in this thesis considered as a whole.  It begins by 
summarising the principal findings (section 8.2).  The strengths and limitations of the work 
are then described (sections 8.3 and 8.4).  This is followed by a discussion of the implications 
for clinical practice and health policy (section 8.5), recommendations for future research 
(section 8.6,) and concluding remarks (section 8.7). 
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8.2 Summary of principal findings 
 
 Spending on anticancer drugs has increased substantially in Australia.  8.2.1
A published study describing the growing costs of anticancer drugs in Australia from 2000 to 
2012 was presented in Chapter 3.  Pharmaceutical Benefits Scheme (PBS) expenditure on 
anticancer drugs increased from A$65 million to A$466 million during this period, with an 
average increase of 19% per year.  In comparison, expenditure on all other PBS-listed drugs 
increased by an average of 9% per year.  The average price per prescription paid by the PBS 
for an anticancer drug increased by 133% in real terms from 2000 to 2012.  The real average 
annual increase in the average price per prescription paid by the PBS for an anticancer drug 
was more than double that for all other drugs listed on the PBS (7.6% vs 2.8%).  The median 
price paid by the PBS for anticancer drugs listed between 2000 and 2012 was approximately 
A$5000 per month.  This study demonstrated that the costs of anticancer drugs in Australia 
had increased substantially, with proportional increases similar to those seen in other high-
income countries.33-35,41  
 
 Most submissions for listing an anticancer drug on the PBS are rejected at least 8.2.2
once and the rejection rate for initial submissions is increasing.  
A published study of the reasons why the Pharmaceutical Benefits Advisory Committee 
(PBAC) rejects submissions to list anticancer drugs on the PBS, and the rejection rates over 
time, was presented in Chapter 4.  The rejection rate for submissions made to the PBAC for 
listing anticancer drugs on the PBS between 2005 and 2014 was 56% (119/213). Of the 110 
indications requested, 69% (76/110) were rejected at least once.  There was no evidence that 
rejection rates increased over time in general, however rejection rates for initial submissions 
were higher from 2010 to 2014 than from 2005 to 2009 (70% vs 54%, p=0.04). Only 19% 
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(17/110) of the indications requested between 2005 and 2014 remained unlisted at the end of 
2015. 
 
 Frequent reasons for the PBAC to reject submissions for public subsidy of 8.2.3
anticancer drugs were inadequate cost-effectiveness, PBAC uncertainty about the 
clinical and economic evidence, and choice of comparator. 
The study reported in Chapter 4 found that inadequate cost-effectiveness, largely attributable 
to high price, was the most frequent reason for rejection of an application for listing a new 
anticancer drug on the PBS.  An incremental cost-effectiveness ratio greater than 
$45000/quality-adjusted life year was associated with 7.7 times the odds of rejection in a 
logistic regression analysis.  PBAC judgements that the clinical or economic evidence was 
uncertain were offered as the reason for rejection in more than half of the submissions 
rejected.  A PBAC judgement of uncertain or problematic clinical evidence was the 
characteristic that best discriminated between a recommendation for listing versus a rejection 
in a recursive partitioning analysis.  Eighty-one percent (73/90) of major submissions that 
were judged by the PBAC to have problematic or uncertain evidence were rejected, versus 
39% (25/64) when the PBAC did not make this judgement.  The choice of an inactive 
comparator was strongly associated with rejection in logistic regression analysis, and if the 
PBAC did not accept the comparator submitted rejection occurred 100% (10/10) of the time.  
 
 Oncologists frequently discuss and prescribe expensive unfunded anticancer 8.2.4
drugs. 
A published report of a survey asking Australian medical oncologists about their experiences 
with unfunded anticancer drugs was presented in Chapter 5.  Oncologists reported discussing 
unfunded anticancer drugs with almost 3 patients per month and reported prescribing them to 
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about 1 patient per month.  Just over two-thirds of oncologists reported prescribing at least 
one unfunded anticancer drug in a recent 3-month period.  This was much higher than a 
comparable study published in 2006 which found that less than 50% of Australian medical 
oncologists reported prescribing an unfunded anticancer drug at all.179  Oncologists in our 
study also reported that they were prescribing more unfunded anticancer drugs than they had 
in the past.  A higher frequency of discussion and prescription of unfunded anticancer drugs 
was associated with clinical practices that were predominantly metropolitan (city based). 
 
 Oncologists estimated that their patients are paying thousands of dollars to access 8.2.5
unfunded anticancer drugs, and oncologists were concerned about causing their 
patients financial harm. 
The survey reported in Chapter 5 found that the median of the maximum amounts oncologists 
estimated their patients had paid out-of-pocket for a course of treatment with an unfunded 
anticancer drug was A$7500, and ranged from a few hundred dollars to A$100,000.  
Oncologists also reported that on most occasions where they prescribed an unfunded 
anticancer drug the cost was partially subsidised by a pharmaceutical company access 
program.  Oncologists estimated that almost one-third of their patients who were prescribed 
an unfunded anticancer drug had paid the full cost.  Eighty-three percent of oncologists 
reported that these out-of-pocket costs influenced their willingness to prescribe unfunded 
anticancer drugs. 
 
Oncologists were concerned about causing their patients financial harm and distress over 
decisions about treatment when they discussed and/or prescribed unfunded anticancer drugs.  
Oncologists wanted easy access to information about what unfunded anticancer drugs were 
available and how much they would cost patients.  They were less enthusiastic about the idea 
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of guidelines or workshops aimed at assisting them with discussing unfunded anticancer 
drugs.  
 
 The magnitude of survival benefits and out-of-pocket costs strongly influence 8.2.6
oncologists’ recommendations about anticancer drugs. 
The results of a discrete choice experiment (DCE) asking oncologists to weigh up differences 
between hypothetical anticancer drugs are reported in Chapter 6.  The odds of recommending 
an anticancer drug to a hypothetical patient with a newly diagnosed, advanced, incurable 
cancer were approximately doubled for every month that the drug would prolong survival, 
and for every 7% absolute increase in the chance it would improve cancer related symptoms.  
The odds of recommending an anticancer drug were approximately halved for every A$8000 
increase in out-of-pocket costs to patients, and for every 11% absolute increase in the chance 
of a serious adverse event.  Previous studies have demonstrated that clinicians’ 
recommendations are influenced by the effects of treatment on survival time.193-196  However, 
no studies have sought to determine the out-of-pocket costs that oncologists were willing to 
subject their patients to for given improvements in survival, accounting for other important 
factors such as reductions in symptoms and/or toxicity. 
 
 Oncologists required a minimum improvement in survival time to recommend an 8.2.7
expensive, unfunded anticancer drug to a hypothetical patient with advanced 
cancer. 
The study reported in Chapter 6 determined the survival benefit oncologists required to justify 
their patients paying significant out-of-pocket costs.  To justify an out-of-pocket cost to 
patients of A$10,000 respondents required an average additional survival time of 1.4 months 
if survival was modelled linearly.  If survival was modelled as an ordinal variable, there was a 
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threshold minimum survival benefit of 2 to 3 months for respondents to recommend an 
expensive, unfunded anticancer drug.  
 
 Recently developed frameworks to assess the value of anticancer drugs could 8.2.8
support decisions about the funding of anticancer drugs and about choosing 
treatments for individuals with cancer. 
A published report comparing two recently developed frameworks to assess the value of 
anticancer drugs is presented in Chapter 7.  These frameworks were developed by the 
American Society of Clinical Oncology (ASCO) and the European Society of Medical 
Oncology (ESMO) to address the problem of valuing new anticancer drugs, and provide 
independent measures of the degree of benefit a treatment offers using data from pivotal 
clinical trials.  They both have different scoring systems for treatments given with curative 
intent versus palliative intent.  Higher value is given to treatments that improve overall 
survival (versus progression free survival or tumour response rates), quality of life, and/or 
reduce toxicity.  The simultaneous development of these frameworks highlights the global 
recognition that rigorous assessments of the value of new treatments are important in this era 
of rapidly rising healthcare costs.  The use of these frameworks by the PBAC would increase 
the transparency of decisions about the funding of anticancer drugs and could help oncologists 
explain the value of new anticancer drugs to their patients. 
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8.3 Strengths 
 
The main strengths of the studies in this thesis as a whole are their coherency and careful a 
priori specification of their individual aims, objectives, hypotheses and analysis plans.  The 
main strengths of each individual study are addressed separately in Chapters 3, 4, 5, and 6, 
and are reiterated and reconsidered together here. 
 
The published studies on the costs of anticancer drugs in Australia and the reasons the PBAC 
rejects submissions to list anticancer drugs on the PBS, presented in Chapter 3 and 4, are the 
first studies of their kind aimed at an Australian clinical audience.  These studies provide a 
useful starting point for Australian oncologists wishing to understand and discuss the costs of 
anticancer drugs and the reasons anticancer drugs have not been listed on the PBS.  The 
findings are also relevant to health policy decision makers by describing the rising costs of 
anticancer drugs, the rate of rejection and the reasons for rejection, and putting them into 
context and perspective.  This might influence decisions and deliberations about reviewing 
and/or modifying the processes of the PBAC, discussed further in section 8.5.   
 
The published study of the reasons the PBAC rejects submissions to list anticancer drugs on 
the PBS, presented in Chapter 4, comprehensively reviewed all PBAC decisions made since 
public summary documents (PSDs) became available up until 2014.  The review included all 
submissions: both major and minor; and both those reported in a PSD and those that were not.  
The set of characteristics extracted from submissions was exhaustive and included those 
previously demonstrated to influence decisions based on health technology assessments.  Data 
was extracted independently by two investigators to minimise observer bias.  The logistic 
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regression model was fitted using generalised estimating equations to account for the nesting 
of, and correlations between, repeated submissions for the same drug and indication. 
 
The published survey of oncologists’ experiences regarding unfunded anticancer drugs, 
presented in Chapter 5, provides original, unique, contemporary data about the reported 
frequency of discussions and prescriptions of unfunded anticancer drugs, and about 
oncologists’ attitudes and beliefs.  It reveals that the use of unfunded anticancer drugs is 
becoming more common, that it is a major concern for oncologists and provides a rationale 
for future research into how oncologists should communicate with patients about the value of 
expensive, unfunded anticancer drugs.  The survey questions were developed with a focus 
group of oncologists, piloted in a small sample and then revised before being distributed 
widely.  
 
The study of oncologists’ recommendations about unfunded anticancer drugs, presented in 
Chapter 6, used a DCE to ask oncologists who practise in a health system that is 
predominantly funded publicly, to reflect on their recommendations to patients when there is 
potential for significant financial harm.  We confirmed that the use of a DCE to elicit 
oncologists’ preferences for recommending unfunded anticancer drugs was feasible and 
allowed quantification of the contributions of various attributes of anticancer drugs to the 
recommendations made to patients.  We constructed the DCE to simulate real world decision 
making to get an accurate understanding of how key attributes of anticancer drugs affected 
oncologists’ recommendations.  A deeper understanding of what influences oncologists’ 
recommendations is important because they are very likely to influence patients’ perception 
and choices about treatments.110,111 
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The studies in this thesis address an important gap due to the lack of previous research 
conducted in Australia that aims to improve understanding of the consequences of the high 
and rising costs of new anticancer drugs, an issue of great importance to the Australian 
community.89,214  Significant attention has been focussed on this issue internationally, 
particularly in the United States (US), but relatively little research has previously been 
conducted in Australia.33,34,215-221 
 
Lastly, the studies in this thesis have focused on cancer in general, rather than on a specific 
cancer type or types.  The intention was to maximise the applicability and potential impact of 
the results. 
 
  
161 
8.4 Limitations  
 
The main limitations of each study are addressed separately in each of the included papers 
(Chapters 3, 4, 5, and 6), and are reiterated and reconsidered together here. 
 
The main limitation of the study on the costs of anticancer drugs in Australia, reported in 
Chapter 3, is that it relies solely on information that is available publicly.  For example, to 
calculate the monthly prices paid by the PBS for new anticancer drugs, prices published in the 
PBS schedule were used, the so called dispensed price for maximum quantity (DPMQ) or 
dispensed price for maximum amount (DPMA).  The DPMQ or the DPMA is not the price 
negotiated by the government and pharmaceutical company which is kept secret in the 
interests of commercial confidence.222 Another relevant limitation of this study in the context 
of this thesis is that the data reported is from 2000 to 2012 and this thesis was submitted in 
2018. Suggestions for updating this work are made in section 8.6.  
 
The study presented in Chapter 4 on the reasons the PBAC rejects submissions to list 
anticancer drugs on the PBS also relies on publicly available information.  The data source 
was PSDs and brief summaries of outcomes that report the recommendations of the PBAC.  
Neither the full submissions prepared by pharmaceutical companies nor the evaluation reports 
prepared by independent experts are made publicly available.  There is no guarantee that all 
information considered by the PBAC is reported in the PSDs, and some information is 
deliberately redacted because pharmaceutical companies want it kept confidential.  
Nonetheless, this remains the best available information on the reasons why the PBAC rejects 
submissions to list anticancer drugs on the PBS. 
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The study of oncologists’ reported experiences with unfunded anticancer drugs, presented in 
Chapter 5, has the usual limitations of all surveys.223  This includes the potential for both 
recall bias and desirability bias, particularly regarding the data about frequency of discussion 
and prescription which might be underestimated or overestimated by respondents.  The results 
of this survey are also susceptible to responder bias because oncologists with strong interests 
or views about expensive unfunded anticancer drugs might have been more or less likely to 
respond to the survey and therefore might not be representative of non-respondents. This 
study did not explore how oncologists perceive type of outcome (e.g. evidence of overall 
survival versus progression free survival), or magnitude of benefit, affect their discussions 
about and prescriptions of unfunded anticancer drugs. Chapter 6 examined how the magnitude 
of overall survival benefit may affect recommendations about expensive drugs but further 
work addressing these important factors is needed. 
 
The study of oncologists’ recommendations about unfunded anticancer drugs, presented in 
Chapter 6, was based on hypothetical clinical scenarios.  It is possible that responding 
oncologists would make different recommendations when faced with the same situations in 
the real world.  However, the convenience and flexibility of the DCE method in adapting to a 
wide variety of valuation problems outweighed the possible disadvantages of using 
hypothetical scenarios.224  The response rate in this study (17%), and the study presented in 
Chapter 5 (27%), were low but typical of electronic surveys distributed to clinicians.183 
 
This thesis has focused on costs of anticancer drugs to the PBS and costs to individuals of 
unfunded anticancer drugs.  A limitation of this thesis as a whole is that costs of anticancer 
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drugs to public and private hospitals, and private health insurers, have not been examined. 
The costs of anticancer drugs to these providers is likely to represent a small proportion of the 
total expenditure on anticancer drugs in Australia however examining costs from the 
perspective of these providers is nevertheless important and relevant.  
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8.5 Implications for clinical practice and health policy  
 
The work in this thesis has implications for oncologists and their patients who wish to seek 
treatment with new anticancer drugs in the Australian healthcare system.  In addition to facing 
the stresses of a cancer diagnosis, its symptoms and the adverse effects of treatment many 
patients now face the challenges of difficult decisions about treatment and its possible 
financial harm.  This is due to the high cost of new anticancer drugs, the challenges faced by 
the health system in providing timely, subsidised access to new anticancer drugs and the 
willingness of oncologists to consider, discuss and recommend treatment with expensive, 
unfunded anticancer drugs. 
 
The rising costs of anticancer drugs described in Chapter 3 pose major funding challenges for 
all health systems.  Those that are predominantly publicly funded are under pressure to 
provide access to treatments that maximise health gains with limited funds.225  Public funding 
of new anticancer drugs requires higher expenditure which must be funded by increasing debt, 
revenue (higher taxes) and/or decreasing other expenditures.  If these options are not taken up 
access to expensive new anticancer drugs is limited to those willing and/or able to bear the 
substantial costs.  
 
PBAC rejections of applications for new anticancer drugs to be listed on the PBS delay broad 
access to new anticancer drugs.  Most indications sought in the study presented in Chapter 4 
required multiple submissions to the PBAC, and the proportion of applications requiring 
multiple submissions appears to be increasing.  If the rejection rate or decision making 
becomes a concern to policymakers, particularly politicians, then this might provoke review 
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of the PBAC system and processes.  Such a review could explore the provision for more 
explicit feedback to sponsors on the reasons for rejection, especially for initial submissions.  
Particular attention should be paid to the reasons that have made the PBAC ‘uncertain’ about 
the clinical and/or economic evidence submitted, and how this can be constructively managed 
to improve timely access to subsidised anticancer drugs.  Recognition and agreement about 
the uncertainty prior to an initial submission may prompt a request for approval through a 
managed entry scheme for the anticancer drug in question, or a lower asking price by the 
sponsor from the outset, to increase the likelihood of a recommendation for listing on the 
PBS. 
 
If there is a delay between a new anticancer drug being listed on the Australian Register of 
Therapeutic Goods (ARTG) and being listed on the PBS, or if a drug is not listed on the PBS 
at all, decisions about paying for new, expensive anticancer drugs shifts from the publicly-
funded health system to privately-funded individuals.  These treatment decisions for 
individuals with cancer are challenging because determining the value of a new anticancer 
drug is difficult.  This is especially true if the benefits are modest, only apply to a minority of 
patients, the price is high and the individual does not have sufficient disposable income to 
cover the costs. 
 
To limit the number of challenging decisions about expensive, unfunded treatments, 
consideration of adjustments to the approval process should be made.  For example, 
anticancer drugs that have Therapeutic Goods Administration approval and fit a pre-specified 
set of criteria (e.g. ESMO MCBS score of 4 or 5) could be “fast-tracked” to a provisional PBS 
listing making them affordable to all those who seek treatment with them.  If the subsequent 
PBAC approval process deems them cost-ineffective then they could be removed from the 
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PBS or a price reduction could be negotiated to maintain the listing.  Any change to the PBS 
listing process needs to be carefully planned because modification of the anticancer drug 
funding approval process in the UK was not considered successful, and delisting anticancer 
drugs is likely to be politically challenging.226  
 
The study presented in Chapter 4 should help oncologists, patients and the broader 
community better understand the challenges of publicly funding anticancer drugs.  The 
information about the frequency of rejection and the reasons why the PBAC rejected a 
submission to list an anticancer drug on the PBS should help patients and their oncologists 
have more informed discussions about expensive, unfunded anticancer drugs.  For example, 
patients may be interested to hear that an anticancer drug has not been funded because of 
doubts about its efficacy rather than because of its high price.  
 
The studies reported in this thesis indicate that Australians with cancer are at risk of suffering 
financial harm from new, expensive, unfunded anticancer drugs.  Treatment with these drugs 
can cost tens of thousands of dollars.  Our study in Chapter 3 identified that patients would 
pay a median of A$5000/month for a new anticancer drug and the survey of oncologists 
presented in Chapter 5 revealed a median estimated cost of A$7500 per course of an 
expensive, unfunded anticancer drug.  This median cost per month is regardless of whether 
the patient responds to the treatment.  For patients who are responding to a treatment, the 
duration is often open-ended and may typically last 6 to 12 months or even longer.  This 
means that the total cost of the course of an anticancer drug is likely to range from A$10,000 
to A$100,000.  These are substantial sums of money that many individuals could not afford. 
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There are important consequences for patients who choose to take on these costs. There is 
growing evidence in the literature, particularly from research done in the US, that significant 
out-of-pocket costs and financial burden are associated with poorer quality of life and shorter 
survival.116,219-221  Individuals with cancer in Australia already report high out-of-pocket costs, 
so embarking on treatment with an expensive, unfunded anticancer drug could significantly 
impair their well-being.214,227  
 
Australian oncologists were concerned about causing financial harm to patients but appeared 
willing to recommend expensive anticancer drugs with modest benefits in the survey and 
DCE presented in Chapters 5 and 6.  These studies should encourage oncologists to reflect on 
their own values, priorities and preferences, and how these might affect their advice and 
recommendations to patients.  For example, oncologists who might avoid recommending an 
anticancer drug to a patient because of its high cost should be careful to ensure that their 
patients feel similarly about avoiding high costs.  
 
Individuals with cancer and their oncologists will need support and education to deal with the 
increasing need to determine the value of new, expensive anticancer drugs, and for finding 
ways to pay for treatments that are wanted.118  Oncologists need more accurate information 
about the costs and benefits of anticancer drugs; junior oncologists should benefit from 
training about how to discuss the costs, benefits, and value of expensive treatments.  
Oncologists may find the frameworks discussed in Chapter 7 useful when assessing and 
explaining the value of new anticancer drugs to individuals affected by cancer. Both these 
value frameworks have been updated since the publication of the Chapter 7 manuscript and 
therefore oncologists should use the updated versions for this purpose.228 
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8.6 Directions for future research  
 
There are four major areas for future research raised by the studies in this thesis: 
i. improving understanding of how individuals with cancer make decisions about 
treatment with expensive, unfunded anticancer drugs;  
ii. how the community (individuals with cancer and individuals without cancer) views 
the value of new anticancer drugs, and the extent to which recommendations made by 
the PBAC reflect the community’s preferences;  
iii. how oncologists should communicate with patients about the value of anticancer 
drugs; and 
iv. improving understanding of the consequences to individuals with cancer who choose 
to pay for treatment with expensive unfunded anticancer drugs  
 
When deciding about treatment with expensive, unfunded anticancer drugs individuals with 
cancer must make trade-offs between various attributes of the available treatment options 
including their effects on survival, quality of life and out-of-pocket costs.  How individuals do 
this, in particular how much they are willing to pay for anticancer treatments with different 
attributes, has been little studied.   A better understanding is needed of the factors that 
influence these decisions which are likely to differ according to an individual’s particular 
circumstances, experiences, attitudes, priorities and financial circumstances.  The effect of 
factors associated with their illness also warrants further research, for example whether the 
intent of treatment is curative or palliative.  Research addressing these knowledge gaps should 
assist oncologists helping individuals with cancer make decisions about their treatment.117  
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Research is also needed to compare the decisions, and influential factors, of patients receiving 
care in health systems that are predominantly funded publicly versus privately. 
 
In Australia it is ultimately the community (taxpayer) that is paying to subsidise the costs of 
expensive, new anticancer drugs that are listed on the PBS.  The taxes they pay provide the 
funds that the Australian government spends on anticancer drugs.  The PBAC judges the 
value of new anticancer drugs on behalf of the Australian government and makes 
recommendations about which new drugs should be listed on the PBS.  The extent to which 
the PBAC’s judgements reflect the wishes of the community remains unknown.  For example, 
how much the community is willing to pay for anticancer drug X with survival benefit Y may 
differ from that of the PBAC.  The community may be more willing than the PBAC to accept 
a higher level of uncertainty about the benefits of anticancer drugs, or they may wish to 
preserve the sustainability of the system by only wishing to see the most valuable anticancer 
drugs subsidised.  The Australian community is made up of a diverse range of individuals 
who are likely to have different beliefs, priorities and values.  Studies which sample members 
of the Australian community, which aim to capture the views of this diverse range of 
individuals (e.g. those affected by cancer and those who are not), should be undertaken to 
understand how they value anticancer drugs.  This can then be compared to PBAC decisions 
and judgements about their value.  
 
There are many unanswered questions about the best ways of communicating the benefits, 
harms and costs of expensive, unfunded anticancer drugs to help individuals with cancer 
determine their value.  For example, there is no single, simple, agreed method for describing 
the effects of different treatments on survival.  How best to inform individuals about the 
possible costs of treatment is also unclear. For an individual with advanced cancer 
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considering treatment with an anticancer drug(s), the cost per month of treatment is usually 
known.  However, individuals may wish and need to know the total cost of treatment, and this 
may be uncertain and vary substantially between individuals according to their response.  
Studies should be done that ask individuals what information about costs they would like to 
have presented to them, as well as studies that aim to determine how the format and framing 
of information about costs, benefits and harms of anticancer drugs influences treatment 
decisions.  This should help oncologists improve the way they communicate benefits, harms, 
and costs, and reduce the risk that their methods do not bias decisions about treatment.  
 
The ASCO and ESMO frameworks developed to assess the value of anticancer drugs, 
discussed in Chapter 7, may prove useful for oncologists and their patients when comparing 
expensive treatment choices.  Research that tests whether these frameworks are useful for this 
purpose should be undertaken.  The results could be used to educate oncologists on how best 
to incorporate the use of these frameworks into discussions about treatment.  If they are 
unsuitable for this purpose then other tools should be developed. 
 
The consequences of paying for expensive unfunded anticancer drugs to individuals with 
cancer and their families have not been explored in detail in the Australian context. The 
survey reported in Chapter 5 determined that oncologists discuss and prescribe expensive 
unfunded anticancer drugs sufficiently often enough to warrant further scrutiny. Interviews 
and surveys should be conducted to assess the impact of paying for expensive anticancer 
drugs on patients and their families. Audits of dispensed unfunded anticancer drugs from 
pharmacies associated with cancer centres could also be performed to more accurately 
quantify the number of prescriptions. 
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The unique challenges faced by specific communities in accessing expensive anticancer drugs 
and discussing their value should also be explored.  In Chapter 5 oncologists practising in 
predominantly regional or remote areas reported they were less likely to discuss or prescribe 
an unfunded anticancer drug.  This suggests that access to expensive, unfunded anticancer 
drugs for individuals with cancer in regional or remote areas may be limited.  A study should 
be undertaken that aims to determine the differences in the frequency of use of unfunded 
anticancer drugs between individuals living in cities and those in regional or remote areas, and 
that explores the potential factors leading to any differences.  It would also be worth exploring 
the challenges of discussing the value of unfunded anticancer drugs with patients with lower 
levels of education, non-English speaking backgrounds, and/or very limited financial 
resources. 
 
Lastly it will be important to update the studies presented in Chapters 3 and 4 to determine 
future trends in the costs of anticancer drugs, and the rates and reasons for PBAC rejection of 
submissions for listing anticancer drugs on the PBS.  Future studies could also include costs 
of anticancer drugs to hospitals and private health insurers.  This information will be 
important to policymakers who may wish to enact changes based upon these trends.  The 
information will also be important to individuals with cancer seeking treatment with 
anticancer drugs and their oncologists who wish to use the information to lobby for their 
patients’ interests, including more timely access to new anticancer drugs.  
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8.7 Conclusions 
 
The high cost of anticancer drugs has consequences for health systems, individuals with 
cancer and their oncologists. The high cost of new anticancer drugs means that not all new 
anticancer drugs can be publicly subsidised. When the use of a new anticancer drug is not 
publicly subsidised, judgements about its value are shifted from healthcare policy makers and 
funders to individuals with cancer and their oncologists who must make difficult decisions 
about pursuing treatment and its resulting out-of-pocket costs.  Individuals who choose to 
have and pay for these expensive, unfunded anticancer treatments are at risk of substantial 
financial harm. 
 
This thesis provides an Australian perspective on the consequences of the rising cost of new 
anticancer drugs.  The studies in this thesis have demonstrated that the costs and prices of 
anticancer drugs in Australia are increasing rapidly, and that inadequate cost-effectiveness is 
the most frequent reason why submissions for the public subsidy of anticancer drugs are 
rejected.  The rejection rate for initial submissions to the PBAC for public subsidy of new 
anticancer drugs is on the rise.  This rate of rejection of initial submissions to list anticancer 
drugs on the PBS, and the reasons for rejection, deserve ongoing scrutiny as rejections delay 
timely and equitable access to new anticancer drugs, which are important to the community 
and individuals with cancer.  
 
Australian medical oncologists reported that they frequently discuss and prescribe expensive 
unfunded anticancer drugs.  They were concerned about the effects on their patients of 
discussing and prescribing these expensive unfunded anticancer drugs, and required a 
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minimum level of survival benefit to consider financially burdening their patients.  Future 
research should study how the magnitudes of benefits and costs, and the way they are framed, 
influence the oncologists’ and patients’ decisions about treatment, and the minimum benefit 
patients judge sufficient to warrant treatment with an expensive unfunded anticancer drug. 
 
Patients and their oncologists must carefully weigh the benefits, harms, and costs of 
anticancer drugs when making decisions about treatment.  The value frameworks developed 
by the major international cancer societies may assist in the process of shared decision-
making with patients, but their use for this purpose requires study and testing.  Tools that help 
oncologists communicate the costs, benefits, and harms of expensive anticancer drugs are 
needed to minimise the risk of avoidable financial harm. 
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10 APPENDICES 
10.1 Monthly prices for newly listed anticancer drugs (adjusted to 2012 prices) 
Drug name Year PBS listed Tumour type Monthly price (A$) 
Temozolomide 2000 Glioblastoma multiforme 4830 
Irinotecan 2000 Colorectal cancer 3946 
Imatinib 2001 Chronic myeloid leukaemia 8461 
Oxaliplatin 2002 Colorectal cancer 3448 
Gefitinib 2004 Non-small cell lung cancer 4920 
Fotemustine 2005 Melanoma 1696 
Pemetrexed 2005 Non-small cell lung cancer 6052 
Thalidomide 2006 Myeloma 1003 
Trastuzumab 2006 Breast cancer 4777 
Dasatinib 2007 Chronic myeloid leukaemia 5483 
Cetuximab 2007 Head and neck cancer 8424 
Bortezomib 2007 Myeloma 10462 
Lapatinib 2008 Breast cancer 3778 
Fludarabine 2008 
Chronic lymphocytic 
leukaemia 
1118 
Erlotinib 2008 Non-small cell lung cancer 3375 
Nilotinib 2008 Chronic myeloid leukaemia 5999 
Sorafenib 2009 Hepatocellular carcinoma 6585 
nab-Paclitaxel 2009 Breast cancer 3319 
Sunitinib 2009 Renal cell carcinoma 5024 
Bevacizumab 2009 Colorectal cancer 3960 
Arsenic trioxide 2009 
Acute promyelocytic 
leukaemia 
12578 
Lenalidomide 2009 Myeloma 7356 
Azacitidine 2011 
Myelodysplatic syndrome, 
acute myeloid leukaemia, 
chronic myeloid leukaemia 
5145 
PBS: Pharmaceutical Benefits Scheme 
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10.2 Full list of characteristics extracted from publicly available information about submissions made to the PBAC for PBS listing of 
anticancer drugs 
CHARACTERISTIC RESPONSE CHOICES DEFINITIONS and EXPLANATIONS CHARACTERISTIC OBTAINED FROM: 
Major 
submission 
with a PSD 
Minor 
submission 
with a PSD 
Minor 
submission 
without a 
PSD 
SUBMISSION TIMING AND OUTCOMES    
Year of submission E.g. 2005, 
2006……….2014 
Year submission assessed by PBAC.    
PBAC recommendation Recommended for listing The PBAC has made a recommendation for the drug to be listed on the PBS.  
   Deferred The PBAC has deferred its decision (this may require the sponsor to make a 
resubmission).  
Rejected The PBAC has not recommended the drug be listed on the PBS 
INFORMATION SUBMITTED TO THE PBAC 
   
Listing request New listing The drug was not already listed on the PBS for another indication.  
   
Extend existing listing The drug was already listed on the PBS for another indication. 
Submission type Initial submission First time the drug had been assessed by the PBAC for the indication requested.  
   
Resubmission The drug had been assessed by the PBAC for the indication requested previously. 
Cancer type                                                                            E.g. Bladder, Bone,
Breast…………Sarcoma 
Type of cancer proposed for treatment with the drug.    
Treatment intent Curative/Adjuvant The aim of treatment with the drug was to increase the chance of cure. 
   
Palliative  Treatment with the drug does not aim to increase the chance of cure. 
204 
Test required before drug 
can be used 
Yes A patient's tumour must be tested to determine whether it is appropriate for them to have 
treatment with this drug (e.g. HER-2 testing for Trastuzumab).    
No 
Comparator type Inactive The main comparator nominated in the submission was best supportive care, placebo or 
no treatment. 
   
Active The main comparator nominated in the submission was any other anticancer treatment 
(e.g. anticancer drug). 
Type of trial evidence 
submitted 
Direct comparison trials 
only 
All clinical trial evidence submitted were randomised trials of the drug versus the 
nominated main comparator. 
   
Indirect comparison trials 
included 
Clinical trial evidence submitted included trials that were not a direct comparison of the 
drug versus the nominated main comparator. 
Evidence of an overall 
survival benefit 
Yes Statistically significant overall survival benefit seen in at least one of the randomised 
trials submitted of the drug versus comparator. 
   No There was no statistically significant overall survival benefit seen in any of the 
randomised trials submitted of the drug versus comparator; or there were no randomised 
trials of the drug versus comparator submitted 
Type of economic analysis Cost-effectiveness 
analysis and/or cost-
utility analysis 
Type of economic evaluation performed 
   Cost-minimisation 
analysis 
Other 
ICER (cost/QALY) ≤$45,000/QALY The base case ICER from the sponsor’s economic model reported in the PSD [Note: 
exact base case ICERs are not reported in PSDs, but rather an indication is given as to a 
range it fell within. The ranges reported include: <$15,000; $15,000-45,000; $45,000-
75,000; $75,000-$105,000, $105,000-200,000, >$200,000]. 
   
>$45,000/QALY 
Estimated impact on the 
PBS budget per year 
<$10 million This is the sponsors estimated cost to the PBS budget per year if the drug was approved 
for listing on the PBS. 
 
   
≥$10 million 
205 
PBAC JUDGEMENTS OF SPONSOR CLAIMS 
   
Comparator claim Accepted PBAC judgement of the comparator(s) proposed in the submission 
   Partially accepted 
Rejected 
Efficacy claim  Accepted PBAC judgement of the efficacy claim put forward in the submission (Sponsors may 
claim the drug is superior, equivalent, or inferior to the nominated comparator). 
   
Partially accepted 
Rejected 
Unclear 
Toxicity claim Accepted  PBAC judgement of the toxicity claim put forward in the submission (Sponsors may 
claim the drug is superior, equivalent or inferior to the nominated comparator).  
   
Partially accepted 
Rejected 
Unclear 
OTHER JUDGEMENTS MADE BY THE PBAC 
   
PBAC judged clinical 
evidence problematic or 
uncertain 
Yes Indicates whether the PBAC has judged clinical evidence submitted to be problematic or 
uncertain.     
No 
PBAC judged economic 
evidence problematic or 
uncertain 
Yes Indicates whether the PBAC has judged economic evidence submitted to be problematic 
or uncertain.     
No 
PBAC judged there to be 
a high clinical need 
Yes Indicates whether the PBAC has judged there to be a high clinical need for a new 
anticancer drug in the therapeutic area.    
No 
ICER = Incremental Cost-Effectiveness Ratio; PBAC = Pharmaceutical Benefits Advisory Committee; PBS = Pharmaceutical Benefits Scheme; PSD = Public Summary Document; QALY = Quality-Adjusted Life Year 
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10.3 Instrument used to survey Australian medical oncologists for study presented 
in Chapter 5 
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10.4 Instrument used to survey Australian medical oncologists for study presented 
in Chapter 6 
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Thank you for participating in this study that aims to explore the influence of out-of-pocket 
costs on oncologists’ recommendations about treatment to patients with advanced cancer.  
We appreciate that decisions to recommend treatments are complex. This study deliberately 
oversimplifies the situation to assess only some of the factors. We also appreciate that such 
decisions generally incorporate the perceived preferences of the patient. However, this study 
focuses solely on the preferences of the oncologist.  
The questionnaire should take less than 15 minutes to complete. 
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We want you to consider a choice between two hypothetical anticancer drugs to recommend 
to a hypothetical patient with advanced cancer. The anticancer drugs will be called Drug A 
and Drug B.   
Drug A and Drug B will each have four different attributes. You can assume everything else 
about the drugs is the same. Each of the attributes is explained in more detail below. 
 
Median overall survival  
This is the median overall survival in months of patients treated with that drug (A or B) from 
a hypothetical randomised phase III trial. Assume that any differences in overall survival were 
statistically significant with a p-value of <0. 01.  
 
Maximum out-of-pocket cost to the patient 
This is the maximum dollar amount the patient will be out-of-pocket to access that drug (A or 
B).  That is, the pharmaceutical company has capped the out-of-pocket cost to the patient to 
access the drug for as long as they need treatment. The dollar amount does NOT include the 
standard pharmacy dispensing and prescription fees. You can assume if a drug has an out-of-
pocket cost of $0 that it is PBS listed or that a pharmaceutical company is supplying it free of 
charge.  
 
Chance of a serious adverse event 
This is the chance of a patient suffering a serious adverse event if they have treatment with 
that drug (A or B). This is based on the proportion of patients with serious adverse events 
from a hypothetical randomised phase III trial. For the purposes of this study, a serious 
adverse event is defined as an adverse event that requires hospitalisation (the majority), or is 
life threating (rare), or is fatal (very rare).  
 
Chance of improvement in cancer related symptoms 
This is the chance of a patient having an improvement in their cancer related symptoms if 
they have treatment with that drug (A or B). This is based on the proportion of patients who 
reported a clinically significant improvement in cancer related symptoms on a validated, 
patient-reported outcome measure, in a hypothetical randomised phase III trial. 
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Here is an example of what the scenarios will look like: 
 DRUG A DRUG B 
Median overall survival  7 months 9 months 
Maximum out-of-pocket cost to 
the patient 
$0 $20,000 
Chance of a serious adverse  event 10 of 100 patients 
receiving this drug 
20 of 100 patients 
receiving this drug 
Chance of improvement in cancer 
related symptoms 
17 of 100 patients 
receiving this drug 
33 of 100 patients 
receiving this drug 
Which drug would you 
recommend to the patient? 
Please tick one box □ □ 
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Here are the characteristics of the patient we would like you to think about when deciding 
between Drug A and Drug B.  
 
The patient: 
• Has an advanced, incurable cancer 
• Has not received any treatment for their cancer in the past, and the only appropriate 
treatment at present is systemic therapy with an anticancer drug 
• Has some symptoms from their cancer which are affecting their quality of life 
• Is fit for treatment and has no medical comorbidities that would interfere with their 
treatment 
• Has indicated they wish to pursue active treatment 
• Has the same capacity to pay for unfunded treatments as the typical patients you see in 
your practice 
 
 
On the following pages you will be presented with 15 scenarios.  
Please review the attributes of Drug A and Drug B for each scenario carefully and indicate 
which drug you would recommend.  
You must make a choice between Drug A or Drug B for each scenario, even if the scenario 
seems implausible. There is no right or wrong answer. 
The scenarios may seem a little repetitive but each one is different.  
After the 15 scenarios there will be some brief follow up questions and some questions asking 
about you and your oncology practice. 
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SCENARIO 1 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Median overall survival  6 months 7 months 
Maximum out-of-pocket cost to 
the patient 
$0 $10,000 
Chance of a serious adverse  event 10 of 100 patients 
receiving this drug 
30 of 100 patients 
receiving this drug 
Chance of improvement in cancer 
related symptoms 
17 of 100 patients 
receiving this drug 
17 of 100 patients 
receiving this drug 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 2 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Median overall survival 12 months 18 months 
Chance of improvement in cancer 
related symptoms   
33 of 100 patients 
receiving this drug 
33 of 100 patients 
receiving this drug 
Chance of a serious adverse  
event  
20 of 100 patients 
receiving this drug 
30 of 100 patients 
receiving this drug 
Maximum out-of-pocket cost to 
the patient    
$0 $20,000 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 3 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Maximum out-of-pocket cost to 
the patient    
$0 $20,000 
Median overall survival 12 months 14 months 
Chance of a serious adverse  
event  
20 of 100 patients 
receiving this drug 
10 of 100 patients 
receiving this drug 
Chance of improvement in cancer 
related symptoms   
33 of 100 patients 
receiving this drug 
33 of 100 patients 
receiving this drug 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 4 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Maximum out-of-pocket cost to 
the patient    
$0 $100,000 
Chance of improvement in cancer 
related symptoms   
17 of 100 patients 
receiving this drug 
67 of 100 patients 
receiving this drug 
Chance of a serious adverse  
event  
20 of 100 patients 
receiving this drug 
20 of 100 patients 
receiving this drug 
Median overall survival 12 months 16 months 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 5 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Chance of a serious adverse  
event  
30 of 100 patients 
receiving this drug 
10 of 100 patients 
receiving this drug 
Chance of improvement in cancer 
related symptoms   
67 of 100 patients 
receiving this drug 
17 of 100 patients 
receiving this drug 
Median overall survival 12 months 12 months 
Maximum out-of-pocket cost to 
the patient    
$0 $10,000 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 6 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Chance of improvement in cancer 
related symptoms   
67 of 100 patients 
receiving this drug 
17 of 100 patients 
receiving this drug 
Chance of a serious adverse  
event  
10 of 100 patients 
receiving this drug 
30 of 100 patients 
receiving this drug 
Maximum out-of-pocket cost to 
the patient    
$0 $0 
Median overall survival 24 months 36 months 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 7 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Median overall survival 24 months 28 months 
Maximum out-of-pocket cost to 
the patient    
$0 $0 
Chance of a serious adverse  
event  
10 of 100 patients 
receiving this drug 
30 of 100 patients 
receiving this drug 
Chance of improvement in cancer 
related symptoms   
67 of 100 patients 
receiving this drug 
17 of 100 patients 
receiving this drug 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 8 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Median overall survival 6 months 7.5 months 
Chance of improvement in cancer 
related symptoms   
17 of 100 patients 
receiving this drug 
17 of 100 patients 
receiving this drug 
Chance of a serious adverse  
event  
10 of 100 patients 
receiving this drug 
30 of 100 patients 
receiving this drug 
Maximum out-of-pocket cost to 
the patient    
$0 $10,000 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 9 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Maximum out-of-pocket cost to 
the patient    
$0 $5,000 
Median overall survival 24 months 24 months 
Chance of a serious adverse  
event  
30 of 100 patients 
receiving this drug 
10 of 100 patients 
receiving this drug 
Chance of improvement in cancer 
related symptoms   
67 of 100 patients 
receiving this drug 
33 of 100 patients 
receiving this drug 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 10 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Maximum out-of-pocket cost to 
the patient    
$0 $5,000 
Chance of improvement in cancer 
related symptoms   
67 of 100 patients 
receiving this drug 
17 of 100 patients 
receiving this drug 
Chance of a serious adverse  
event  
30 of 100 patients 
receiving this drug 
10 of 100 patients 
receiving this drug 
Median overall survival 6 months 6 months 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 11 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Chance of a serious adverse  
event  
20 of 100 patients 
receiving this drug 
20 of 100 patients 
receiving this drug 
Chance of improvement in cancer 
related symptoms   
33 of 100 patients 
receiving this drug 
33 of 100 patients 
receiving this drug 
Median overall survival 6 months 8 months 
Maximum out-of-pocket cost to 
the patient    
$0 $10,000 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 12 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Chance of improvement in cancer 
related symptoms   
33 of 100 patients 
receiving this drug 
67 of 100 patients 
receiving this drug 
Chance of a serious adverse  
event  
20 of 100 patients 
receiving this drug 
20 of 100 patients 
receiving this drug 
Maximum out-of-pocket cost to 
the patient    
$0 $0 
Median overall survival 24 months 30 months 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 13 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Median overall survival 6 months 6 months 
Chance of a serious adverse  
event  
10 of 100 patients 
receiving this drug 
30 of 100 patients 
receiving this drug 
Chance of improvement in cancer 
related symptoms   
33 of 100 patients 
receiving this drug 
33 of 100 patients 
receiving this drug 
Maximum out-of-pocket cost to 
the patient    
$0 $20,000 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 14 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Maximum out-of-pocket cost to 
the patient    
$0 $100,000 
Chance of improvement in cancer 
related symptoms   
17 of 100 patients 
receiving this drug 
67 of 100 patients 
receiving this drug 
Chance of a serious adverse  
event  
20 of 100 patients 
receiving this drug 
10 of 100 patients 
receiving this drug 
Median overall survival 24 months 32 months 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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SCENARIO 15 
Please compare the two anticancer drugs below and decide which you would 
recommend to the patient described earlier. 
 DRUG A DRUG B 
Chance of a serious adverse  
event  
30 of 100 patients 
receiving this drug 
10 of 100 patients 
receiving this drug 
Chance of improvement in cancer 
related symptoms   
17 of 100 patients 
receiving this drug 
67 of 100 patients 
receiving this drug 
Median overall survival 12 months 16 months 
Maximum out-of-pocket cost to 
the patient    
$0 $100,000 
Which drug would you 
recommend to the patient? 
Please tick one box □     □     
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We would like to ask you some follow up questions about how you made 
your choices 
1. Please rank the importance of the attributes in making your choices from 1-4, 
with 1 being the most important and 4 being the least important.  
□ Median overall survival 
□ Maximum out-of-pocket cost 
□ Chance of a serious adverse event 
□ Chance of improvement in cancer related symptoms 
 
2. Please indicate which of the following attributes you ignored (if any) when 
you were making your choice between Drug A and Drug B 
□Median overall survival 
□Maximum out-of-pocket cost 
□Chance of a serious adverse event 
□Chance of improvement in cancer related symptoms  
□ I did not ignore any attribute(s)  
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We would like to ask some general questions about you and your practice 
 
1. Which of the following best describes you? 
⃝ Qualified medical oncologist  
⃝ Advanced trainee in medical oncology 
 
 
2. How many years have you worked in medical oncology (including advanced 
training)?  
 
____________________ 
 
 
3. In which state or territory have you predominantly practiced? 
⃝ QLD 
⃝ NSW 
⃝ ACT 
⃝ VIC 
⃝ TAS 
⃝ SA 
⃝ WA 
⃝ NT 
 
 
4. What is your age? 
 
____________________ 
 
 
5. What is your sex? 
⃝ Male 
⃝ Female 
 
 
6. Do you have dependent children? 
⃝ Yes 
⃝ No 
 
 
 
7. How many hours per week on average do you spend in clinics currently? 
 
____________________ 
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8. How many hours per week on average do you spend in research currently? 
 
____________________ 
 
 
9. In which of the following settings is most of your clinical practice? 
⃝ Public practice 
⃝ Private practice 
⃝ An equal mix of public and private practice 
⃝ N/A – I currently don’t have a clinical practice 
 
 
10. Is most of your clinical practice located in? 
⃝ A metropolitan area 
⃝ A regional/rural area 
⃝ An equal mix of metropolitan and regional /rural areas 
⃝ N/A – I currently don’t have a clinical practice 
 
 
11. Approximately how many patients did you enrol into clinical trials in the 
past 12 months? 
 
 
____________________ 
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Thank you very much for taking the time to complete this questionnaire. 
 
If you have any questions or concerns about this study, please contact: 
 
Deme Karikios BSc MBBS FRACP 
NHMRC Clinical Trials Centre, University of Sydney 
 
Chris O’Brien Lifehouse 
Level 6, 119-143 Missenden Road 
Camperdown NSW 2050 
 
Ph: +61 2 8036 5233 
 
Email: deme.karikios@ctc.usyd.edu.au 
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Abstract
Background: Anticancer drugs are often expensive and are contributing to the
growing cost of cancer care. Concerns have been raised about the effect rising costs may
have on availability of new anticancer drugs.
Aim: This study aims to determine the recent changes in the costs of anticancer drugs
in Australia.
Methods: Publicly available expenditure and prices paid by the Australian Pharmaceu-
tical Beneﬁts Scheme (PBS) for anticancer drugs from 2000 to 2012 were reviewed.
The measures used to determine changes in cost were total PBS expenditure and
average price paid by the PBS per prescription for anticancer drugs and for all PBS listed
drugs. An estimated monthly price paid for newly listed anticancer drugs was also
calculated.
Results: Annual PBS expenditure on anticancer drugs rose from A$65 million in
1999–2000 to A$466 million in 2011–2012; an average increase of 19% per annum. The
average price paid by the PBS per anticancer drug prescription, adjusted for inﬂation,
increased 133% from A$337 to A$786. The real average annual increase in the price per
anticancer drug prescription was more than double that for all other PBS drugs com-
bined (7.6% vs 2.8%, difference 4.8%, 95% conﬁdence interval −0.4% to 10.1%, P =
0.07). The median price for a month’s treatment of the new anticancer drugs listed was
A$4919 (range A$1003 to A$12 578, 2012 prices).
Conclusions: PBS expenditure and the price of anticancer drugs in Australia rose
substantially from 2000 to 2012. Dealing with these burgeoning costs will be a major
challenge for our health system and for those affected by cancer.
Introduction
The cost of healthcare is rapidly rising. Health spending in
Australia in recent years has increased at a faster rate
than spending on all other goods and services.1 This
increase in costs creates major challenges for healthcare
systems, particularly those like Australia’s that are
publically funded.
The cost of cancer care has more than doubled over the
past 20 years with a most recent estimate of over A$5
billion per year in 2009.2 The causes are complex and
include the growing availability and use of new and
expensive anticancer drugs.3 Spending on drugs is one of
the fastest growing components of healthcare costs in
developed countries.1 Anticancer drugs are estimated to
represent 10% of cancer costs in Organisation for Eco-
nomic Co-operation and Development countries.4
Concerns have been raised about the effects of rising
prices on the availability of new anticancer drugs.4–6 In
Australia, widespread access to expensive drugs depends
on whether they are listed on the Pharmaceutical Ben-
eﬁts Scheme (PBS). PBS listing requires a favourable
assessment of cost-effectiveness which is not forthcoming
for every effective anticancer drug. Gaining access to
effective anticancer drugs that are not listed on the PBS is
a major dilemma for patients and doctors. However, we
were unable to ﬁnd published reports focusing on the
costs of anticancer drugs in Australia that might inform
clinicians and patients facing this increasingly common
challenge.
The aims of this study were to: (i) determine changes in
PBS expenditure on anticancer drugs from 2000 to 2012;
(ii) compare price increases for anticancer drugs to other
Funding: D. J. Karikios is supported by a National Health and
Medical Research Council Postgraduate Scholarship and a
Sydney Catalyst Top-Up Research Scholar Award.
Conﬂict of interest: G. Salkeld has received an honorarium and
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cost-effectiveness of drug selection and reimbursement. J.
Trotman has conducted clinical trials for Roche, Novartis,
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Roche Advisory Boards (non-renumerated) and lectured at
Roche Symposia (non-renumerated).
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drugs listed on the PBS; (iii) determine the monthly price
paid for newly listed anticancer drugs; and,
(iv) consider the reasons for, and implications of, our
ﬁndings.
Methods
PBS expenditure and average
prescription prices
We determined annual expenditure and prescription
volumes for all PBS listed drugs, and for anticancer drugs
(using the PBS subcategory Anti-neoplastics), from the
publicly available Pharmaceutical Beneﬁts Pricing
Authority Annual Reports (2000–2010) and Pharmaceu-
tical Beneﬁts Scheme Expenditure and Prescription
reports (2003–2012).7,8 The average price paid by the PBS
per prescription was calculated by dividing the total
expenditure by prescription volumes for each year.
Patient co-payments were not included in these calcula-
tions. All prices were adjusted to reﬂect 2012 values
(‘real’ prices) using the average health prices inﬂation
ﬁgure of 3.0% from 1999–2000 to 2010–2011.1,9
Monthly prices of newly listed
anticancer drugs
PBS schedules from January 2000 to June 2012 were
searched for listings of new anticancer drugs that were
categorised under the PBS subcategory Anti-neoplastics.10
Drugs that were listed on the PBS prior to 2000 but
granted additional indications from 2000 to 2012 were
not included. Prices paid by the PBS for a month’s treat-
ment (28 days) were calculated for each new anticancer
drug using the recommended schedule and ‘typical’ dose
calculated for a patient with body surface area (1.73 m2)
and/or body weight (70 kg).11 If a drug dose varied
during a treatment protocol, then the dose used for the
majority of the protocol was chosen for the typical dose
calculation.
For each new anticancer drug listed, the dispensed price
for maximum quantity was determined from the PBS
schedule in the year the drug was listed.10 An approxi-
mation of the price paid by the PBS for each dose was
determined by calculating the proportion of the
maximum quantity required for a typical dose. For intra-
venous drugs, we determined the price using the most
efﬁcient combination of vials required for the typical
dose. The estimated price paid per month was deter-
mined by multiplying the price per dose by the number of
doses required per month.
We did not consider anticancer drugs listed under sub-
categories other than Anti-neoplastics, for example, endo-
crine therapies, vaccines, supportive care drugs and drugs
for non-melanoma skin cancer.
Statistical analysis
Descriptive statistics were used to analyse the monthly
prices of new drugs listed on the PBS. A paired t-test was
used to compare the annual average price rise in anti-
cancer drugs to the annual average price rise for all other
PBS listed drugs combined. Data were analysed with SPSS
version 20.
Results
PBS expenditure on anticancer drugs and the average
price paid by the PBS for anticancer drugs both climbed
markedly from 2000 to 2012. Expenditure on anticancer
drugs rose from A$64.8 million in 1999–2000 to A$466.3
million in 2011–2012. The peak expenditure occurred in
2010–2011 and was A$561.3 million (Fig. 1). PBS
expenditure, excluding anticancer drugs, climbed at a
lower rate from A$3.1 billion in 1999–2000 to A$8.6
billion in 2011–2012. The average annual increase in PBS
expenditure on anticancer drugs over this time period
was 19.1% compared with 9.0% for all other drugs com-
bined. Expenditure on anticancer drugs was a small but
growing proportion of total PBS expenditure: 2.0% in
1999–2000, 6.4% in 2010–2011 and 5.1% in 2011–2012
(Fig. 2).
The average price paid by the PBS per anticancer drug
prescription increased 133% in real terms from A$338 in
1999–2000 to A$786 in 2011–2012 (all adjusted to 2012
prices, Fig. 3). The average price reached a peak of A$850
in 2009–2010. The average price paid by the PBS for all
prescriptions, excluding anticancer drugs, increased 37%
Figure 1 Pharmaceutical Beneﬁts Scheme (PBS) expenditure on anti-
cancer drugs (without adjustment for inﬂation).
Rising cost of anticancer drugs
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in real terms from A$32 to A$44. The real average annual
increase in the average price paid by the PBS per anti-
cancer drug prescription from 2000 to 2012 was more
than double that for all other PBS drugs combined (7.6%
vs 2.8%), but this trend was not statistically signiﬁcant
(difference 4.8%, 95% conﬁdence interval −0.4% to
10.1%, P = 0.07).
There were 23 new anticancer drugs listed on the PBS
between January 2000 and June 2012 (Table 1). Most
drugs were listed in the second half of the study period,
and 14 of the 23 (61%) were listed for treatment of solid
malignancies. Chronic myeloid leukaemia was the malig-
nancy with the highest number of new drugs listed. The
median price for a month’s treatment of the new anti-
cancer drugs listed during the study period was A$4919
(2012 prices). Prices per month for individual drugs
ranged from A$1003 to A$12 578 (Fig. 4; See Appendix I
for list of individual drugs).
Discussion
This is the ﬁrst report in the medical literature describing
the increasing costs of anticancer drugs to the Australian
PBS. The sevenfold increase in expenditure from 2000 to
2012 is identical to that seen in Europe from 1993 to
2004.12 The median price paid by the PBS for a year’s
treatment of the new anticancer drugs listed during the
study period was approximately A$60 000 in 2012 prices.
The average price paid by the PBS per prescription for
Figure 2 Percentage of Pharmaceutical Beneﬁts Scheme (PBS) expendi-
ture on anticancer drugs.
Figure 3 Average price paid by the Pharmaceutical Beneﬁts Scheme
(PBS) per prescription: all anticancer drugs versus all other PBS drugs
(adjusted to 2012 prices). , Anticancer drugs; , All other PBS
drugs.
Table 1 Characteristics of newly listed anticancer drugs (2000–2012)
Drug characteristics n (%)
Total 23
Year PBS listed
2000–2006 9 (39)
2007–2012 14 (61)
Drug class
Cytotoxics 8 (35)
Tyrosine kinase inhibitors 8 (35)
Monoclonal antibodies 3 (13)
Other 4 (17)
Tumour type
Chronic myeloid leukaemia 4 (17)
Myeloma 3 (13)
Breast 3 (13)
Colorectal 3 (13)
Lung 3 (13)
Other 7 (30)
PBS, Pharmaceutical Beneﬁts Scheme.
Figure 4 Monthly prices for newly listed anticancer drugs (adjusted to
2012 prices).
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anticancer drugs has more than doubled in real terms,
climbing an average of 7.6% per annum, which echo US
price rises over a similar period.13 In comparison, the
average price paid by the PBS for all other PBS drugs
combined has increased more gradually.
The many and complex reasons for the rise in PBS
expenditure on anticancer drugs include increases in the
prevalence of cancer and in the proportions of patients
for whom there are suitable treatments.14 The 7.6% rise
per annum in the average price paid by the PBS per
prescription for anticancer drugs is driven by rapid
growth in the number of new expensive drugs. This may
explain why the average prices paid for prescriptions
used to treat other high-burden diseases, in which the
number of newly available drugs has grown more slowly,
have changed much less. For example for drugs used to
treat diabetes, the average annual increase in the average
prescription price paid by the PBS over the study
period was 1.6%, while for lipid-modifying drugs
and psychoanaleptics used to treat mental illness, there
have been average annual falls of 2.4% and 2.0%
respectively.7,8
The effort to develop newer and better drugs to treat
patients with cancer has resulted in over 70 anticancer
drugs being currently listed on the PBS, many with multi-
ple indications.10 The US Food and Drug Administration
approved 12 new anticancer drugs in 2012 alone.15 Some
have argued that the price of new anticancer drugs is
increasing rapidly because of the increasing cost of drug
development, with estimates ranging from A$500 million
to A$2 billion per new drug approved.16 This ﬁgure
includes substantial expenditure on drugs that fail to reach
the market. For example, it is estimated that of the 920
drugs tested in clinical trials between 1990 and 2006, only
32were approved in the United States.17 Debate continues
about whether these costs justify the asking price for new
anticancer drugs, particularly when marketing budgets
and proﬁts are also substantial.15
Many new anticancer drugs are molecularly targeted
and are substantially more expensive than traditional
cytotoxic drugs.12 The beneﬁcial effects of targeted anti-
cancer drugs are usually conﬁned to a subgroup of all
patients. The presence of a testable molecular target offers
the potential to identify and treat only those for whom
treatment is most likely to be beneﬁcial. This reduces the
total number of patients to be treated, which should
reduce total costs, but also provides a commercial ration-
ale for increasing the price to make up for a smaller
market. Another factor tending to increase the total costs
of molecularly targeted agents is that they are often used
for longer periods than their cytotoxic counterparts.18
Furthermore, older anticancer drugs are commonly not
phased out with the introduction of new drugs but rather
used sequentially or in combination which also signiﬁ-
cantly contributes to growing costs.19
Reductions in prices of anticancer drugs due to the
availability of generic equivalents can help mitigate the
effect of expensive new drugs on the growth rate of
expenditure. Australia’s pricing and reimbursement
system may result in a lower price for new drugs, but a
higher price for generic drugs, in comparison with simi-
larly developed countries.20 Therefore, the potential cost
savings due to the use of generic drugs may not be as
substantial in Australia as in other developed countries,
an effect that is compounded by the speed of oncology
drug development. Newer, more expensive versions of
existing anticancer drugs that are either equivalent or
offer only modest additional beneﬁts may penetrate the
market and reduce the use of cheaper generics by making
them seem suboptimal and superseded.19
This study is limited by its short time frame (2000 to
2012) and focus on drugs listed under the Anti-neoplastics
subcategory which does not include endocrine drugs
used to treat breast cancer or prostate cancer or
immunomodulating drugs, such as the colony stimulat-
ing factors commonly used in conjunction with chemo-
therapy. Our estimates of the monthly prices for new
anticancer drugs are based on the price listed on the PBS
schedule, whereas the actual prices paid by the PBS are
negotiated in conﬁdence by the Pharmaceutical Beneﬁts
Pricing Authority, and can involve special pricing
arrangements and risk sharing agreements.21 This study
also ignores variations in total costs attributable to vari-
ations in durations of use.
It was surprising to see that total expenditure on anti-
cancer drugs and the average prescription price paid by
the PBS dropped in 2011–2012. This was partly due to
PBS listing of cheaper generics for high-use drugs, such as
docetaxel and the introduction of the Australian
Commonwealth government’s Efﬁcient funding of chemo-
therapy drugs policy.22
Despite rapid rises in total expenditure on anticancer
drugs, and in the average price paid by the PBS per
prescription, anticancer drugs accounted for less than 6%
of the total PBS budget in 2012. Anticancer drugs are
estimated to account for about 10–15% of expenditure
on cancer care; hospitalisation of cancer patients is esti-
mated to account for about 70%.23 Nevertheless, the
rising costs of anticancer drugs substantially strain pub-
licly funded healthcare systems like Australia’s.
The Pharmaceutical Beneﬁts Advisory Committee
(PBAC), the body that makes recommendations to the
Federal health minister as to whether new drugs should
be publically reimbursed, is just as likely to make a posi-
tive recommendation for an anticancer drug as it is for
other drugs.24 Despite this, the high price asked for many
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new anticancer drugs often results in an initial rejection
for PBS listing due to the PBAC’s reasonable assessment
of unsatisfactory cost-effectiveness. This delays, and
therefore reduces access to reimbursed new anticancer
drugs.
This study indicates that patients wanting to use new
anticancer drugs that are not reimbursed currently face
bills of about A$5000 per month. Physicians will increas-
ingly ﬁnd themselves in the difﬁcult position of having to
discuss with patients whether the ﬁnancial toxicity of
these new drugs is warranted by their beneﬁts, which are
often relatively modest.25
Conclusion
This study demonstrates a substantial increase in the
average prescription price paid by the PBS for anticancer
drugs, over and above inﬂation for health prices in
general, alongside a rapid growth in total government
expenditure on anticancer drugs. Dealing with these bur-
geoning costs at both the societal level, and for individ-
uals, while retaining effective, equitable and readily
accessible cancer care, poses a major challenge for all
health systems.
References
1 Australian Institute of Health and
Welfare. Health Expenditure Australia
2010–11. Canberra: AIHW; 2012. [cited
2013 Apr 8]. Available from URL:
http://www.aihw.gov.au/WorkArea/
DownloadAsset.aspx?id=10737423003
2 Australian Institute of Health and
Welfare. Australia’s Health 2012.
Canberra: AIHW; 2012. [cited 2013 Apr
8]. Available from URL: http://www
.aihw.gov.au/WorkArea/DownloadAsset
.aspx?id=10737422169
3 Meropol NJ, Schulman KA. Cost of
cancer care: issues and implications. J
Clin Oncol 2007; 25: 180–6.
4 Sullivan R, Peppercorn J, Sikora K,
Zalcberg J, Meropol NJ, Amir E et al.
Delivering affordable cancer care in
high-income countries. Lancet Oncol
2011; 12: 933–80.
5 Kefford RF. Drug treatment for
melanoma: progress, but who pays?
[editorial]. Med J Aust 2012; 197: 198–9.
6 Lord E Cancer drugs too costly for PBS.
Australian Doctor 2013 [cited 2013 Sep
9]. Available from URL: http://www
.australiandoctor.com.au/news/latest
-news/.cancer-drugs-too-costly-for-pbs
7 Pharmaceutical Beneﬁts Pricing
Authority. Pharmaceutical Beneﬁts Pricing
Authority Annual Reports (2000–2010).
Canberra: Commonwealth of Australia;
2000–2010. [cited 2013 Apr 8].
Available from URL: http://www.pbs
.gov.au/info/industry/pricing/pbs-items/
historical/pbpa-annual-reports
8 Pharmaceutical Beneﬁts Scheme. PBS
Expenditure and Prescriptions (2003–2012).
Canberra: Commonwealth of Australia;
2003–2012. [cited 2013 Apr 8].
Available from URL: http://www.pbs
.gov.au/info/browse/statistics
#Expenditure
9 Australian Institute of Health and
Welfare. Health Expenditure Australia
2009–10. Canberra: AIHW; 2011. [cited
2013 Apr 8]. Available from URL:
http://www.aihw.gov.au/WorkArea/
DownloadAsset.aspx?id=10737420254
10 Australian Government Department of
Health and Ageing. Schedule of
Pharmaceutical Beneﬁts. Canberra:
Commonwealth of Australia;
2000–2013.
11 Cancer Institute New South Wales. eviQ
Cancer Treatments Online. Sydney, NSW:
Cancer Institute New South Wales;
2013. [cited 2013 Apr 8]. Available from
URL: https://www.eviq.org.au
12 Dranitsaris G, Ortega A, Lubbe MS,
Truter I. A pharmacoeconomic modeling
approach to estimate a value-based
price for new oncology drugs in
Europe. J Oncol Pharm Pract 2012;
18: 57–67.
13 Fojo T, Grady C. How much is life
worth: cetuximab, non-small cell lung
cancer, and the $440 billion question. J
Natl Cancer Inst 2009; 101: 1044–8.
14 Bach PB. Limits on Medicare’s ability to
control rising spending on cancer drugs.
N Engl J Med 2009; 360: 626–33.
15 Kantarjian HM, Fojo T, Mathisen M,
Zwelling LA. Cancer drugs in the United
States: Justum Pretium – the just price.
J Clin Oncol 2013; 31: 3600–4.
16 Savage P. Development and economic
trends in cancer therapeutic drugs in the
UK from 1955 to 2009. J Oncol Pharm
Pract 2012; 18: 52–6.
17 Reichert JM, Wenger JB. Development
trends for new cancer therapeutics and
vaccines. Drug Discov Today 2008; 13:
30–7.
18 Amir E, Seruga B, Martinez-Lopez J,
Kwong R, Pandiella A, Tannock IF et al.
Oncogenic targets, magnitude of
beneﬁt, and market pricing of
antineoplastic drugs. J Clin Oncol
2011; 29: 2543–9.
19 Siddiqui M, Rajkumar SV. The high cost
of cancer drugs and what we can do
about it. Mayo Clin Proc 2012; 87:
935–43.
20 Clarke PM. Challenges and opportunities
for the Pharmaceutical Beneﬁts Scheme.
Med J Aust 2012; 196: 153–4.
21 Robertson J, Walkom EJ, Henry DA.
Transparency in pricing arrangements
for medicines listed on the Australian
Pharmaceutical Beneﬁts Scheme. Aust
Health Rev 2009; 33: 192–9.
22 Australian Government Department of
Health and Ageing. Revised Arrangements
for the Efﬁcient Funding of Chemotherapy
Drugs & Streamlined Authority Data
Capture. Canberra: Commonwealth of
Australia; 2013. [cited 2013 Apr 8].
Available from URL: http://www.pbs.gov
.au/info/publication/factsheets/shared/
revised-arrangements-for-chemotherapy
23 Soria JC, Blay JY, Spano JP, Pivot X,
Coscas Y, Khayat D. Added value of
molecular targeted agents in oncology.
Ann Oncol 2011; 22: 1703–16.
24 Chim L, Kelly PJ, Salkeld G, Stockler
MR. Are cancer drugs less likely to be
recommended for listing by the
Pharmaceutical Beneﬁts Advisory
Committee in Australia?
Pharmacoeconomics 2010; 28: 463–75.
25 Schrag D. The price tag on progress –
chemotherapy for colorectal cancer. N
Engl J Med 2004; 351: 317–19.
Karikios et al.
© 2014 The Authors
Internal Medicine Journal © 2014 Royal Australasian College of Physicians462
260
Appendix I
Monthly prices for newly listed anticancer drugs (adjusted to 2012 prices)
Drug name Year PBS listed Tumour type Monthly price (A$)
Temozolomide 2000 Glioblastoma multiforme 4830
Irinotecan 2000 Colorectal cancer 3946
Imatinib 2001 Chronic myeloid leukaemia 8461
Oxaliplatin 2002 Colorectal cancer 3448
Geﬁtinib 2004 Non-small-cell lung cancer 4920
Fotemustine 2005 Melanoma 1696
Pemetrexed 2005 Non-small-cell lung cancer 6052
Thalidomide 2006 Myeloma 1003
Trastuzumab 2006 Breast cancer 4777
Dasatinib 2007 Chronic myeloid leukaemia 5483
Cetuximab 2007 Head and neck cancer 8424
Bortezomib 2007 Myeloma 10 462
Lapatinib 2008 Breast cancer 3778
Fludarabine 2008 Chronic lymphocytic leukaemia 1118
Erlotinib 2008 Non-small-cell lung cancer 3375
Nilotinib 2008 Chronic myeloid leukaemia 5999
Sorafenib 2009 Hepatocellular carcinoma 6585
nab-Paclitaxel 2009 Breast cancer 3319
Sunitinib 2009 Renal cell carcinoma 5024
Bevacizumab 2009 Colorectal cancer 3960
Arsenic trioxide 2009 Acute promyelocytic leukaemia 12 578
Lenalidomide 2009 Myeloma 7356
Azacitidine 2011 Myelodysplatic syndrome, acute myeloid leukaemia, chronic myeloid leukaemia 5145
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Abstract
Background: Australians access anticancer drugs predominantly through the Pharma-
ceutical Beneﬁts Scheme (PBS).
Aim: To determine why the Pharmaceutical Beneﬁts Advisory Committee (PBAC)
rejects submissions to list anticancer drugs on the PBS.
Methods: We reviewed publicly available information about submissions made to the
PBAC for PBS listing of anticancer drugs from 2005 to 2014. Submission characteristics,
including clinical and economic evidence, PBAC recommendations, and the reasons
offered for rejection were recorded. Two reviewers independently categorised the rea-
son for rejection offered by the PBAC. Logistic regression was used to determine sub-
mission characteristics associated with rejection.
Results: We identiﬁed 213 submissions for 110 unique indications of 60 anticancer
drugs. The overall rejection rate was 56% (119/213). Of the 110 indications assessed,
69% (76/110) were rejected at least once. The annual rejection rate ranged from 50 to
73% with little evidence of a trend over time (P = 0.2). Submission characteristics
strongly associated with rejection in multivariable analysis included: PBAC judged the
clinical evidence to be problematic or uncertain (P < 0.001); PBAC judged the eco-
nomic evidence to be problematic or uncertain (P < 0.001); and, inactive comparator
used (P < 0.001). The most frequent reasons for rejection offered by the PBAC was
‘inadequate cost-effectiveness or drug price too high’ (75/109, 69%).
Conclusions: Inadequate cost-effectiveness and PBAC uncertainty about the clinical
and economic evidence were the most frequent reasons for rejection. Clarity of infor-
mation about PBAC deliberations and their reasons for rejection are important for
patients and doctors grappling with decisions about the use of expensive unfunded
anticancer drugs.
Introduction
The Australian Pharmaceutical Beneﬁts Scheme (PBS)
is a multibillion dollar, government-funded, national
drug formulary, which subsidises the cost to patients
of listed prescription drugs, including anticancer
drugs.1 Submissions for listing a drug on the PBS are
prepared by a sponsor, usually a pharmaceutical com-
pany, and assessed by the Pharmaceutical Beneﬁts
Advisory Committee (PBAC) using the following cri-
teria: safety and effectiveness; cost-effectiveness and
budget impact; certainty of the evidence; and, degree
of clinical need.2
Submissions to the PBAC fall under two broad cate-
gories – major or minor. A major submission requires an
economic evaluation and includes submissions to list
new drugs on the PBS or to make substantial changes to
an existing listing. A submission can be classiﬁed as
minor if it is a resubmission without substantiative
changes (e.g. a price reduction only); or, if the purpose
Funding: D. J. Karikios has been supported by a National Health
and Medical Research Council Postgraduate Scholarship and a
Sydney Catalyst Top-Up Research Scholar Award.
Conﬂict of interest: L. Chim is currently employed by Alexion
Pharmaceuticals (Australia).
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of the submission is to make minor changes to an exist-
ing listing (e.g. the addition of a new strength).2
The type of economic evaluation required for a major
submission depends on the therapeutic claim put for-
ward. If the claim is superiority to the standard of care,
then the sponsor will usually submit a cost-effectiveness
analysis. If the claim is therapeutic equivalence or non-
inferiority, then a cost-minimisation analysis is sufﬁcient.
These analyses are required to help the PBAC appraise
the clinical effect and cost of the new drug relative to the
current standard of care.
After assessing a submission, the PBAC can recom-
mend that a drug be listed on the PBS, reject the submis-
sion for listing or defer its decision. A rejected
submission can be reconsidered if new evidence is pro-
vided.3 The PBAC ﬁrst announces its recommendations
on the website of the Department of Health, and subse-
quently provides more details about the rationale under-
pinning these recommendations as public summary
documents (PSD).4
Understanding the rationale for rejections of submis-
sions to list anticancer drugs on the PBS is important to
those affected by cancer and their doctors. A rejection
for listing will often make a new drug unaffordable to
all, but those with the resources needed to cover the
substantial treatment costs. The details are also impor-
tant for oncologists to have informed discussions with
their patients about the value and costs of unfunded
anticancer drugs.5–7
The main purpose of this study was to determine the
reasons why the PBAC rejected submissions to list antic-
ancer drugs on the PBS. We sought to determine the
characteristics of rejected submissions for listing of antic-
ancer drugs, the reasons offered for rejection by the
PBAC, and if there were changes over time in the rate of
rejection.
Methods
We reviewed all submissions made to the PBAC for list-
ing of anticancer drugs on the PBS from July 2005 to
July 2014. Details about these submissions were identi-
ﬁed from PSD and brief summaries of outcomes (BSO)
published on the PBS website.8,9 July 2005 was chosen
as the start date as this was the ﬁrst time PSD was made
available. We reviewed both major submissions, which
were always reported in PSD and BSO, and minor sub-
missions, which were sometimes only reported in BSO.
We included submissions about anticancer drugs used
for the treatment of solid cancers (including non-
melanoma skin cancers), haematological cancers and
bone metastases. We excluded submissions about drugs
used for supportive care during treatment (e.g. anti-
emetics and immunomodulating drugs), submissions
requesting simultaneous assessment of more than two
indications for a single drug, and minor submissions
when clinical or economic data were not considered. Dif-
ferent indications identiﬁed from the same PSD or BSO
were considered as separate submissions.
The set of characteristics extracted from submissions
was developed from characteristics previously reported
as being inﬂuential in the decision making of the PBAC
and similar health technology assessment bodies in other
countries.2,10–15 The characteristics included information
submitted to the PBAC (e.g. clinical trial evidence of an
overall survival beneﬁt), judgements or opinions of the
PBAC that were reported in PSD, and recommendations
made by the PBAC (see Supporting Information Table S1
for full list of characteristics). Deﬁnitions of characteris-
tics and possible responses were speciﬁed before data
were extracted. Recommendations made by the PBAC
were dichotomised as either a recommendation for list-
ing or a rejection (including rejections and deferrals).
The reasons for rejection offered by the PBAC, as dis-
tinct from the characteristics of the submission, were
exclusively extracted from the ﬁnal section of the PSD
that speciﬁcally records this information. Reasons for
rejection were extracted verbatim, and then later cate-
gorised after the initial data entry was completed. Two
of the authors extracted all data from submissions inde-
pendently and resolved any disagreements by
consensus.
Standard descriptive statistics were used to summarise
the characteristics of all submissions, and the reasons for
rejection offered by the PBAC. An association between
the submission year and likelihood of rejection was
tested using a logistic regression. The logistic regression
model was ﬁtted using generalised estimating equations
to account for repeated submissions for the same drug
and indication. Individual characteristics were evaluated
for univariable associations with rejection using logistic
regression (ﬁtted with generalised estimating equations).
Characteristics that were statistically signiﬁcant on uni-
variable analysis, from major submissions, and not
explicit judgements of sponsor claims (e.g. acceptance of
efﬁcacy claim) were then evaluated in a recursive parti-
tioning analysis. The subset of these characteristics that
had wide applicability across the major submissions was
included in a multivariable logistic regression model.
Backward elimination was used to select variables that
were independently signiﬁcant at P < 0.05. Recursive
partitioning analysis was performed with the rpart pack-
age in R (R Foundation for Statistical Computing,
Vienna, Austria). All other statistical analyses were per-
formed with SAS version 9.3 (SAS Institute Inc., Cary,
NC, USA).
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Results
We identiﬁed 213 evaluable submissions for PBS listing
of anticancer drugs between July 2005 and July 2014,
182 in both PSD and BSO and 31 in BSO alone. Of the
213 submissions, 154 (72%) were a major submission
and 59 (28%) were a minor submission. All major sub-
missions were reported in a PSD compared with just
under half (28) of minor submissions. There was a simi-
lar proportion of resubmissions (113, 53%) and initial
submissions (100, 47%), and 86 (40%) submissions
were for anticancer drugs not already listed on the PBS
for another indication.
The 213 submissions covered 110 unique indications
for 60 anticancer drugs. Of the 110 indications assessed,
the most common tumour types were breast cancer
(19, 17%), non-small cell lung cancer (12, 11%) and
colorectal cancer (12, 11%); 90 (82%) were for treat-
ment with non-curative or palliative intent; and,
36 (33%) required testing for a biomarker or treatment
target as a condition of use.
The rejection rate for all submissions was 119 of
213 (56%), and for the subset of submissions reported in
a PSD, it was 109 of 182 (60%). Of the 110 indications
assessed, 76 (69%) were rejected at least once, and
31 (28%) were rejected more than once (Fig. 1). By
October 2015, of the 110 indications assessed over the
study period, 91 (83%) were listed on the PBS and
19 (17%) remained unlisted. The rejection rate by calen-
dar year from 2005 to 2014 ranged from 50 to 73% with
little evidence of a trend over time (P = 0.2) (Fig. 2).
However, the rate of rejection for initial submissions was
higher from 2010 to 2014 than from 2005 to 2009
(37/50 = 70% vs 27/50 = 54%, P = 0.04).
Results of the univariable logistic regression analyses
used to identify submission attributes associated with
rejection are shown in Table 1. Submissions in which the
PBAC did not accept the sponsors’ comparator or efﬁcacy
claims were strongly associated with rejection, as were
submissions in which the PBAC judged either the clinical
or the economic evidence, problematic or uncertain.
Rejection was also associated with submissions that had
indications with a palliative intent, inactive comparators
and base case incremental cost-effectiveness ratios
(ICERs) > $45 000/quality-adjusted life year (QALY).
Only 1 of 20 submissions with an ICER range > $75
000/QALY was recommended for listing on the PBS.
The one submission with an ICER range < $15 000/
QALY was rejected. All 10 submissions that the PBAC
judged to have an inappropriate comparator were
rejected.
Table 2 shows the results of our multivariable logistic
regression analysis. A PBAC judgement of problematic
or uncertain clinical evidence and an inactive compara-
tor had the strongest association with rejection. The
results of the recursive partitioning analysis applied to
characteristics that were signiﬁcantly associated with
rejection in the univariable analysis are illustrated in
Figure 3. The characteristic that best discriminated
between rejection and a recommendation for listing was
PBAC judged the clinical evidence problematic or uncer-
tain – 81% (73/90) of major submissions with this char-
acteristic were rejected, versus 39% (25/64) without this
characteristic. Of the 64 major submissions without this
characteristic, an ICER > $45 000/QALY was the strong-
est discriminator between a recommendation for listing
and rejection. Major submissions most likely to be
rejected were those when the PBAC judged the clinical
evidence problematic or uncertain and an inactive com-
parator was used (24/25, 96%).
Table 3 summarises our categorisation of the reasons
for rejection offered by the PBAC. Multiple reasons were
documented for nearly all submissions that were rejected
(101/109, 93%); the most frequent number of reasons
per rejection was 3 (27/109, 25%). The reason for rejec-
tion that we categorised as most frequent was cost-
effectiveness was inadequate or the drug price too high
(75/109, 69%).
2%
7%
19%
41%
31%
Rejected four times
Rejected three times
Rejected twice
Rejected once
Never rejected
Figure 1 Frequency of rejection among 213 submissions for 110 indica-
tions assessed by the Pharmaceutical Beneﬁts Advisory Committee.
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Figure 2 Submission rejection rate by calendar year.
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Table 1 Univariable logistic regression analyses of the associations between each individual submission characteristic and rejection
Submission characteristic Reject (n (%)) Approve (n (%)) Total P value†
Information submitted to the PBAC
Listing request‡ 0.11
New listing 54 (63%) 32 (37%) 86
Extend existing listing 65 (51%) 62 (49%) 127
Submission type‡ 0.01
Initial submission 64 (64%) 36 (36%) 100
Resubmission 55 (49%) 58 (51%) 113
Treatment intent 0.006
Curative/adjuvant 10 (33%) 20 (67%) 30
Palliative 99 (65%) 53 (35%) 152
Test required before drug can be used 0.59
Yes 41 (65%) 22 (35%) 63
No 68 (57%) 51 (43%) 119
Comparator type 0.003
Active 68 (57%) 51 (43%) 119
Inactive (e.g. placebo, best supportive care) 30 (86%) 5 (14%) 35
Type of trial evidence submitted 0.43
Direct comparison trial(s) only 43 (67%) 21 (33%) 64
Indirect comparison trials included 55 (62%) 34 (38%) 89
Evidence of an overall survival beneﬁt 0.28
Yes 38 (70%) 16 (30%) 54
No 32 (60%) 21 (40%) 53
Type of economic analysis 0.01
Cost-effectiveness analysis and/or cost-utility analysis 90 (66%) 47 (34%) 137
Cost-minimisation analysis; other 17 (41%) 24 (59%) 41
ICER (cost/QALY) <0.001
≤$45 000/QALY 12 (41%) 17 (59%) 29
>$45 000/QALY 62 (78%) 18 (23%) 80
Estimated impact on the PBS budget per year 0.04
<$10 million 55 (59%) 38 (41%) 93
≥$10 million 41 (76%) 13 (24%) 54
PBAC judgements of sponsor claims
Comparator claim 0.005
Accepted 69 (58%) 50 (42%) 119
Partially accepted; rejected 25 (89%) 3 (11%) 28
Efﬁcacy claim <0.001
Accepted 39 (48%) 42 (52%) 81
Partially accepted; rejected; unclear 59 (81%) 14 (19%) 73
Toxicity claim 0.47
Accepted 42 (67%) 21 (33%) 63
Partially accepted; rejected; unclear 56 (62%) 35 (38%) 91
Other judgements made by PBAC
PBAC judged clinical evidence problematic or uncertain <0.001
Yes 73 (81%) 17 (19%) 90
No 25 (39%) 39 (61%) 64
PBAC judged economic evidence problematic or uncertain <0.001
Yes 75 (76%) 24 (24%) 99
No 22 (41%) 32 (59%) 54
PBAC judged there to be a high clinical need 0.12
Yes 32 (73%) 12 (27%) 44
No 66 (60%) 44 (40%) 110
†Logistic regression ﬁtted with GEE. ‡No PSD is required to determine these variables and so applicable to all 213 submissions. All other variables
were determined from the 182 submissions with a PSD. GEE, generalised estimating equations; ICER, incremental cost-effectiveness ratio; PBAC, Phar-
maceutical Beneﬁts Advisory Committee; PBS, Pharmaceutical Beneﬁts Scheme; PSD, public summary document; QALY, quality-adjusted life year.
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Discussion
Our study has found several important factors contribut-
ing to rejection by the PBAC of submissions for listing of
anticancer drugs. The importance of inadequate cost-
effectiveness was demonstrated, amongst applicable sub-
missions, by the association between rejection and an
ICER > $45 000/QALY in both the univariable analysis
and the recursive partitioning analysis. Inadequate cost-
effectiveness or drug price too high was also the most
Table 2 Multivariable logistic regression analysis of the associations between submission characteristics and rejection
Univariable† Multivariable†
Submission characteristic OR 95% CI P value OR 95% CI P value
PBAC judged clinical evidence problematic or uncertain (yes vs no) 6.76 3.24–14.1 <0.001 8.47 3.25–22.1 <0.001
Comparator type (inactive vs active) 4.29 1.66–11.1 0.003 10.8 3.20–36.3 <0.001
PBAC judged economic evidence problematic or uncertain (yes vs no) 4.54 2.21–9.30 <0.001 4.35 1.82–10.4 <0.001
Estimated impact on the PBS budget per year (≥$10 million vs <$10 million) 2.17 1.05–4.55 0.037 4.17 1.56–11.1 0.005
Treatment intent (palliative vs curative/adjuvant) 3.85 1.47–10.0 0.006 2.70 1.00–7.14 0.05
Type of economic analysis (cost-effectiveness and/or cost-utility vs cost-
minimisation or other)
2.68 1.26–5.70 0.010 NS – –
ICER (>$45 000/QALY vs ≤$45 000/QALY) 7.70 2.9–20.4 <0.001 NA‡ – –
†Logistic regression ﬁtted with GEE. ‡Not included as a candidate variable in principal analysis as only applicable to 57% (88/154) of major submissions.
In a sensitivity analysis when it was included, an ICER > $45 000/QALY was signiﬁcantly associated with rejection, as were: PBAC judged clinical evi-
dence problematic or uncertain; PBAC judged economic evidence problematic or uncertain; and an inactive comparator. CI, conﬁdence interval; ICER,
incremental cost-effectiveness ratio; NA, not applicable; NS, not signiﬁcant; OR, odds ratio; PBAC, Pharmaceutical Beneﬁts Advisory Committee; PBS,
Pharmaceutical Beneﬁts Scheme; QALY, quality-adjusted life year.
Major submissions 
154 
Rejected - 98 (63%) 
Recommended - 56 (37%) 
PBAC judged clinical evidence 
problematic or uncertain 
(NO) 
64 
Rejected - 25 (39%) 
Recommended - 39 (61%) 
PBAC judged clinical evidence 
problematic or uncertain 
(YES) 
90 
Rejected - 73 (81%) 
Recommended - 17 (19%) 
Cost/QALY
(≤$45,000 or ICER not
applicable to submission)
44
Rejected - 9 (20%)
Recommended - 35 (80%)
Cost/QALY
(>$45,000)
20
Rejected - 16 (80%)
Recommended - 4 (20%)
Active comparator
(YES)
65
Rejected - 49 (75%)
Recommended - 16 (25%)
Active comparator
(NO)
25
Rejected - 24 (96%)
Recommended - 1 (4%)
Figure 3 Recursive partitioning analysis applied to characteristics from major submissions associated with rejection on univariable analysis.
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frequent reason for rejection based on our categorisation
of the reasons for rejection offered by the PBAC. PBAC
uncertainty about the clinical and economic evidence
was also an important factor. PBAC judgements of
uncertain or problematic clinical evidence, and uncertain
or problematic economic evidence, were submission
characteristics signiﬁcantly associated with rejection in
our multivariable logistic regression analysis and were
frequently offered as reasons for rejection based on our
categorisation. The recursive partitioning analysis also
demonstrated that a PBAC judgement of uncertain or
problematic clinical evidence best discriminated between
a recommendation for listing and rejection.
We were surprised to ﬁnd that submissions for drugs
without a demonstrated survival beneﬁt over their
nominated comparator were no more likely to be
rejected. At ﬁrst glance, this suggests the erroneous con-
clusion that survival beneﬁts are unimportant to the
PBAC. Recommendations for listing in the absence of a
demonstrated survival beneﬁt may have been based on
strong evidence from important surrogate end-points,
such as progression-free survival or because of demon-
stration of non-inferiority with a drug already proven
effective. For example, recommendations for erlotinib
and geﬁtinib in the treatment of non-small cell lung can-
cer with driver mutations of the gene for epidermal
growth factor receptor, were based on improvements in
important surrogate end-points, progression-free sur-
vival and quality of life, in comparison with chemother-
apy using a platinum-based doublet, the prior standard
of care. Pazopanib was recommended for listing for the
treatment of metastatic renal cell carcinoma based on
evidence of non-inferiority in comparison with sunitinib,
which had already been PBS listed for this indication.
Such submissions will not have been recorded as
demonstrating evidence of a survival beneﬁt in our
study, even if there is available evidence for the
anticancer drugs in question against placebo or other
unnominated comparators.
Conversely, some submissions for listing drugs with a
demonstrable survival beneﬁts were rejected by the
PBAC. Examples in our study include the ﬁrst submis-
sion for listing bevacizumab in combination with chemo-
therapy as ﬁrst-line treatment of metastatic colorectal
cancer, and the ﬁrst submission for listing abiraterone in
metastatic, castration-resistant prostate cancer, following
treatment with chemotherapy. Robust evidence of a sub-
stantial survival beneﬁt may justify a high asking price,
but a higher asking price will reduce cost-effectiveness,
perhaps resulting in rejection. It is important to note that
most submissions for listing anticancer drugs with a
demonstrable survival beneﬁt, including the previous
examples, were eventually approved. Of the 19 indica-
tions assessed in our study that remained unlisted in
October 2015, only ﬁve were supported by statistically
signiﬁcant survival beneﬁts.
The main strength of this study is its comprehensive
review of all submissions made to the PBAC regarding
the PBS listing of anticancer drugs since PSD became
available up until July 2014. This is timely given the
growing community concern about the issue of high cost
anticancer drugs and a recent Senate Inquiry into access
to innovative cancer drugs in Australia.16,17 Inclusion of
all PBAC recommendations since 2005, not just those
reported in PSD, ensures that the rejection rate is not
overestimated. Independent data extraction by two
investigators also contributes to the credibility of our
results. This study builds on our previous study by
exploring the reasons the PBAC rejects anticancer drugs
for listing.10 Other studies, including our previous one,
were not limited to analysis of anticancer drugs, but also
found that the frequency of rejections by PBAC was
increased by uncertainty, inadequate cost-effectiveness
and health budget impact.10,12,18–20
Table 3 Our classiﬁcation of reasons offered by the PBAC for rejecting submissions for listing on the PBS
Reason for rejection
Rejected submissions (n = 109)
Number of submissions in which
reason was offered %
PBAC stated the cost-effectiveness was inadequate or the drug price too high 75 69
PBAC judged economic evidence problematic or uncertain 73 67
PBAC stated they were uncertain about the cost-effectiveness 64 59
PBAC judged clinical evidence problematic or uncertain 61 56
PBAC judged the drug’s nominated clinical place and/or comparator problematic or uncertain 41 38
Supplementary data or analysis was required by the PBAC 22 20
PBAC had concerns about the PBS or health budget impact 16 15
PBAC had concerns about the safety or toxicity of the drug 11 10
PBAC had concerns about the test required as a condition of use 8 7
Other miscellaneous reasons 17 16
PBAC, Pharmaceutical Beneﬁts Advisory Committee; PBS, Pharmaceutical Beneﬁts Scheme.
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The main limitations of our study stem from its reli-
ance on publicly available information. PSD aims to
provide the public information about PBAC recommen-
dations, but they arose as a result of requests for more
transparency about the basis of subsidy of pharmaceuti-
cals to Australians, as part of the Australian-United
States Free Trade Agreement.4 The PBAC is governed by
the National Health Act, therefore content published in
PSD is subject to Commonwealth law, and is negotiated
by the PBAC and the sponsor to protect commercial con-
ﬁdentiality.21 As a result, pertinent information consid-
ered by the PBAC may be omitted.
Uncertainty about the cost-effectiveness of a new
anticancer drug reduces the likelihood that it will be pub-
licly funded, especially if the price of a new anticancer
drug is high and would result in substantial total expend-
iture.13,22 Sources of uncertainty for the PBAC include
aspects of clinical trial design that obscure the magnitude
of beneﬁt (e.g. crossover from control group to experi-
mental treatment); applicability of submitted trial evi-
dence to the Australian context (e.g. inappropriate
comparator); and assumptions or ﬂaws in the economic
models submitted (e.g. extrapolation of trial results
beyond the duration of follow-up).23–25 PSD for drugs
rejected by the PBAC because of ‘uncertainty’ are often
unclear about whether the ‘uncertainty’ is about the ben-
eﬁts, the costs, the cost-effectiveness or some other
unspeciﬁed consideration. We recommend that PSD
should explicitly specify the areas and reasons for uncer-
tainty and how these uncertainties contributed to the
PBAC’s recommendation.
Despite challenges faced by the PBAC, such as high
prices and uncertain beneﬁts, our study has not demon-
strated clear evidence of an increasing linear trend over
time in the rejection rate for anticancer drugs. The rejec-
tion rate of initial submissions was nevertheless greater
in the second half of the study period compared to the
ﬁrst. Policy arrangements that promote rapid access to
new anticancer drugs to allay the concerns of patients
and doctors, while ensuring value for money is still con-
sidered, should be encouraged.26,27
Funding decisions in health systems that fund antican-
cer drugs signiﬁcantly affect the practice of medical
oncologists and the anticancer drugs that are accessible
to patients.28 Surveys demonstrate that patients want
information about the availability of high cost, unfunded
drugs, and may feel that it is unfair that these drugs are
not funded.6,29 Understanding that a drug was rejected
because of doubts about its efﬁcacy, rather than its high
cost, might help patients in deciding whether or not to
pursue an expensive treatment.
Cancer is sometimes paid special attention by health
technology assessment agencies and reimbursement
authorities.30 For example, a ‘Cancer Drugs Fund’ was
created in the United Kingdom to provide access to
anticancer drugs, which were increasingly receiving neg-
ative recommendations from the National Institute for
Health and Care Excellence.31,32 Our study of recom-
mendations from 2005 to 2008 showed that the PBAC
was equally likely to recommend or reject drugs for can-
cer versus other indications, but recommendations since
2008 warrant analysis.10 Further research is also needed
to determine the extent to which the criteria used by
PBAC to value new anticancer treatments match those
of the wider community.33
Conclusion
The rapidly rising cost of new anticancer drugs has made
rigorous determination of their value an urgent and
important priority. Rejection of a submission for listing
on the PBS moves the problem from the domain of
health policy to that of individual clinical decision mak-
ing. This makes it even more important that the PBAC
provide clear information about its deliberations and the
reasons for rejection or recommendation for listing of
expensive new anticancer drugs. Better information
about the reasons for rejection should help patients and
doctors make more informed decisions about the use of
expensive unfunded treatments.
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ABSTRACT
Objective Australia has a publicly funded universal 
healthcare system which heavily subsidises the cost of 
most registered anticancer drugs. The use of anticancer 
drugs that are unfunded, that is, not subsidised by the 
government, entails substantial out-of-pocket costs for 
patients. We sought to determine how frequently Australian 
medical oncologists discuss and prescribe unfunded 
anticancer drugs, and their attitudes and beliefs about 
their use.
Methods Members of the Medical Oncology Group of 
Australia (MOGA) completed an online survey about 
their clinical practices over a recent 3-month period. A 
negative binomial regression model was used to examine 
the influence of respondent characteristics on the rate 
of discussions about, and prescription of, unfunded 
anticancer drugs.
Results Of the 154 respondents (27% of 575 MOGA 
members), 92% had discussed and 68% had prescribed at 
least one unfunded anticancer drug in the last 3 months. 
Respondents reported discussing unfunded anticancer 
drugs with an average of 2.5 patients per month (95% CI 
2.1 to 2.9), and prescribed them to an average of 0.9 
patients per month (95% CI 0.7 to 1.2). The rate of 
discussing unfunded anticancer drugs was associated with 
being fully qualified (p=0.01), and being in a metropolitan 
practice (p=0.009), the rate of prescription was associated 
only with being in metropolitan practice (p=0.006). The 
concerns about discussing and prescribing unfunded 
anticancer drugs rated most important were as follows: 
‘potential to cause financial hardship’ and ‘difficulty for 
patients to evaluate the benefits versus the costs’.
Conclusions Australian medical oncologists frequently 
discuss and prescribe unfunded anticancer drugs, and 
are concerned about their patients having to face difficult 
decisions and financial hardship. Further research is 
needed to better understand the factors that affect how 
oncologists and patients value expensive, unfunded 
anticancer drugs.
INTRODUCTION
The number of drugs developed to treat 
cancer has greatly increased over recent 
years. Over 60 new anticancer drugs were 
approved by the USA Food and Drug Admin-
istration between 2005 and 2014, and a 
further 70 existing anticancer drugs had their 
indications expanded.1 The growth in the 
number of new anticancer drugs is welcomed 
by patients and oncologists as new treatments 
can increase response rates, delay progres-
sion, extend survival, improve the quality 
of life of patients with cancer and in some 
circumstances increase the chance of cure.
Along with the benefits of new anticancer 
drugs comes their considerable expense.2 
The prices of new anticancer drugs have 
created challenges for payers, providers and 
patients.3 In predominantly publicly funded 
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SUMMARY BOX
What is already known about this subject?
 Ź The price of new anticancer drugs has created 
challenges for patients and their oncologists.
 Ź Patients and oncologists have to grapple with 
determining the value of new anticancer drugs 
which can be difficult if the benefits are modest or 
uncertain, and the costs are high.
 Ź Patients who receive treatment with expensive 
anticancer drugs are often faced with a significant 
financial burden, which oncologists may spend time 
and effort trying to reduce.
What does this study add?
 Ź This study provides the first data estimating 
the frequency of discussion and prescription of 
expensive unfunded anticancer drugs by medical 
oncologists in a health system like Australia’s in 
which most anticancer drugs are publicly funded.
 Ź The study provides an insight into the attitudes 
and practices of Australian medical oncologists 
regarding unfunded anticancer drugs.
 Ź This study also highlights some important potential 
concerns and barriers to discussing and prescribing 
unfunded anticancer drugs in Australia.
How might this impact on clinical practice?
 Ź Even in publicly funded health systems, oncologists 
discuss and prescribe expensive unfunded 
anticancer drugs frequently and are concerned 
about causing their patients psychological distress 
and financial hardship.
 Ź Further research and education are needed to 
identify better ways of thinking and talking about 
unfunded anticancer drugs with patients, and 
to better understand the complex factors that 
contribute to how oncologists value expensive 
unfunded anticancer drugs, and their willingness to 
discuss and prescribe them.
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health systems like Australia’s, payers grapple with deter-
mining whether the benefits of a new anticancer drug are 
worth the extra cost. To be lawfully supplied in Australia, 
prescription drugs require marketing approval from 
the Therapeutic Goods Administration.4 If the drug is 
approved, pharmaceutical companies can submit applica-
tions to the Pharmaceutical Benefits Advisory Committee 
for drugs to be listed on the Pharmaceutical Benefits 
Scheme (PBS).5 Drugs listed on the PBS are provided to 
patients at a heavily subsidised price.
Even in Australia, where most prescription medicines 
are subsidised, the rising cost of anticancer drugs creates 
problems for patients.6 For example, it is often months, 
and sometimes years, from the publication of positive 
trial results to the listing of a drug on the PBS.7 If a new 
anticancer drug is not listed on the PBS, then accessing it 
may require patients to pay its full cost, which can amount 
to thousands of dollars per month.8 9 In some instances, 
pharmaceutical companies provide access to these drugs 
via compassionate access programmes or cost-sharing 
programmes; however, these still may involve substantial 
out-of-pocket costs. This means that the cost of treatment 
can become a major factor in decision making for cancer 
patients.10 Many patients will forego high-cost treatments 
altogether, or discontinue them early if the expense 
becomes prohibitive.11
A recent survey of medical oncologists from the USA 
indicated that the vast majority felt obliged to offer all 
available treatment options to their patients regardless of 
their cost.12 Discussing expensive treatment options can 
be difficult for oncologists who do not wish to impose 
a financial hardship on their patients, especially if the 
incremental benefit of the treatment is modest or uncer-
tain.13 Oncologists may also spend time and effort trying 
to find ways to reduce or avoid this financial hardship for 
their patients, for example, by seeking alternative sources 
of funding.14 As the cost of anticancer drugs continues to 
rise, oncologists and their patients will increasingly have 
to face the difficulty of determining their value.15
Unfunded anticancer drugs are those that are not 
subsidised by the government and therefore entail 
substantial out-of-pocket costs to patients. A study of the 
practices and attitudes of Australian medical oncologists 
regarding disclosure of expensive unfunded anticancer 
drugs in 2006 found that almost half of the responding 
oncologists reported prescribing at least one unfunded 
anticancer drug.16 Since then, the available number of 
unfunded anticancer drugs has grown. A recent study at a 
single Australian institution found that almost half of the 
anticancer drug treatment protocols contained a drug 
that was not PBS listed.17 The extent to which Austra-
lian medical oncologists currently discuss and prescribe 
unfunded anticancer drugs is unknown. The aim of this 
study was to examine the current practices, attitudes 
and beliefs of Australian medical oncologists regarding 
the discussion and prescription of unfunded anticancer 
drugs.
METHODS
We performed a cross-sectional survey of medical oncolo-
gists and medical oncology trainees throughout Australia. 
We asked respondents to recall their discussions about, 
and prescriptions of, unfunded anticancer drugs over 
the last 3 months. Based on previous definitions used in 
Australian studies, we defined unfunded anticancer drugs 
as any prescription anticancer drug that:
 Ź was not listed on the PBS;
 Ź was not used as part of a clinical trial or free access 
programme;
 Ź may require the patient to pay substantially more 
than standard pharmacy dispensing fees.8 16
Respondents also provided details about their personal 
and practice characteristics and their attitudes and opin-
ions about issues related to unfunded anticancer drugs, 
including concerns about discussing and prescribing 
them.
The survey instrument was developed by three medical 
oncologists. A focus group of five medical oncologists was 
used to assess face validity, content validity and clarity, 
before wider distribution. The final version of the survey 
is available online (supplementary material).
Potential participants were members of the Medical 
Oncology Group of Australia (MOGA). MOGA is the 
peak national body representing medical oncologists in 
Australia. All members of MOGA (medical oncologists 
and medical oncology trainees) were invited to partici-
pate by email in August 2014. The email included a brief 
explanation of the survey, a participant information 
statement and a hypertext link to the survey. The survey 
took approximately 15 min to complete, and respon-
dents were not offered any inducements to complete the 
survey. A reminder email was sent to all potential partic-
ipants 1 month after the initial invitation. The study was 
approved by the University of Sydney Human Research 
Ethics Committee (Project number: 2014/173). All 
responses to the survey were anonymous and non-iden-
tifiable.
The analysis set comprised respondents who answered 
at least one question about the discussion or prescrip-
tion of unfunded anticancer drugs. A negative binomial 
regression model was used to examine the influence of 
personal and professional characteristics on the rate of 
discussion and prescription of unfunded anticancer 
drugs. Characteristics were first tested individually, and 
then after adjusting for clinical workload (hours per 
week on average spent in outpatient clinics). Backwards 
elimination was used to develop a multivariable model 
comprising statistically significant, independent predic-
tors adjusting for clinical workload.
RESULTS
We received evaluable responses from 154 of the 575 
(27%) medical oncologists in the MOGA database, 
including 142 who answered all questions. The character-
istics of the 154 respondents are summarised in table 1. 
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Qualified oncologists outnumbered trainees by 4:1, but 
more than half the respondents were 40 years or younger, 
and only 40% had more than 10 years’ experience in 
oncology practice. The numbers of females and males 
were similar. Most respondents practiced in public clinics 
in metropolitan areas.
In a recent 3-month period, respondents currently in 
practice reported discussing unfunded anticancer drugs 
with an average of 2.5 patients per month (95% CI 2.1 
to 2.9), and prescribing unfunded anticancer drugs 
to an average of 0.9 patients per month (95% CI 0.7 
to 1.2). Almost all of the respondents had discussed 
(99%) or prescribed (93%) an unfunded anticancer 
drug at some time in the past. Ninety-two per cent of 
respondents had discussed, and 68% had prescribed, an 
unfunded anticancer drug in the last 3 months. Sixty-
nine per cent thought they were currently prescribing 
more unfunded anticancer drugs than they had 5 years 
ago, and 77% thought they would be prescribing more 
unfunded anticancer drugs in 10 years’ time than they 
are now.
Respondents reported discussing or prescribing 
unfunded anticancer drugs more often to patients consid-
ering palliative treatment (88% of respondents) versus 
adjuvant/curative treatment (12%); patients consid-
ering last-line treatment (68%) versus first-line treatment 
(32%); and patients younger than 70 (96%) versus older 
than 70 (4%). Respondents reported that, on average, 
patients or their support person initiated about 15% of 
discussions about unfunded anticancer drugs. Respon-
dents reported that, on average, they recommended 
against treatment with an unfunded anticancer drug in 
about 27% of discussions.
Associations between the characteristics of respon-
dents, and the rate of both discussion and prescription 
of unfunded anticancer drugs, are summarised in 
table 2. Working in private practice and working in 
a metropolitan practice were each associated with an 
increased rate of both discussion and prescription in 
univariable analyses adjusting for clinical workload. 
Metropolitan practice was the only variable significantly 
associated with both discussion and prescription rate 
in multivariable analysis. Being a qualified medical 
oncologist, rather than a trainee, was also significantly 
associated with the rate of discussion, but not with the 
rate of prescription, in both univariable and multivari-
able analyses.
The median maximum out-of-pocket cost respon-
dents estimated that their patients had paid, or would 
be expected to pay, for a course of an unfunded anti-
cancer drug, typically lasting a few months, was A$7500 
(around US$5800; €5400); range: A$200 to A$100 000. 
The frequency with which various methods were used 
to cover the costs of unfunded anticancer drugs is 
summarised in figure 1. Respondents estimated that 
60% of prescriptions were partially subsidised through 
a pharmaceutical company access programme, and that 
approximately 30% of the prescriptions were fully paid 
for by their patients.
Out-of-pocket costs to patients were reported to influ-
ence the willingness to prescribe an unfunded anticancer 
drug, ‘somewhat’ or ‘a lot’ by 83% (118/143) of respon-
dents, and not at all by 6% (9/143) of respondents. 
Eleven per cent (16/143) of respondents felt it was never 
appropriate for a patient to pay for treatment with an 
unfunded anticancer drug. Just over half the respondents 
(55%, 78/142) said they were comfortable discussing 
out-of-pocket costs with patients.
The concerns we presented about discussing and 
prescribing unfunded anticancer drugs that were rated 
most important by respondents were ‘potential to cause 
financial hardship’ and ‘difficulty for patients to evaluate 
Table 1 Personal and professional characteristics of 154 
responding oncologists
Age n (%)
  ≤30 4 (3)
  31–40 81 (52)
  41–50 34 (22)
  51–60 23 (15)
  >60 12 (8)
Role
  Qualified oncologist 30 (81)
  Trainee oncologist 124 (19)
Sex
  Female 72 (47)
  Male 82 (53)
Years worked in medical oncology
  ≤10 91 (59)
  11–20 29 (19)
  >20 34 (22)
Hours spent in outpatient clinics per week
  ≤20 89 (58)
  >20 65 (42)
Hours spent in research per week
  ≤20 129 (84)
  >20 25 (16)
Practice type
  Mostly public 105 (68)
  Mostly private 21 (14)
  Other* 28 (18)
Practice location
  Mostly metropolitan 121 (79)
  Mostly regional/rural 26 (17)
  Other† 7 (5)
*Includes respondents with an equal mix of public and private 
practice, or no clinical practice.
†Includes respondents with an equal mix of metropolitan and 
regional/rural practice, or no clinical practice.
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the benefits versus the costs’ (figure 2). Concerns about 
the ‘time it takes to discuss unfunded anticancer drugs 
with a patient’ and ‘the need to refer a patient to another 
centre’ were rated least important.
We presented a list of possible aids to facilitate discus-
sions about unfunded anticancer drugs (figure 3). Those 
rated most useful by respondents were ‘a website with a list 
of access programmes available for unfunded anticancer 
drugs’ and ‘a clear understanding of what drug costs private 
health funds will cover’. Those rated least useful were 
‘written guidelines about how oncologists should communi-
cate out-of-pocket costs with patients’ and ‘communication 
workshops focusing on discussions with patients about 
out-of-pocket costs’.
DISCUSSION
This survey indicates that in a health system which is 
predominantly publicly funded, responding medical 
oncologists discussed unfunded anticancer drugs with 
approximately three patients per month, prescribed 
them to approximately one patient per month and that 
nearly all had prescribed an unfunded anticancer drug. 
This is much higher than a comparable study published 
10 years ago which found that <50% of Australian 
medical oncologists had prescribed an unfunded anti-
cancer drug.16
The median maximum out-of-pocket costs that respon-
dents recalled their patients had paid, or were expected 
to pay, for a course of an unfunded anticancer drug 
Table 2 Associations between respondents’ characteristics and the rates of discussion and prescription of unfunded 
anticancer drugs
Outcome/characteristic
Univariable analysis (adjusted 
for clinical workload)
Multivariable analysis (adjusted 
for clinical workload)
Rate ratio 95% CI p Value Rate ratio 95% CI p Value
Discussion rate
Role
  Qualified oncologist 1.60 1.08 to 2.37 0.020 1.67 1.13 to 2.46 0.01
  Trainee oncologist (reference group) – –
Sex
  Male 1.29 0.92 to 1.81 0.14 –
  Female (reference group)
Age (per decade) 1.14 0.97 to 1.35 0.11 –
Years worked in medical oncology (per decade) 1.09 0.92 to 1.28 0.32 –
Practice type
  Mostly private/other 1.66 1.17 to 2.36 0.005 –
  Mostly public (reference group)
Practice location
  Mostly metropolitan 1.61 1.08 to 2.39 0.02 1.68 1.14 to 2.48 0.009
  Mostly regional/rural/other (reference group)
Prescription rate
Role
  Qualified oncologist 1.63 0.94 to 2.83 0.08 –
  Trainee oncologist (reference group)
Sex
  Male 0.89 0.56 to 1.40 0.61 –
  Female (reference group)
Age (per decade) 1.22 0.98 to 1.51 0.08 –
Years worked in medical oncology (per decade) 1.21 0.97 to 1.51 0.09 –
Practice type
  Mostly private/other 1.70 1.03 to 2.80 0.04 –
  Mostly public (reference group)
Practice location
  Mostly metropolitan 2.20 1.25 to 3.87 0.006 2.20 1.25 to 3.87 0.006
  Mostly regional/rural and other (reference group)
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was A$7500. This is a considerable amount of money in 
conjunction with other costs of care and may be unaf-
fordable for many patients. Costs were likely to be much 
higher for the 30% of patients who were meeting the 
full cost of the drugs. Recommendations against treat-
ment with an unfunded anticancer drug occur in over a 
quarter of discussions about them in our study but we did 
not ascertain whether the high cost was the main reason 
for recommending against their use. It is likely to be a 
factor given that the potential to cause financial hardship 
was the concern rated most highly by respondents when 
discussing or prescribing unfunded anticancer drugs. 
Other factors such as the type of evidence used to make 
recommendations, the strength of that evidence or the 
incremental benefit over less costly options may also be 
important, but we did not ascertain these in our study. 
Patient factors and disease factors are also likely to have a 
significant role as respondents reported that it was more 
likely they would discuss and prescribe unfunded anti-
cancer drugs to patients who were younger, had incurable 
disease or were considering last-line therapy. It would be 
interesting to explore how much willingness to discuss 
or prescribe an unfunded anticancer drug in the last-
line setting correlates with the level of discomfort of the 
oncologist in discussing palliative care.
The proportion of respondents (16% (23/142)) that 
reported being uncomfortable with discussing the out-of-
pocket costs of unfunded anticancer drugs was lower 
than anticipated. An Australian study published in 2008 
reported that discussing high-cost drugs was one of the 
most difficult communication issues for Australian oncol-
ogists.13 However, it may be that levels of discomfort have 
decreased over time as the frequency of these discussions 
has increased. Like their North American counterparts, 
most Australian oncologists think that out-of-pocket costs 
affect their willingness to prescribe an unfunded anti-
cancer drug, a finding that warrants further research.11 18
Respondents reported that approximately six of ten 
occasions they prescribed unfunded anticancer drugs 
involved partial subsidies via pharmaceutical company 
access programmes. Although these programmes allow 
earlier access to novel therapies that are not yet PBS 
9%
10%
10%
30%
60%
Parally subsidized by the hospital/cancer
centre
Parally subsidized by a charitable
organisaon
Parally subsidized by a private health
insurer
Paent met the full cost
Parally subsidized through pharmaceucal
company access program
Figure 1 Estimated frequency of methods used to cover 
the cost of unfunded anticancer drugs (more than one 
method possible for each prescription).
0% 20% 40% 60% 80% 100%
I would have to refer my paent to another centre
It takes too much me to discuss unfunded ancancer
drugs with a paent
It is hard for me ﬁnd out how much an unfunded
ancancer drug will cost a paent
The ethics of pharmaceucal company shared access
programs concerns me
It takes too much work to obtain paral funding and/or
organise treatment
There is oen an excessive delay between recommending
and starng treatment
Asking paents to make decisions about unfunded
ancancer drugs is not fair
I am concerned about distressing paents by discussing
unfunded ancancer drugs
I am concerned about not being able to oﬀer the same
treatment to all my paents in my pracce
It is diﬃcult for paents to evaluate the beneﬁts versus the
costs
The potenal ﬁnancial hardship to the paent and/or their
family concerns me
Figure 2 Percentage of responding oncologists who rated as important the specified concerns about discussing and 
prescribing unfunded anticancer drugs.
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listed, their widespread use raises a number of ethical 
dilemmas reported to be a concern by 41% of respon-
dents, such as their use as a medical marketing tool, the 
changing requirements of the programmes depending 
on commercial imperatives and the favouring of patients 
able to afford substantial contributions associated with 
the cost-sharing programmes.19 Pharmaceutical compa-
nies are not permitted to advertise these programmes 
directly to patients in Australia, and this may explain why 
over a third of respondents reported it was hard for them 
to find the costs of unfunded anticancer drugs. This may 
also be why respondents judged that the most useful aids 
for clinical practice would be better access to information 
about the costs and methods of accessing unfunded anti-
cancer drugs. This lack of knowledge or resources about 
the costs of care was rated the most important barrier to 
cost discussions by US oncologists in a recent survey.12
Respondents in predominantly metropolitan prac-
tices were more likely to discuss and prescribe unfunded 
anticancer drugs than those in predominantly regional 
or rural practices. Possible explanations include differ-
ences in treatment preferences of oncologists and/or 
patients in regional or rural areas, and greater barriers to 
accessing unfunded drugs (or information about them) 
in these areas. The lower likelihood that medical oncology 
trainees discussed unfunded anticancer drugs is likely to 
reflect their lower confidence and level of responsibility, 
but also supports the need for education about discussing 
unfunded anticancer drugs.
The main strengths of our study are that it reflects 
the contemporary practice and attitudes of Australian 
medical oncologists and contributes to the growing 
evidence that the high cost of new anticancer drugs is a 
major concern and influence on the practice of medical 
oncologists. It also provides the first information about 
the frequency of their discussions about, and prescription 
of, unfunded anticancer drugs. The main limitation of 
our study is the response rate of 27%, typical of physician 
surveys, and similar to a US study about communicating 
the costs of therapy.20 21 The age, gender and proportion 
of trainees among responders were similar to that of the 
general MOGA membership, but this does not ensure 
that our respondents’ answers would accurately reflect 
those of non-responders. Recall bias is another limitation 
because the study relied on medical oncologists’ recollec-
tions of past practice. Responding oncologists may have 
overestimated the frequency of their discussions and 
prescriptions. However, even so, it is clear that the issue 
of unfunded anticancer drugs is sufficiently common and 
important to warrant further research and attention.
This study shows that Australian medical oncologists 
frequently discuss and prescribe unfunded anticancer 
drugs, and that they are concerned about causing their 
patients psychological distress and financial hardship. 
Our study suggests that medical oncologists would value 
better information about the costs to their patients 
and methods for accessing unfunded anticancer drugs. 
Research and education are needed to identify and imple-
ment better ways of thinking and talking about unfunded 
anticancer drugs with patients, and to better understand 
the complex factors that contribute to how oncologists 
value expensive unfunded anticancer drugs, and their 
willingness to discuss and prescribe them.
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Perspectives
Valuing the beneﬁts of new anticancer drugs
Improvements in survival and cancer-related symptoms must be weighed up against
treatment-related adverse effects and ﬁnancial burden
Annual expenditure on anticancer drugs by thePharmaceutical Beneﬁts Scheme (PBS) has risenfrom $65 million in 1999e00 to $466 million in
2011e12— an average annual increase of 19%.1 This is
more than double Australia’s average annual increase in
health expenditure of 8% over the same period.2 New
techniques in radiation oncology and surgical oncology
have also increased expenditure on cancer. It has never
been more important to assess the value of new cancer
treatments, weighing up the balance between beneﬁts,
harms and costs. In oncology, clinical beneﬁt is deﬁnedby
improvements in survival and cancer-related symptoms,
and must be traded off against treatment-related adverse
effects and ﬁnancial burden. In Australia, evaluation of
the trade-offs for new anticancer drugs has been
predominantly a matter of health care policy, and
determined by the Pharmaceutical Beneﬁts Advisory
Committee (PBAC).
People affected by cancer also face decisions about paying
for unfunded treatments and need to understand the
degree of beneﬁt a treatment may offer. This is not
straightforward, as illustrated by an American study
published in 2012, which reported that 69% of patients
with metastatic lung cancer and 81% of patients with
metastatic colorectal cancer did not understand that their
treatment was “not at all likely to cure” their cancer.3 It is
evenmore difﬁcult to balance modest beneﬁts in survival
against toxicity and cost, especially when new treatments
are portrayed in the media as major breakthroughs.
Theworld’s two leadingmedical oncology organisations,
the American Society of Clinical Oncology (ASCO) and
theEuropeanSociety forMedicalOncology (ESMO), have
recently formulated the ﬁrst objective, validated and
reproducible frameworks to assess the value of anticancer
drugs.4,5 These frameworks aim to improve transparency
and provide independent measures of the degree of
beneﬁt a treatment offers. Both frameworks use data from
individual trials to assess the value of a new treatment in
comparison with the standard of care used in the trial.
Important similarities between the frameworks include
separate scoring systems for treatments given with
curative intent versus palliative intent; higher value given
to improvements in overall survival than to
improvements in surrogate endpoints such as
progression-free survival (PFS) or response rate; and
upward adjustments for improvements in quality of life
or reductions in toxicity. In this article, we summarise and
compare the frameworks using two examples, and
discuss their relevance to clinical practice and health
care policy.
The ASCO has developed two instruments— one for
potentially curable disease (adjuvant setting) and another
for advanced disease— that yield a net health beneﬁt
(NHB) score for a new treatment in comparison with the
standard of care, using published trial data. In advanced
disease, the maximum NHB score is 130, indicating
substantial improvements in overall survival, toxicity,
cancer-related symptomsand treatment-free interval. The
primary outcome contributes a maximum of 80 points to
NHB, with higher scores for bigger improvements and
beneﬁts in overall survival rather than PFS or objective
tumour response rate. The adjustment for toxicity ranges
from 20 formuchmore toxic toþ 20 formuch less toxic.
Signiﬁcant improvements in cancer-related symptoms
contribute an additional 10 points. An improvement in
the treatment-free interval (from completion of the new
treatment to initiation of the next treatment) contributes a
maximum of 20 points. The total NHB score is judged
against the cost of acquiring the drug and patient
copayments. The ASCO framework does not deﬁne
benchmarks for the NHB indicating high value, or a level
that justiﬁes funding, leaving individuals and policy
makers to draw their own conclusions.
The ASCO framework is summarised with two worked
examples in the Box. An evaluation of erlotinib versus
chemotherapy as ﬁrst-line treatment for metastatic non-
small cell lung cancer with a driver mutation of the
epidermal growth factor receptor (EGFR-mutated)6
yielded an NHB score of 44/130 using the ASCO
framework, indicating moderate beneﬁt. In contrast, an
evaluation of bevacizumab used in addition to
chemotherapy inunselectedpatientswithmetastatic non-
small cell lung cancer7 yielded an NHB score of 16/130,
indicatingmodest beneﬁt. TheASCO framework can also
be used to compare the prices of two treatment strategies;
however, inAustralia, determining the additional costs of
the new treatments is complex. Erlotinib is listed on the
PBS for the indication above and, in 2016, costs patients
$38.30 per month ($6.20 per month for concession-card
holders), with an approximate price paid by the PBS of
$1500/month. Bevacizumab is not listed on the PBS for
the indication above, andwould cost patients about $8000
per month.
The ESMO instruments categorise the beneﬁts of
anticancer drugs comparedwith current standard of care.
The instruments yield an alphabetic grade (A, B or C)
for treatments that are potentially curative, and a
numerical grade (5, 4, 3, 2 or 1) for treatments unlikely
to be curative, both ranked in diminishing order of
beneﬁt. The grades are assigned based on the observed
beneﬁts in survival or PFS in both relative terms
(hazard ratios [HRs]) and absolute terms (numbers of
months). This ensures an emphasis on beneﬁts that are
clinically important rather than just statistically
signiﬁcant. The ESMO framework evaluates the survival
“[TheASCOand
ESMO]
frameworks
provide
importantﬁrst
steps towards
standard
deﬁnitions,
metrics and
criteria for
assessing the
valueof new
anticancerdrugs”
Nicola J Lawrence
BHB, MB ChB, FRACP1
Glenn Salkeld
PhD, MPH,
GradDipHealthEcon2
Martin R Stockler
MBBS, FRACP, MSc(ClinEpi)1,3
Deme Karikios
BSc, MBBS, FRACP1
1 NHMRC Clinical
Trials Centre,
University of Sydney,
Sydney, NSW.
2 University of Wollongong,
Wollongong, NSW.
3 Sydney Cancer Centre,
Chris O’Brien Lifehouse,
Sydney, NSW.
nicola.lawrence@
ctc.usyd.edu.au
doi: 10.5694/mja15.01362
MJA 204 (11) j 20 June 2016 403
277
beneﬁt ﬁrst, and then adjusts the beneﬁt grade for toxicity
and quality of life. Financial cost was deliberately
excluded from the ESMO framework because of
differences between countries in costs and health service
delivery. ESMO proposes that each health care
jurisdictionmake its own independent judgements about
value for money and willingness to pay after considering
the grade of clinical beneﬁt.
The ESMO framework is summarised using the same two
worked examples in the Box. Erlotinib compared with
standard chemotherapy as ﬁrst-line treatment for
metastatic EGFR-mutated non-small cell lung cancer6
was assigned a grade 4 beneﬁt using the ESMO
framework, the highest possible grade for a non-curative
treatment with PFS as the primary endpoint. Erlotinib
received a high clinical value rating as it substantially
reduced the rate of progression (HR, 0.37), improved
median PFS by 4.5 months, and had less toxicity than
standard-of-care chemotherapy. In contrast,
bevacizumab in combination with chemotherapy for
unselected metastatic non-small cell lung cancer7 was
assigned a grade of 2, because the survival beneﬁts
were judged modest (HR for death, 0.79, with an
absolute improvement in median survival of 2 months),
and were not associated with improvements in toxicity
or quality of life.
The ASCO and ESMO frameworks led to similar
conclusions in the two examples, yielding higher beneﬁt
ratings for erlotinib in EGFR-mutated non-small cell lung
cancer than for bevacizumab in unselected non-small cell
lung cancer. The conclusions are consistent with the
PBACdecision to fund erlotinib, but not bevacizumab, for
the indications speciﬁed.
The simultaneous development of these frameworks
highlights the global recognition that health care costs are
increasing rapidly while resources are limited, and the
need to establish rigorous assessments of the value of new
treatments. This is important regardless of whether it is a
jurisdiction or an individual decidingwhether to pay for a
new expensive anticancer drug.
In Australia, the Therapeutic Goods Administration
(TGA) approves the marketing of new drugs based on
safety and efﬁcacy, but it is the PBAC that makes
recommendations to the Health Minister, based on
clinical and economic considerations, about which drugs
should be PBS listed and hence funded by the
government. In the United States, the Food and Drug
Administration is the sole agency responsible for the
approval of new drugs for marketing, but it is not
permitted to consider cost or cost-effectiveness in its
deliberations. The ASCO and ESMO frameworks allow
American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) frameworks for evaluating
clinical beneﬁt in advanced cancer: worked examples
Domain
ASCO framework ESMO framework
Description
Erlotinib v
chemotherapy
for EGFR-mutated
NSCLC6
Bevacizumab þ
chemotherapy
v chemotherapy
alone for NSCLC7 Description
Erlotinib
v chemotherapy
for EGFR-mutated
NSCLC6
Bevacizumab þ
chemotherapy
v chemotherapy
alone for NSCLC7
Main
outcome
Maximum scores of
80 for doubling OS;
55 for doubling PFS;
40 for OTRR of 80%;
lower scores for more
modest improvements
PFS prolonged by
4.3 months (87%)
from 5.2 months in
control group to
9.7 months in
erlotinib
group: score, 44
OS prolonged by
2.0 months (19%)
from 10.3 months
in control group to
12.3 months in
bevacizumab group:
score, 16
Preliminary grade
from 1 (smallest
improvement in
OS or PFS) to 4
(biggest improvement
in OS or PFS)
PFS prolonged by
4.3 months from
5.2 months in control
group to 9.7 months
in erlotinib group
(HR, 0.37): grade 3
OS prolonged by
2.0 months from
10.3 months in control
group to 12.3 months
in bevacizumab group
(HR, 0.79): grade 2
Toxicity The number of severe
toxicities differs
between the
treatment groups by
50% or more:
score, 20 to þ20
33% reduction from
12 in control group
to 8 in erlotinib
group: score, 0
46% increase from
15 in control group
to 22 in
bevacizumab
group: score, 0
Upgrade one level
if there is a statistically
signiﬁcant reduction in
severe toxicities
affecting daily
wellbeing
15% fewer severe
toxicities: upgrade
from preliminary
grade 3 to grade 4
No signiﬁcant
reduction in severe
toxicities: remains at
preliminary grade 2
Other Signiﬁcant palliation
of symptoms:
maximum score, 10
Symptoms no
better: score, 0
Symptoms no
better: score, 0
Upgrade one level if
QOL improved
QOL not improved:
no upgrade
QOL not improved:
no upgrade
TFI prolonged
by 20%: maximum
score, 20
TFI not prolonged
by 20%: score, 0
TFI not prolonged
by 20%: score, 0
Total
score
Net health beneﬁt
score:  12 (more toxic
and no beneﬁt) to 130
(substantially better
OS, TFI, symptoms
and toxicity)
44/130 16/130 Final adjusted clinical
beneﬁt grade: 1
(least beneﬁt) to
5 (greatest beneﬁt)
Grade 4 Grade 2
HR=hazard ratio. NSCLC=non-small cell lung cancer. OS=overall survival. OTRR=overall tumour response rate. PFS=progression-free survival. QOL=quality of life.
TFI = treatment-free interval.u
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policy makers and health care funders from different
health care systems to consider the value of a new
treatment together with local considerations such as
costs, disease prevalence and competing priorities.
These frameworks provide an independent, objective
and structured approach that could increase the
transparency of decisions made by the PBAC and similar
agencies.
Clinicians should ﬁnd the frameworks useful when
assessing and explaining the value of new anticancer
drugs, because they provide standardised metrics for
expressing beneﬁt. This should allow clearer
communication with patients, particularly in situations
where new treatments are unfunded, expensive and
have modest beneﬁts. The ESMO framework is
probably easier to use and expresses value in simple
grades. The ASCO framework is more complex, and
expresses valuewith a numerical score that requiresmore
explanation and interpretation. The ASCO plans further
development of its framework to facilitate doctorepatient
communication and shared decision making.4 An
important enhancement would be the capacity for
individuals and groups to assign weights to the factors
that are most important to them. For example, some
prioritise survival beneﬁts regardless of cost or toxicity,
whereas others prioritise quality of life over survival
time. The incorporation of such weights would help
communities, patients and doctors make decisions that
better reﬂect their preferences.
The costs of health care are burgeoning and this
approach warrants consideration beyond oncology.
All treatments require rigorous assessments of efﬁcacy,
safety and cost-effectiveness. These frameworks provide
important ﬁrst steps towards standard deﬁnitions,
metrics and criteria for assessing the value of new
anticancer drugs.
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